The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses, Airway Inflammation and Aspects of Airway Remodeling in Subjects With Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma (HDM)-Allergic Asthma
Phase: PHASE2
Conditions: Asthma, COPD
Sponsor: Foresee Pharmaceuticals Co., Ltd.

The effect of FP-025, a MMP-12 inhibitor, on allergen-induced 
airway responses, airway inflammation and aspects of airway 
remodeling in subjects with mild eosinophilic house dust mite 
(HDM)-allergic asthma 
(HDM)-allergic asthma 
 
Protocol Number:  FP02C-18-001 
NCT: 03858686 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 1 of 100 
 
 
 
 
Protocol title 
The effect of FP-025, a MMP-12 inhibitor, on allergen-induced 
airway responses, airway inflammation and aspects of airway 
remodeling in subjects with mild eosinophilic house dust mite 
(HDM)-allergic asthma 
Protocol ID 
FP02C-18-001 
 
Authors 
 
Document type 
Clinical Study Protocol 
 
Study Phase 
IIa 
 
Document status/version       Amendment 3 
Date 
06 September 2021 
EudraCT 
2017-005164-17 
Confidentiality Statement 
The information contained in this document, especially unpublished data, is the property of the sponsor of this 
study, Foresee Pharmaceuticals Co., Ltd. It is therefore provided to you in confidence as an investigator, potential 
investigator, or consultant, for review by you, your staff, and an Ethics Committee or Institutional Review Board. 
It is understood that this information will not be disclosed to others without written authorization from Foresee 
Pharmaceuticals Co., Ltd, except to the extent necessary to obtain informed consent from those persons to whom 
the study drug may be administered. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 2 of 100 
 
 
KEY STUDY PERSONNEL 
PRINCIPAL INVESTIGATOR: 
, pulmonologist – 
clinical pharmacologist 
QPS Netherlands B.V. 
Hanzeplein 1, entrance 53 
9713 GZ Groningen 
The Netherlands 
 
 
Amsterdam UMC, University of Amsterdam 
K0-150, Depts. Respiratory Medicine and 
Experimental Immunology 
Meibergdreef 9 
1105 AZ Amsterdam 
The Netherlands 
 
COLLABORATING PARTIES / 
 clinical 
SUB-INVESTIGATORS: 
pharmacologist 
QPS Netherlands B.V. 
Hanzeplein 1, entrance 53 
9713 GZ Groningen 
The Netherlands 
 
, pulmonologist 
Amsterdam UMC, University of Amsterdam 
F5-149, Dept. Respiratory Medicine 
Meibergdreef 9 
1105 AZ Amsterdam 
The Netherlands 
 
, MD PhD, pulmonologist 
University Medical Center Groningen 
Dept of Respiratory Medicine 
Hanzeplein 1 
9713 GZ Groningen 
The Netherlands 
 
CLINICAL FACILITY: 
QPS Netherlands B.V. 
Hanzeplein 1, entrance 53 
9713 GZ Groningen 
The Netherlands 
 
Amsterdam UMC, University of Amsterdam 
C2, Lung Function Laboratory 
Meibergdreef 9 
1105 AZ Amsterdam 
The Netherlands 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 3 of 100 
 
 
CLINICAL LABORATORY: 
KCL Bioanalysis B.V. 
Borniastraat 34 
8934 AD Leeuwarden 
PO Box 850 
8901 BR Leeuwarden 
The Netherlands 
 
Academic Medical Centre, Amsterdam 
G1-110, Dept. Experimental Immunology 
Meibergdreef 9 
1105 AZ Amsterdam 
The Netherlands 
 
University Medical Center Groningen 
Dept. Laboratory Medicine, HPC EA40 
P.O. Box 30.001 
9700 RB Groningen 
The Netherlands 
 
BIOANALYTICAL: 
QPS Netherlands B.V. 
Petrus Campersingel 123 
9713 AG Groningen 
The Netherlands 
 
DATA MANAGEMENT: 
QPS Qualitix Taiwan 
5F., No. 12, Sec. 2 
Ren-Ai Road 
Taipei 
Taiwan 
 
PHARMACY: 
QPS Netherlands B.V. 
Petrus Campersingel 123 
9713 AG Groningen 
The Netherlands 
 
PHARMACOKINETIC ANALYSIS: 
QPS, LLC 
3 Innovation Way, Suite 240 
Newark, DE 19711 
USA 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 4 of 100 
 
 
STATISTICAL ANALYSIS: 
QPS Qualitix Taiwan 
5F., No. 12, Sec. 2 
Ren-Ai Road 
Taipei 
Taiwan 
 
EXTERNAL STATISTICAL 
, PhD 
CONSULTANT: 
Amsterdam UMC, University of Amsterdam 
Department 
of 
Clinical 
Epidemiology, 
Bioinformatics, and Biostatistics 
Meibergdreef 9 
1105 AZ Amsterdam 
The Netherlands 
 
SERIOUS ADVERSE EVENT 
QPS Safety Unit 
REPORTING: 
Parking 12 
8074 Raaba-Grambach 
Austria 
Email: safetyFP025@qps.com 
+43 316 25 8111 
 
MEDICAL MONITOR: 
 Chief Medical Officer 
Foresee Pharmaceuticals, Co. Ltd. 
001 408-823-4807 
 
 
ETHICS COMMITTEE: 
Stichting BEBO 
Stationsstraat 9 
9401 KV Assen 
The Netherlands 
 
SPONSOR: 
Foresee Pharmaceuticals Co., Ltd 
, Senior Vice President 
3F., No. 19-3, Sanchong Rd., NanKang District 
Taipei 115, Taiwan 
+1 650-518-9886 (US) 
 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 5 of 100 
 
 
1 SIGNATURE PAGE FOR SPONSOR 
Hereinafter called Foresee Pharmaceuticals Co., Ltd. 
 
Investigational drug name: FP-025 
Protocol number: FP02C-18-001 
 
 
 
 
Senior Vice-President 
08 September 2021 | 06:23 PDT 
Signature 
Date 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 6 of 100 
 
 
2 SIGNATURE PAGE FOR INVESTIGATOR 
 
Investigational drug name: FP-025 
Protocol number: FP02C-18-001 
 
I agree to the terms and conditions relating to this study as defined in this Protocol, electronic 
Case Report Form (eCRF), and any other protocol-related documents. I fully understand that 
any changes instituted by the investigator(s) without previous agreement with the sponsor 
would constitute a violation of the protocol, including any ancillary studies or procedures 
performed on study subjects (other than those procedures necessary for the well-being of the 
subjects). 
I agree to conduct this study in accordance with the Declaration of Helsinki and its 
amendments, International Conference on Harmonization (ICH) Good Clinical Practice (GCP) 
guidelines and applicable regulations and laws. In particular, I will obtain approval by an Ethics 
Committee or Institutional Review Board (EC/IRB) prior to study start and signed informed 
consent from all subjects included in this study. In addition, I will allow direct access to source 
documents and agree to inspection by auditors from the sponsor and Health Authorities. I will 
ensure that the study drug(s) supplied by the sponsor are being used only as described in this 
protocol. Furthermore, I confirm herewith that the sponsor is allowed to enter and utilize my 
professional contact details and function in an electronic database for internal purposes and for 
submission to worldwide Health Authorities. 
 
 
 
 
 
 
 
 
 
 
Principal Investigator 
 
 
 
 
 
Principal Investigator 
06 September 2021 | 08:56 EDT 
Signature 
Date 
08 September 2021 | 00:17 PDT 
Signature 
Date 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 7 of 100 
 
 
PROTOCOL CHANGES LOG 
Amendment 3, dated 06 September 2021, amendment 2 issued on 22 April 2021, 
amendment 1 issued on 09 August 2018, original protocol issued 05 March 2018. 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20EC of the European Parliament and the Council of the European Union. 
With this amendment, an interim analysis is added to compute the conditional power of a 
significant difference between FP-025 and placebo treatment at the planned end of the study, 
using unblinded data of at least 11 completed subjects. 
 
Section 
Update 
Header 
22 April06 September 2021, Amendment 23 
QPS Logo has been updated. 
Title page 
Document status version Amendment 23 
Date 22 April 06 September 2021 
Section 6.2.3 
Methacholine/Hist 
amine Challenge 
Although interacting with different receptors, both histamine and 
methacholine are regarded as ‘a direct agent’ by agonist’ producing 
bronchoconstriction as outlined in the international guidelines by 
leading societies (ATS/ERS)), and both have been (interchangeably) 
used to assess nonspecific airway hyperresponsiveness according to the 
same protocol in standard clinical practice as well as in the context of 
the allergen bronchoprovocation test [15, 16]. 
Section 8.3 
Inhaled allergen 
(HDM) challenge 
Subjects with an LAR will be contacted for a phone call check up by 
research staff usually within 24-48 hours after the challenge day, or 
otherwise at the discretion of the investigator. 
Section 8.4.2.1 
Baseline 
Characteristics 
• Hematology and clinical chemistry and urinalysis (refer to 
Section 8.4.4.78) 
Section 8.4.4.7 
Overall Asthma 
Symptoms 
Overall asthma symptoms will be assessed using a visual analogue scale 
(VAS). A standard VAS includes a scale of 100 mm. When a scale of 
another size is used, the values will be adjusted to match the 
standard VAS size of 100 mm. 
Section 8.9.2 
Treatment 
Assignment 
TheFor the purpose of an interim analysis (see Section 10.9), the 
randomization code of the subjects who have completed the study will 
be unblinded and made available for data analysis only. Unblinding of 
the randomization code will also apply after study closure, i.e., when 
the study has been fully completed, the protocol deviations determined 
and the clinical database declared complete, accurate, and locked. 
Section 8.9.3 
Double-blinding 
The study is performed in a double-blinded fashion. The investigator 
and study staff, the subjects, the monitors and the sponsor’s staff will 
remain blinded to the treatment until study closure. The investigational 
drug and  its  matching placebo  are  indistinguishable  and  medication 
containers will be packaged in the same way. The randomization code 
will be kept strictly confidential. It is accessible only to the  pharmacist 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 8 of 100 
 
 
 
on site, who is not involved in the conduct and analysis of the study, and 
will keep the randomization code/scheme strictly confidential. 
The investigator and research staff, the subjects, the monitors and 
the sponsor’s staff will remain blinded to the treatment until study 
closure. For the interim analysis (see Section 10.9), only the 
independent statistician will be unblinded to the study treatment of 
those subjects who have completed the study and have been 
included in the interim analysis. 
Section 10.1 
Statistical 
Analysis Plan 
A statistical analysis plan (SAP) will be written and finalized before the 
final study closure, i.e., database closure and unblinding of the 
randomization code of the study. The SAP will provide full details of 
the individual analyses, the data displays and the algorithms to be used 
for data derivations. A SAP for safety, tolerability and PD will be written 
by QPS Qualitix Taiwan. A PKAP for the PK analyses will be written 
by QPS LLC. All analyses on efficacy outcomes including their 
relationships 
or 
relationships 
between 
PK 
and 
PD/clinical/biomarker 
outcomes 
will 
be 
overseen 
by 
the 
independent statistician (Prof A.H. Zwinderman). 
The SAP will include the link of major protocol deviations/violations to 
the analysis sets. 
Section 10.2.1 
Sample Size 
The sample sizes for this study are based on previous allergen challenge 
studies [9] and previous local experiences including several outcomes 
(airway physiology and several (diluted) biomarkers), taking into 
account additional variability due to a 2 centercentre setup. 
Section 10.2.2 
Procedure for 
accounting for 
missing, unused, 
and spurious data 
In the calculation of percentages, subjects with missing data if not 
included in an analysis will not be considered in numerator or 
denominator unless otherwise specified. 
Section 10.3 
Pharmacodynamic 
Parameters 
Analyses of all other(including additional) PD parameters and any 
relationships between parameters will be detailed in the SAP. 
Section 10.8 
Exploratory 
Analyses 
Exploratory data-driven analyses can be performed at a later time point, 
i.e. after finalizing the CSR and can be later on added as an addendum 
later on. 
Section 10.9 
Interim Analysis 
After at least 11 subjects have successfully completed both 
treatment periods (with fully analyzable data sets of airway 
responses and sputum cytospins), an interim analysis will be 
conducted in order to compute the conditional power of a significant 
difference between FP-025 and placebo treatment on the LAR as 
well as on the sputum eosinophil counts (reflecting target 
engagement), at the planned end of the trial in the presence of 
sufficiently high PK levels and at the original expectation of the 
effect of FP-025 on the LAR. If the conditional power is less than 
25%, the trial may be stopped for futility. However, such a decision 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 9 of 100 
 
 
 
will depend on the size of the FP-025 treatment-effect on secondary 
and exploratory outcomes. 
In addition, the size of a potential carry-over effect of active 
treatment in the first treatment period into effects of treatment in 
the second treatment period will be investigated. If the size of the 
carry-over is larger than expected, the statistical analysis for the 
remaining subjects may be amended. 
No adjustment of the sample size is made because with the intended 
sample size of 32 evaluable subjects, the power of the original effect 
is over 95% and this remains the case with the addition of the 
interim analysis. 
In the absence of any clinically relevant AEs, recruitment and study 
conduct will continue during (preparation of) the interim analysis. 
Section 10.10 
Clinical Study 
Report 
The CSR will include the data and the analysis of both the primary and 
secondary parameters; exploratory parameters and analyses may be 
added later on in an addendum to the CSR later on. 
Section 12.1.3.2 
Database 
Management and 
Quality Control 
Any changes to the eCRF after that time require a database unlock and 
can only be made after receipt of written approval of the Sponsor. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 10 of 100 
 
 
Amendment 2, dated 22 April 2021, amendment 1 issued on 09 August 2018, original 
protocol issued 05 March 2018. 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20EC of the European Parliament and the Council of the European Union. 
Currently, there is a ubiquitous shortage of the raw materials to produce methacholine, 
making it difficult to obtain the methacholine needed for the methacholine challenges in this 
study. Methacholine will therefore be replaced by histamine, whenever there is an insufficient 
supply of methacholine. Both agents produce similar effects within the airways and in clinical 
practice are used interchangeably to document airway hyperresponsiveness. Importantly, both 
are well-documented in connection to bronchial allergen challenge. Within the study, subjects 
will receive either methacholine or histamine. 
 
Section 
Update 
Header 
09August 201822 April 2021, Amendment 12 
Title page 
Document status version Amendment 12 
Date 09August 201822 April 2021 
Key Study 
Personnel 
The order of the collaborating parties/sub-investigators was updated: 
Khalid Adb-Elaziz was placed before Els Weersink. 
Abbreviations 
Added: 
PC20FEV1(Hist): Provocative concentration of histamine causing a 
20% fall in FEV1 
Section 5 Protocol 
Synopsis 
Secondary objectives: 
• To determine the treatment effect (i.e. Day 1 versus Day 10) of 
multiple oral doses of FP-025 versus placebo on baseline 
parameters (such as blood eosinophils, FeNO and 
PC20methacholine). PC20FEV1(Meth)/PC20FEV1(Hist)). 
Section 5 Protocol 
Synopsis 
Secondary endpoints: 
o Airway hyperresponsiveness expressed as PC20FEV1(Meth) or 
PC20FEV1(Hist) (Day 10-Day 12); 
• Potential treatment effect (FP-025 versus placebo) on baseline 
parameters (i.e. Day 1 versus Day 10), including: 
o Blood eosinophils; 
o PC20FEV1(Meth) or PC20FEV1(Hist); 
o FeNO. 
Exporatory endpoints: 
• Potentially longer lasting treatment effects 14 days following 
Period 2 (FP-025 versus placebo) (spirometry (baseline FEV1), 
PC20FEV1(Meth) or PC20FEV1(Hist) and airway and systemic 
biomarkers (i.e. blood/urine/exhaled air (FeNO, EBC), NAL/NAB; 
sputum). 
Section 5 Protocol 
Synopsis 
Summary of Study Design 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 11 of 100 
 
 
 
On 
Screening 
Day 
2, 
spirometry 
with 
subsequent 
methacholine/histamine 
challenge 
(for 
calculation 
of 
the 
PC20FEV1(Meth) or PC20FEV1(Hist)) will be performed, followed by 
sputum induction (SI). 
Following a washout period of at least 3 weeks and up to approximately 
7 weeks, eligible subjects will be enrolled into the study and randomized 
on Day 1 if their asthma is within continuation criteria of screening (as 
assessed by history, (rescue) medication use, baseline FEV1 and 
PC20FEV1(Meth) or PC20FEV1(Hist)). 
On Day 1, after a short checklist, the following tests will be performed 
for baseline purposes, i.e. blood and urine sampling (both for routine 
safety and biomarkers), FeNO, IOS (if logistics allow), spirometry, 
EBC, NAL, NAB, methacholine/histamine challenge (with calculation 
of PC20FEV1(Meth) or PC20FEV1(Hist) for stability/eligibility check) 
and SI. 
On Day 1 of Period 1, subjects should still have stable asthma (based on 
continuation criteria as applicable in the allergen challenge: i.e. 
history/medication 
use/spirometry 
and 
PC20Methacholine 
PC20FEV1(Meth)/PC20FEV1(Hist)) in order to be randomized by a 
blinded pharmacist and start with the study drug administration. 
On Day 10 (i.e. approximately 24 hours pre-allergen), approximately 
30-60 minutes after first daily dosing, subjects undergo the same 
procedures as on Day 1 (i.e. safety/stability check, blood and urine 
collection (biomarkers), FeNO, EBC, NAL, NAB, IOS (if logistics 
allow), spirometry, methacholine/histamine challenge and SI. 
Fourteen (14) days (± 2 days) after final administration of FP-025 or 
placebo on Day 12 of Period 2, a follow-up visit will be scheduled. This 
visit will not only serve as a follow-up visit (e.g. checking weight and 
AEs, performing physical examination, ECG and pregnancy test, 
checking vital signs and collecting blood for clinical safety laboratory 
assessments), the ‘duration of efficacy’ will also be explored by 
performing the same procedures as performed on Day 1 and Day 10 (i.e. 
blood and urine samplings (safety/biomarkers), FeNO, EBC, NAL, 
NAB, IOS (if logistics allow), spirometry, methacholine/histamine 
challenge and SI). 
Section 5 Protocol 
Synopsis 
Inclusion criteria 
8 
On Screening Day 2, PC20FEV1(Meth) should be <16 mg/mL if 
methacholine chloride is used (or adjusted by a factor of 1.2 if 
methacholine bromide is used). If histamine is used, PC20FEV1(Hist) 
should be <16 mg/mL. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 12 of 100 
 
 
 
Section 5 Protocol 
Synopsis 
Pharmacodynamic parameters 
Secondary parameters 
Methacholine/histamine challenge: 
• Provocative concentration of methacholine or histamine causing 
20% fall of the FEV1 from baseline (PC20FEV1(Meth) or 
PC20FEV1(Hist)) 
Exploratory parameters 
Impulse-oscillometry (IOS) post-metacholinemethacholine/histamine 
challenge 
Section 5 Protocol 
Synopsis 
Statistical methodology 
Pharmacodynamics 
• Changes in allergen-induced AHR: i.e: PC20FEV1(Meth) or 
PC20FEV1(Hist) pre-post allergen (Day 10 versus Day12) 
• Changes in blood eosinophils, FeNO and PC20FEV1(Meth) or 
PC20FEV1(Hist) Day 1 versus Day 10 (potential treatment effect) 
Exploratory 
• Treatment effects: differences in changes in the following 
parameters (Day 1 versus Day 10): spirometry (baseline FEV1), 
PC20FEV1(Meth)/PC20FEV1(Hist) and airway and systemic 
biomarkers (i.e. in blood/urine/exhaled air (FeNO, EBC), 
NAL/NAB; sputum). 
• Potentially longer lasting treatment effects 14 days following Period 
2 (spirometry (baseline FEV1), PC20FEV1(Meth)/PC20FEV1(Hist) 
and airway and systemic biomarkers (i.e. in blood/urine/exhaled air 
(FeNO, EBC), NAL/NAB; sputum). 
• IOS measurements following inhaled allergen and eventual 
methacholine/histamine challenges to assess the effect of study 
medication on the peripheral airways and for additional safety. 
Table 5-1: Visit 
and Assessment 
Schedule 
Methacholine/histamine challenge 
Footnote 
b: 
FeNO, 
EBC, 
NAL, 
NAB, 
spirometry, 
methacholine/histamine challenge and SI to be performed in the 
morning (pre-dose). On Day 1, spirometry will be performed 
immediately after FeNO (since eligibility criterion). 
Footnote 
e: 
By 
Medical 
history/Medication 
use/FEV1 
and 
PC20methacholine PC20FEV1(Meth)/PC20FEV1(Hist). 
Footnote l: To be performed before and after inhaled allergen challenge 
and methacholine/histamine challenge and after administration of 
ventolin. 
Footnote m: To be performed after eligibility check (including FEV1) 
and methacholine/histamine challenge with subsequent 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 13 of 100 
 
 
 
PC20FEV1(Meth) or PC20FEV1(Hist) calculation on Day 1 of 
Treatment Period 1. 
Section 6.2 Study 
Rationale 
Added: 
Section 6.2.3 Methacholine/Histamine Challenge 
Currently, there is a ubiquitous shortage of the raw materials to 
produce methacholine, making it difficult to obtain the 
methacholine needed for the methacholine challenges in this study. 
In case of insufficient supply of methacholine, histamine will be used 
instead in this study. 
Although interacting with different receptors, both histamine and 
methacholine are regarded as ‘a direct agent’ by agonist’ producing 
bronchoconstriction as outlined in the international guidelines by 
leading societies (ATS/ERS)), both have been (interchangeably) 
used to assess nonspecific airway hyperresponsiveness according to 
the same protocol in standard clinical practice as well as in the 
context of the allergen bronchoprovocation test [15, 16]. 
Furthermore, both histamine (which was historically the first agent) 
and methacholine have been used to predict the allergen PC20 in a 
similar way [9, 16]. Therefore, switching to histamine will not harm 
the subject safety nor the study objectives, particularly as the 
allergen-induced airway response on several (bio)markers will be 
compared within subjects. To allow for scientifically sound within- 
subject comparisons, whenever possible, subjects will receive the 
same challenge agent (i.e. methacholine or histamine) throughout 
the study. Both methacholine and histamine challenges will be 
performed 
according 
to 
the 
QPS 
standard 
operating 
procedures/work instructions in line with the above-mentioned 
international guidelines. 
Section 7.2 
Secondary 
Objectives 
To determine the treatment effect (i.e. Day 1 versus Day 10) of multiple 
oral doses of FP-025 versus placebo on baseline parameters (such as 
blood 
eosinophils, 
FeNO 
and 
PC20methacholine). 
PC20FEV1(Meth)/PC20FEV1(Hist)). 
Section 8.1.2 
Secondary 
Endpoints 
o Airway hyperresponsiveness expressed as PC20FEV1(Meth) or 
PC20FEV1(Hist) (Day 10-Day 12); 
• Potential treatment effect (FP-025 versus placebo) on baseline 
parameters (i.e. Day 1 versus Day 10), including: 
o Blood eosinophils; 
o PC20FEV1(Meth) or PC20FEV1(Hist); 
o FeNO. 
Section 8.1.3 
Exploratory 
Endpoints 
• Potentially longer lasting treatment effects 14 days following 
Period 2 (FP-025 versus placebo) (spirometry (baseline FEV1), 
PC20FEV1(Meth) or PC20FEV1(Hist) and airway and systemic 
biomarkers (i.e. blood/urine/exhaled air (FeNO, EBC), NAL/NAB; 
sputum). 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 14 of 100 
 
 
 
Section 8.2 
Overall Study 
Design 
On 
Screening 
Day 
2, 
spirometry 
with 
subsequent 
methacholine/histamine 
challenge 
(for 
calculation 
of 
the 
PC20FEV1(Meth) or PC20FEV1(Hist)) will be performed, followed by 
sputum induction (SI). 
Following a washout period of at least 3 weeks and up to approximately 
7 weeks, eligible subjects will be enrolled into the study and randomized 
on Day 1 if their asthma is within continuation criteria of screening (as 
assessed by history, (rescue) medication use, baseline FEV1 and 
PC20FEV1(Meth) or PC20FEV1(Hist)). 
On Day 1, after a short checklist, the following tests will be performed 
for baseline purposes, i.e. blood and urine sampling (both for routine 
safety and biomarkers), FeNO, IOS (if logistics allow), spirometry, 
EBC, NAL, NAB, methacholine/histamine challenge (with calculation 
of PC20FEV1(Meth) or PC20FEV1(Hist) for stability/eligibility check) 
and SI. 
On Day 1 of Period 1, subjects should still have stable asthma (based on 
continuation criteria as applicable in the allergen challenge: i.e. 
history/medication 
use/spirometry 
and 
PC20Methacholine 
PC20FEV1(Meth)/PC20FEV1(Hist)) in order to be randomized by a 
blinded pharmacist and start with the study drug administration. 
On Day 10 (i.e. approximately 24 hours pre-allergen), approximately 
30-60 minutes after first daily dosing, subjects undergo the same 
procedures as on Day 1 (i.e. safety/stability check, blood and urine 
collection (biomarkers), FeNO, EBC, NAL, NAB, IOS (if logistics 
allow), spirometry, methacholine/histamine challenge and SI. 
Fourteen (14) days (± 2 days) after final administration of FP-025 or 
placebo on Day 12 of Period 2, a follow-up visit will be scheduled. 
This visit will not only serve as a follow-up visit (e.g. checking weight 
and AEs, performing physical examination, ECG and pregnancy test, 
checking vital signs and collecting blood for clinical safety laboratory 
assessments), the ‘duration of efficacy’ will also be explored by 
performing the same procedures as performed on Day 1 and Day 10 
(i.e. blood and urine samplings (safety/biomarkers), FeNO, EBC, 
NAL, NAB, IOS (if logistics allow), spirometry, 
methacholine/histamine challenge and SI). 
Section 8.3 
Inhaled allergen 
(HDM) challenge 
Continuation criteria allergen challenge: 
Furthermore, PC20FEV1(Meth) or PC20FEV1(Hist) on Day 1 of 
Period 1 should be within 1.5 doubling doses of Screening and on Day 
1 of Period 2 within 1 doubling dose of Day 1 of Period 1. Should the 
subject’s values on Day 1 of either study period fall outside these ranges, 
subject may be rescheduled depending on the cause and at the discretion 
of the investigator. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 15 of 100 
 
 
 
Section 8.4.2.1 
Baseline 
Characteristics 
Eligible subjects will furthermore be screened for the following baseline 
assessments/inclusion criteria: 
• Spirometry (refer to Section 8.4.3.5) 
• Methacholine/histamine challenge (refer to Section 8.4.3.6) 
Section 8.4.3.5 
IOS and 
Spirometry 
IOS: 
If logistics allow, IOS measurements will also be performed 
approximately 4-5 minutes before spirometric measurements scheduled 
on 
days 
without 
allergen 
challenge, 
or, 
in 
case 
of 
methacholine/histamine challenge, as defined in the respective 
SOPs/WIs. 
Section 8.3.4.6 
Methacholine 
Challenge 
Changed section title to: Methacholine/Histamine Challenge 
Methacholine/histamine challenge will be performed according to the 
SOP in line with current guidelines. When methacholine bromide is 
not available, histamine should be used for the challenge. Whenever 
possible, subjects should receive the same challenge agent (i.e. 
methacholine or histamine) throughout the study. 
Shortly, incremental doses of methacholine bromide/histamine will be 
inhaled for 2 minutes by tidal breathing at approximately 5 minutes 
intervals. The challenge will be discontinued if a fall in FEV1 of ≥20% 
from post-diluent baseline has been reached, or until the highest 
concentration has been administered. If a fall in FEV1 of ≥20% from 
baseline has been reached, a PC20FEV1(Meth) or PC20FEV1(Hist) will 
be calculated by extrapolation as defined in the manual/SOP/WI. After 
the challenge, subjects will be given salbutamol to aid recovery and lung 
function will be measured after approximately 15-30 minutes (as per 
manual/SOP/WI). 
Section 8.4.6 
Order of 
Assessments 
During the study periods, all protocol related-assessments will be 
conducted at the same time of the day +/- 1 hour. This means that, e.g. 
if the methacholine/histamine challenge has been conducted on Day 1 
at 10:00, then on Day 10 and 12 this should be done between 9-11 am 
(starting time); applicable for both study periods. 
Section 8.4.7 
Allowed Time 
Windows for PD, 
Safety and PK 
Assessments 
Scheduled time for exhaled air, EBC, NAL, NAB, IOS, spirometry, 
methacholine/histamine challenge and SI 
Section 8.5.1 
Inclusion Criteria 
8 
On Screening Day 2, PC20FEV1(Meth) should be <16 mg/mL if 
methacholine chloride is used (or adjusted by a factor of 1.2 if 
methacholine bromide is used). If histamine is used, PC20FEV1(Hist) 
should be <16 mg/mL. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 16 of 100 
 
 
 
Section 8.10.1 
Pharmacodynamic 
Parameters 
Secondary parameters 
Methacholine/histamine challenge: 
• Provocative concentration of methacholine or histamine causing 
20% fall of the FEV1 from baseline (PC20FEV1(Meth) or 
PC20FEV1(Hist)) 
Exploratory parameters 
Impulse-oscillometry (IOS) post-methacholine/histamine challenge 
Section 10.3 
Pharmacodynamic 
Parameters 
All FEV1 values post-allergen will be expressed as %fall from post- 
diluent baseline (FEV1) and the highest, technically satisfactory FEV1 
value per pre-defined time point will be included into analysis. This 
excludes additional time points from analysis (e.g. if between a time 
interval additional spirometry has been performed for safety reasons – 
these values do not need to be included into analysis). PC20FEV1(Meth) 
or PC20FEV1(Hist) will be calculated as defined in the SOP. Analyses 
of all other parameters will be detailed in the SAP. 
Secondary: 
• Changes in allergen-induced AHR: i.e: PC20FEV1(Meth) or 
PC20FEV1(Hist) pre-post allergen (Day 10 versus Day12) 
• Changes in blood eosinophils, FeNO and PC20FEV1(Meth) or 
PC20FEV1(Hist) Day 1 versus Day 10 (potential treatment effect) 
Exploratory: 
• Treatment effects: differences in changes in the following 
parameters (Day 1 versus Day 10): spirometry (baseline FEV1), 
PC20FEV1(Meth)/PC20FEV1(Hist) and airway and systemic 
biomarkers (i.e. in blood/urine/exhaled air (FeNO, EBC), 
NAL/NAB; sputum). 
• Potentially longer lasting treatment effects 14 days following Period 
2 (spirometry (baseline FEV1), PC20FEV1(Meth)/PC20FEV1(Hist) 
and airway and systemic biomarkers (i.e. in blood/urine/exhaled air 
(FeNO, EBC), NAL/NAB; sputum). 
• IOS measurements following inhaled allergen and eventual 
methacholine/histamine challenges to assess the effect of study 
medication on the peripheral airways and for additional safety. 
Section 11 
References 
15. Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave 
FE. (1978) Reproducibility and comparison of responses to inhaled 
histamine and methacholine. Thorax. 33(6): 705–710. 
16 Ravensberg AJ, Van Rensen ELJ, Grootendorst DC, De 
Kluijver J, Diamant Z, Ricciardolo FLM, Sterk PJ. (2007) Validated 
safety predictions of airway responses to house dust mite in asthma. 
Clin Exp Allergy 37(1):100-7. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 17 of 100 
 
 
Amendment 1, dated 09 August 2018, original protocol issued 05 March 2018. 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20EC of the European Parliament and the Council of the European Union. 
The address information was updated, additional IOS measurements were added, optional 
asthma symptoms evaluations using VAS were added, duration of the screening period was 
extended, the number and timing of phone calls was updated, prior and concomitant 
medications were further specified, an additional blood biomarker sampling was added, and a 
section on pregnancy was added. 
 
Section 
Update 
Header 
QPS: CS0290 – 160508160509 
05 March 201809August 2018, Version 1Amendment 1 
Title page 
Document status version Version 1Amendment 1 
Date 05 March 201809August 2018 
Key 
study 
personnel 
Prof. Zuzana Diamant, MD PhD, pulmonologist – clinical pharmacologist 
QPS Netherlands B.V. 
Petrus Campersingel 123 
Hanzeplein 1, entrance 53 
9713 AGGZ Groningen 
The Netherlands 
Rene Lutter, PhD 
Academic Medical Centre,Amsterdam UMC, University of Amsterdam 
Collaborating parties / Sub-investigators: 
Els Weersink 
Academic Medical Centre,Amsterdam UMC, University of Amsterdam 
Khalid Abd-Elaziz, MBBS MD, clinical pharmacologist 
QPS Netherlands B.V. 
Petrus Campersingel 123 
Hanzeplein 1, entrance 53 
9713 AGGZ Groningen 
The Netherlands 
Maarten van den Berge, MD PhD, pulmonologist 
Clinical Facility: 
QPS Netherlands B.V. 
Petrus Campersingel 123 
Hanzeplein 1, entrance 53 
9713 AGGZ Groningen 
Academic Medical Centre,Amsterdam UMC, University of Amsterdam 
C3, Lung Function Laboratory 
Prof. A.H. Zwinderman, PhD 
Academic Medical Centre,Amsterdam UMC, University of Amsterdam 
Depts. Respiratory Medicine and Experimental Immunology 
Department of Clinical Epidemiology, Bioinformatics, and Biostatistics 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 18 of 100 
 
 
 
QPS PVSafety Unit 
Email: safetypv@qps.com 
Email safetyFP025@qps.com 
Section 4, List of 
abbreviations 
PV Pharmacovigilance 
VAS Visual Analogue Scale 
Section 
5, 
Protocol 
synopsis 
Section 
8.1.2, 
Secondary 
endpoints 
Secondary endpoints: 
• Safety 
parameters 
include 
physical 
examination, 
clinical 
signs/symptoms reporting (MedDRA), (S)AEs, vital signs, lung 
function measurements, overall asthma symptoms, ECG and 
clinical safety laboratory outcomes (blood/urine). 
Section 
5, 
Summary 
of 
study design 
Section 
8.2, 
Overall 
study 
design 
Prior to the study, there will be a Screening period consisting of 3 clinic 
visits (within 9 daysapproximately 6 weeks) to test subject eligibility. 
On Screening Day 1, the following procedures will take place: signing of 
the informed consent, a check of the inclusion/exclusion criteria, medical 
history and demographics, physical examination, measurements of vital 
signs, height and weight, calculation of body mass index (BMI), blood 
sampling for blood eosinophils and clinical safety laboratory assessments, 
ECG, allergy testing and screening for drug and alcohol use, smoking (i.e. 
cotinine), pregnancy and HIV, Hepatitis B and Hepatitis C (i.e. serology). 
At the discretion of the Principal Investigator (PI) or sub-investigators, 
some Screening Day 1 assessments (e.g. safety lab/pregnancy test/drug 
screen/cotinine screen/physical examination) may be moved to and/or 
repeated on Screening Day 2 and/or Screening Day 3. 
AfterWithin approximately 40 days after Screening Day 1, potentially 
eligible subjects will start with more specific screening procedures (on 2 
separate days within 5 days).(Screening Day 2 and Screening Day 3), 
preferably within 5 days, but maximally within 8 days). Subjects will 
be called by a physician or research staff within approximately 1 week 
prior to Screening Day 2 to check their asthma stability/medication 
intake/general health status. On Screening Day 2, spirometry with 
subsequent 
methacholine 
challenge 
(for 
calculation 
of 
the 
PC20FEV1(Meth)) will be performed, followed by sputum induction (SI). 
If logistics allow, IOS will be added to spirometric measurements. On 
Screening Day 3, there will be an inhaled HDM challenge with airway 
response measurements (including IOS and spirometry) during and up to 
approximately 8 hours post-allergen. On completion of all response 
measurements following both inhalational challenges on Screening Day 
2 and 3, subjects will receive rescue bronchodilator medication and 
lung function will be measured. Upon leaving the clinic, all subjects will 
be provided with rescue medication (short acting beta2-agonist) to be used 
on an ‘as needed basis’ throughout the study. After every HDM challenge 
the patient will receive patient emergency instructionsIn addition, after 
each inhalational challenge, subjects will receive emergency 
instructions, and will be provided rescue medication (Ventolin). Within 
approximately 48 hours after Screening Day 3, subjects will be called 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 19 of 100 
 
 
 
by a physician or research staff to check their asthma status/rescue 
medication use and general health. 
Following a washout period of at least 3 weeks and up to approximately 7 
weeks, eligible subjects will be randomizedenrolled into the study. and 
randomized on Day 1 if their asthma is within continuation criteria of 
screening (as assessed by history, (rescue) medication use, baseline 
FEV1 and PC20FEV1(Meth)). The study will consist of two identical study 
periods of 12 treatment days each, separated by a washout period of at least 
3 weeks (and no more thanup to approximately 7 weeks). 
Subjects will be called by a physician or research staff within 
approximately 1 week prior to Day -1 of each study period to check 
their asthma stability/ medication intake/ general health status. On Day 
-1, the checks performed on Screening Day 1 (i.e. medical history (includes 
asthma medication use, Adverse Events and asthma stability check)), 
physical examination, vital signs, weight, ECG, blood collection for clinical 
safety laboratory assessments and drug, alcohol, cotinine and pregnancy 
testing) will be repeated to reconfirm eligibility. Subjects stay overnight 
in the unit at the discretion of the PI or subinvestigator. 
On Day 1, after a short checklist, the following tests will be performed for 
baseline purposes, i.e. blood and urine sampling (both for routine safety and 
biomarkers), FeNO, IOS (if logistics allow), spirometry, EBC, NAL, NAB, 
methacholine challenge (with calculation of PC20FEV1(Meth) for 
stability/eligibility check) and SI. 
On Day 1 of Period 1, subjects should still have stable asthma (based on 
history/AEscontinuation criteria as applicable in the allergen challenge: 
i.e. history/medication use/spirometry and PC20Methacholine) in order to 
be randomized by a blinded pharmacist and start with the study drug 
administration. Should a subject not comply to the stability criteria, 
(s)he may be rescheduled at the discretion of the (co)PI or co- 
Investigator, depending on the underlying cause. 
In the event study medication will be taken at home (between 6-10 am/pm), 
the subject will be contacted twice a day on dosing days to receive 
confirmation of study medication intake. 
On Day 10 (i.e. approximately 24 hours pre-allergen), approximately 30-60 
minutes after first daily dosing, subjects undergo the same procedures as on 
Day 1 (i.e. safety/stability check, blood and urine collection (biomarkers), 
FeNO, EBC, NAL, NAB, IOS (if logistics allow), spirometry, 
methacholine challenge and SI. Subjects stay overnight in the unit. On Day 
11, approx. 30-60 minutes after the morning dose, an inhaled allergen 
(HDM) challenge will be performed with airway response measurements 
(IOS and spirometry). During this study day, repeated PK sampling and 
blood biomarker sampling will be performed. IOS measurements, EBC, 
NAL and NAB will be performed at approximately 6.5 hours post allergen 
challenge. Subjects stay overnight in the unit. 
There will be a check on the subjects within 1 week after each study period 
orWithin approximately 72 hours after Day 12 of each study period, 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 20 of 100 
 
 
 
subjects will be called by a physician to check their asthma/medication 
intake/AEs and general health. If deemed necessary by the (co)PI, there 
may be another check on the subjects before and/or after each study 
period and in any case following drop-out (either by phone or if needed 
and in case of drop-out, onsite the clinic). 
Fourteen  (14)  days  (±   2   days)   after   final   administration   of FP-
025 or placebo on Day 12 of Period 2, a follow-up visit will be scheduled. 
This visit will not only serve as a follow-up visit (e.g. checking weight and 
AEs, performing physical examination, ECG and pregnancy test, checking 
vital signs and collecting blood for clinical safety laboratory assessments), 
the ‘duration of efficacy’ will also be explored by performing the same 
procedures as performed on Day 1 and Day 10 (i.e. blood and urine 
samplings (safety/biomarkers), FeNO, EBC, NAL, NAB, IOS (if logistics 
allow), spirometry, methacholine challenge and SI). 
Section 
5, 
Pharmacodyna 
mic parameters 
Impulse-oscillometry (IOS), post-allergen challenge, mainly: 
Exploratory parameters: 
Impulse-oscillometry (IOS) post-methacholine challenge 
Section 5, Safety 
parameters 
• Physical examination 
• (Optional) asthma symptoms evaluation (a VAS scale may be used 
for this purpose) 
• Clinical signs/symptoms reporting (MedDRA) 
• (S)AEs 
• Vital signs (HR, BP, temperature +/- SpO2) 
• Lung function measurements (FEV1, FEV1/FVC, PEF, IOS) 
Section 
8.10.2, 
Safety 
 
and 
tolerability 
parameters 
Section 
5, 
Statistical 
methodology 
• To explore the effect of study medications on gene-transcriptomics from 
NAB pre- versus post-allergen. 
• IOS measurements following inhaled allergen and eventual 
methacholine challenges to assess the effect of study medication on 
the peripheral airways and for additional safety. 
• Only the MedDRA (safety) and PK parameters will be reported 
descriptively; the others will be analyzed either by paired t-testings or 
by ANOVA. 
Section 
10.3, 
pharmacodynam 
ic parameters 
Section 5, Table 
5-1 
Screening within 9 days6 weeks 
(washout period of 3-7weeksapproximately 7 weeks between periods) 
S3a 
In-/exclusion criteriad 
Reconfirmation of Eligibilityde 
Footnotes were updated. 
PatientSubject instructions and/or diary reviewor 
Urine drug screen, alcohol breath test, cotinine screen moved from Day 10 
to Day 9. 
(Optional) overall asthma symptoms on Day 1, Day 10, Day 11, and Day 
12. 
Randomization on Day 1 
Optional ambulant visit <7 days after dosing on Day 12. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 21 of 100 
 
 
 
Check health status optional on Day S2, S3, and Day 9. On Day -1, 1, 
10, 11, and 12. 
Phone call on Day S2, S3, -1, 2-4 5, and 6-8 days after dosing. Optional 
on Day 9. 
Footnotes: 
a. Screening Day S3 should start within 5 days after Day S2. 
a. 
At the discretion of the PI or sub-investigator, Screening Day S1 some assessments (e.g. 
safety lab//pregnancy test/drug screen/cotinine screen/physical examination) can be 
moved to and/or repeated on Screening Day S2 and/or Screening Day S3. Screening Day 
S2 should start within approximately 40 days after Screening Day S1. Screening Day S3 
preferably should start within 5 days after Day S2 but maximally within 8 days after Day 
S2. 
b. 
FeNO, EBC, NAL, NAB, spirometry, methacholine challenge and SI to be performed in the 
morning (pre-dose); order of assessments depends on the day: on). On Day 1, spirometry will 
be performed immediately after FeNO (since eligibility criterion). 
d. 
Only on Screening Day S1, Screening Day S2 and Day-1 of Treatment Period 1. 
e. 
By Medical history/AEs/Medication use/FEV1 and PC20methacholine. 
j. 
IOS to be performed approximately 4-5 mins before all spirometric measurements during 
inhaled allergen challenge, in any case at baseline, after diluent, and t=0.5, 1, 2, 3, 4, 5, 6, 7 
and 8 hours after inhaled allergen challenge., and after rescue medication. If logistics allow, 
IOS will also be performed approximately 4-5 minutes before spirometric measurements 
on days without inhaled allergen challenge. 
k. 
Screening Day S3 and Day 11: spirometry to be performed t=0, (i.e. pre-allergen and 10 mins 
post-diluent) and 10, 20, 30, 45 minutes and t=1, 1.5, 2, 3, 4, 5, 6, 7 and 8 hours after inhaled 
allergen challenge. If required for safety, additional spirometry to be performed e.g. at t=2.5, 
3.5, 4.5, 5.5, 6.5 and 7.5 hours after inhaled allergen challenge. If at Screening, there is a fall 
of 10-15% from baseline at 8 hours post-allergen, FEV1 can be measured up to 9 h post- 
allergen. 
l. 
To be performed before and after inhaled allergen challenge and methacholine challenge 
and after administration of ventolin. 
m. 
To be performed after eligibility check (including FEV1) and methacholine challenge with 
subsequent PC20FEV1(Meth) calculation on Day 1 of Treatment Period 1. 
n. 
On Day 12 and at Follow-up, collected together with blood collection for clinical safety. 
On Day 11 together with pre-dose PK blood collection and approximately 6-7 hours post- 
allergen challenge. Additional PD blood sampling for PBMC collection only on Day 1 and 
Day 10. 
p. 
Collection times PK Day 11: (before first daily dose (t=0 hours), 1, 2, 4, 6, 8 and 9 hours post 
first daily dose). If clashing with other measurements then the efficacy measurements will 
prevail. At Follow-up, collected together with blood collection for clinical safety and 
biomarkers. 
q. 
Subjects have to stay overnight from Day -1 to Day 1 and from Day 10 to Day 12 for each 
period. An overnight stay from S2 to S3 is optional as is an overnight stay from Day 9 to 
Day 10. Residence is preferred, but depending on the personal situation of the subject (at the 
discretion of the investigator, including living far or close from the clinic) and his/her medical 
condition a subject may or may not stay overnight. Subjects can only be dismissed from the 
unit at the discretion of the investigator and with rescue medication, personalized written 
instructions on how and when to use the rescue medication and emergency phone numbers. 
s. Phone call by a physician or research staff will be performed within approximately 1 
week prior to Screening Day S2, within approximately 48 hours after Screening Day S3, 
within approximately 1 week prior to Day -1 of each treatment period, twice a day during 
the treatment periods when study medication is taken at home, within approximately 72 
hours after Day 12 of each treatment period and within approximately 1 week after 
dosing on Day 12 of each period. If deemed necessary by the (co)PI more frequent phone 
calls or check-up visits may be scheduled during Screening/study. 
Section 
6.2.2, 
Allergen 
challenge model 
Inhaled allergen challenge can be safely conducted in dedicated research 
settings with ample expertise and experience with this disease model and 
the management of acute bronchoconstriction. Safety aspects and rescue 
medication will be managed and customized per subject by the investigator 
[9], and may include anycombinations of the following: administration of 
rescue  medication  (i.e.  short-acting  beta2-agonist)  following  allergen 
challenge,  written  instructions,  emergency  phone  numbers,  a follow-up 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 22 of 100 
 
 
 
phone call and rescue medication; or any other safety measures as deemed 
necessary by the investigator. 
Section 
8.3, 
Inhaled allergen 
(HDM) 
challenge 
The allergen challenge will be conducted using a standardized technique 
with incremental doses of inhaled house dust mite (HDM) extract as 
described in the literature [9] and as further detailed in the standard 
operating procedure (SOP) and work instruction (WI). 
During the study, IOS recordings (see Section 8.4.3.5) will precede 
spirometric measurements, and hence, will be performed within 
approximately 4-5 min before actual spirometry time points at pre-, during 
and post-allergen challenge. 
PatientsSubjects with an LAR will be contacted for a phone call check up 
by research staff usually within 24-48 hours after the challenge day, or 
otherwise at the discretion of the investigator. 
During both study periods, generally, the 3 highest incremental doses of 
HDM extract will be used that provoked (an EAR and subsequently) a 
LAR during Screening. If during screening the EAR (and subsequent 
LAR) was reached following inhalation of 1 or 2 allergen doses, an 
additional lowestlower dose will (to complete in total 3 doses) may be 
added at the discretion of the investigator to ensure consistency of the 
procedure across subjects. All other However, safety will always prevail, 
meaning that in some cases, subjects will receive fewer allergen doses 
during Screening and the study periods. While allergen challenge 
(number and allergen concentrations) will be customized per subject, 
the same number and concentrations of allergen extract will be inhaled 
during both study periods by the same subject. All details will be 
described in the SOP and WI. 
Baseline FEV1 at least 70% of predicted value at Screening Day 2 
(inclusive) and FEV1 on Screening Day 3 within 10% (counted from the 
absolute value in litresliters) of Screening Day 2 and ≥65% predicted (and 
≥1.8 L). On Day 1 of Period 1, FEV1 should be within 10% (again from 
absolute value in litresliters) of Screening baseline FEV1 (i.e. mean baseline 
FEV1 Screening Day 2 and Screening Day 3; and ≥65% predicted (and ≥1.8 
L). Baseline FEV1 (in litresliters) in both study periods should be within 
10% and ≥65% predicted (and ≥1.8 L). 
Section 
8.4.2.2, 
Prior 
 
and 
concomitant 
medications 
All lung and anti-allergic medications and vaccines taken from 3 months 
prior to screening until EOS or started during the course of the study and 
all other medications taken from screening until EOS or started during 
the course of the study will be recorded on the Concomitant Medications 
page. 
Section 
8.4.3.1, 
Exhaled 
nitric 
oxide 
Fractionated nitric oxide (FeNO) will be measured from exhaled air by Niox 
Vero® device (Circassia, Oxford, United Kingdom) according to guidelines 
as detailed in our SOP/WI. 
Section 
8.4.3.2, 
Exhaled  breath 
condensate 
(EBC) 
Exhaled breath condensate will be collected according to our SOP/WI using 
an Ecoscreen condenser (CareFusion, San Diego, CA, United States). 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 23 of 100 
 
 
 
Analysis will be performed in the AMC according to local SOP. In addition, 
FP-025 concentration may be exploratively quantified in (some of) the 
samples. 
Section 
8.4.3.3, 
Nasal 
 lavage 
(NAL) 
Analysis will be performed in the AMC. 
Section 
8.4.3.4, 
Nasal 
brush 
(NAB) 
Processing, storage and analysis of the NAB samples will be described in 
the respective SOPs/WIs. Analysis will be performed in UMCG. 
Section 
8.4.3.5, 
IOS 
 
and 
Spirometry 
Spirometry 
Lung function tests will be performed with a standardized/calibrated 
spirometer according to the SOPs/WIs in line with current guidelines. 
IOS 
IOS measurements will be performed approximately 4-5 minutes before 
spirometry pre-all spirometric measurements during and after allergen 
challenge and post-, in any case at baseline, after diluent, and subsequently 
at 0.5, 1, 2, 3, 4, 5, 6, 7, 8 h post-allergen challenge and at recovery (post- 
salbutamol). If logistics allow, IOS measurements will also be performed 
approximately 
4-5 
minutes 
before 
spirometric 
measurements 
scheduled on days without allergen challenge, or, in case of 
methacholine challenge, as defined in the respective SOPs/WIs. 
Section 
8.4.3.6, 
Methacholine 
challenge 
Methacholine challenge will be performed according to the SOP in line with 
current guidelines. Shortly, incremental doses of methacholine bromide will 
be inhaled for 2 minutes by tidal breathing at approximately 5 minutes 
intervals. The challenge will be discontinued if a fall in FEV1 of ≥20% from 
post-diluent baseline has been reached, ofor until the highest concentration 
has been administered. If a fall in FEV1 of ≥20% from baseline has been 
reached, a PC20FEV1(Meth) will be calculated by extrapolation. as defined 
in the manual/SOP/WI. After the challenge, subjects will be dosed 
withgiven salbutamol to aid recovery. and lung function will be measured 
after approximately 15-30 minutes (as per manual/SOP/WI). 
Section 
8.4.3.7, 
Sputum 
induction 
Sputum induction will be performed according to guidelines as detailed in 
the SOPsSOP/WI. 
Sputum samples will be processed by a trained and qualified technician 
within 2 hours of induction onsite the respective research centrecenter, 
according to the SOPsSOP/WI. The cell pellets will be cytospinned and 
supernatants will be frozen in tubes pending analysis. Staining (DiffQui(c)k 
or Giemsa (when required)) of the cytospins and differential cell counts in 
addition to analysis of soluble biomarkers from the supernatants will be 
performed in the AMC according to respective SOPs. 
Section 
8.4.4.6, 
Allergy testing 
Allergy testing will include at least the following allergens: house dust mite 
(D. Pteronyssinus/ D. farinae), animal dander (at least cat, and dog and 
horse), fungi (Asp Fumigatus, Alternaria Alternata), and pollen (grass, 
trees, Artemisia Vulgaris). 
Section 
8.4.4.7, 
Overall asthma 
symptoms 
Overall asthma symptoms will be assessed using a visual analogue scale 
(VAS). 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 24 of 100 
 
 
 
Section 
8.4.6, 
Order 
of 
assessments 
Blood biomarker sampling (eosinophils and biomarkers): Day 1; Day 10 
(together with the safety lab); Day 11 (together with pre-dose PK 
measurements) and approximately 6-7 hours post-allergen challenge; 
Day 12; and at Follow-up (together with the safety lab). 
Section 
8.4.11, 
Total 
blood 
volume 
Table 8-2: Blood volume 
Vol x Frequency 
Total (mL) 
Blood Chemistry (incl. virus 
serology, pregnancy testing) 
4.5 mL x 108 and 3.5 
mL x 1 
45.039.5 mL 
Hematology 
3.0 mL x 8 
24.0 mL 
Coagulation 
2.7 mL x 8 
21.6 mL 
PK 
6.0 mL x 15 
90.0 mL 
PD (inflammation markers 
and biomarkers) 
43.0 mL x 911 (EDTA) 
     
and 
3.5.0 mL x 911 (serum) 
and 4.0 mL x 
11(heparin) 
81.0115.5 mL 
PD (PBMC) 
2018.0 mL x 4 
(heparineheparin) 
8072.0 mL 
Total blood volume 
341362.6 mL 
Section 
8.6.2, 
Rescue 
medication 
On Screening Day 3, all patientssubjects will be provided with a short 
acting beta2-agonist (100 µg salbutamol/dose). PatientsSubjects will be 
instructed to use it throughout the study as rescue medication on an ‘as 
needed basis’. 
Section 
8.6.6, 
Study 
drug 
administration 
In the event the study medication is taken at home the number of capsules 
taken will be recorded in patienta subject dairy. 
Section 
8.10.2, 
Safety 
 
and 
tolerability 
parameters 
• Overall asthma symptoms (VAS) 
• Lung function measurements (FEV1, FEV1/FVC, PEF, IOS) 
Section 
9.1.5, 
Follow-up 
of 
adverse events 
Adverse events still ongoing 96 hours after drug intake must be followed 
until resolution, or to a maximum of 28 days after study drug 
discontinuation. 
If an AE is present at the follow-up visit/ end-of-study visit, it should be 
followed to resolution or stabilization unless the subject is lost to follow- 
up. Resolution means the subject has returned to baseline state of 
health or the Investigator does not expect any further improvement or 
worsening of the event. 
Section 
9.2.1.2, 
Pregnancy 
All initial reports of pregnancy, including pregnancy outcome (follow- 
up) in female subjects or in partners of male subjects, must be reported 
to the QPS Safety Unit (SU) by the investigator within 24 hours of 
his/her knowledge of the event using a Pregnancy Form. 
The investigator will contact the subject at the expected time of delivery 
for follow-up. Abnormal pregnancy outcomes (e.g., spontaneous or 
induced abortion, stillbirth, neonatal death, congenital abnormality, 
birth defect) are considered SAEs and must be reported using the 
Serious Adverse Event Form. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 25 of 100 
 
 
 
Section 9.2.2.1 
Before 
study 
drug initiation 
Serious adverse events occurring after signature of the Informed Consent 
and up to study drug initiation must be reported to QPS PVSafety unit only 
if they are considered by the investigator to be related to study- mandated 
procedures. 
Section 
9.2.2.3, 
After study drug 
discontinuation 
Therefore, these treatment-emergent SAEs are entered both in the Foresee 
Pharmaceuticals Co., LtdQPS drug safety and clinical databases, and must 
be reconciled before study closure. 
Section 
9.2.2.4, 
Reporting 
procedures 
All SAEs must be reported by the investigator to QPS PVSafety unit within 
24 hours of the investigator's knowledge of the event. 
These SAE forms must be e-mailed to QPS PVSafety unit (see contact 
details page 4). The investigator must complete the SAE form in English 
(unless otherwise specified) and assess the relationship to study drug. 
Follow-up information about a previously reported SAE must also be 
reported within 24 hours of receiving it. QPS PVSafety unit may contact 
the investigator to obtain further information. 
Suspected (considered related to the study drug) and Unexpected (not 
previously described in the reference safety document), Serious Adverse 
Reactions (SUSARs) will be expedited by QPS PVSafety unit to Health 
Authorities, ECs/IRBs and investigators, as appropriate. SUSARs will not 
be subject to systematic unblinding. 
Section 
9.2.2.5, 
Procedure 
for 
unblinding 
of 
serious 
suspected 
adverse 
reactions 
The unblinding procedure for serious suspected adverse reactions is 
defined in the safety management plan. 
Section 
9.2.3, 
Follow-up 
of 
serious adverse 
events 
New SAEs occurring at any time after the End-of-Study or after the 28-day 
follow-up period after study drug discontinuation (whichever comes first) 
may be reported to QPS PVSafety unit within 24 hours of the investigator's 
knowledge of the event, if felt appropriate by the investigators. 
Section 
10.4, 
Safety 
and 
tolerability 
parameters 
The medical history is coded using the MedDRA version 20.1 or higher 
and listed. 
All AEs and SAEs are coded using the MedDRA version 20.1 or higher. 
The number and percentage of patientssubjects who experienced AEs 
coded with the same preferred term and SOC will be summarized by 
treatment group (in descending order according to the incidence in the 
investigational study drug group). 
Section 
10.7, 
Baseline 
characteristics 
and concomitant 
medications 
Summary statistics (mean, median, SD, min, max, number of available 
observations) will be provided for continuous demographic variables (e.g., 
age, height, weight). Individual patientsubject listings of demographic data 
will be provided. 
Qualitative demographic characteristics (gender, race) will be summarized 
by counts and percentages. Other baseline patientsubject characteristics 
(medical history, physical examination clinical findings, previous 
medications, inclusion/exclusion checklist) will only be listed. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 26 of 100 
 
 
3 TABLE OF CONTENTS 
1 
Signature Page for Sponsor ................................................................................................ 5 
2 
Signature Page for Investigator .......................................................................................... 6 
Protocol Changes Log ................................................................................................................ 7 
3 
Table of Contents ............................................................................................................. 26 
4 
List of Abbreviations ....................................................................................................... 31 
5 
Protocol Synopsis ............................................................................................................ 34 
6 
Introduction and Rationale ............................................................................................... 52 
6.1 
Introduction ............................................................................................................... 52 
6.2 
Study Rationale ......................................................................................................... 55 
Dose Selection ................................................................................................... 56 
Allergen Challenge Model ................................................................................. 56 
Methacholine/Histamine Challenge ................................................................... 57 
7 
Study Objectives .............................................................................................................. 58 
7.1 
Primary objective ...................................................................................................... 58 
7.2 
Secondary objectives ................................................................................................. 58 
7.3 
Exploratory objectives ............................................................................................... 58 
8 
Study Design .................................................................................................................... 59 
8.1 
Endpoints ................................................................................................................... 59 
Primary Endpoint ............................................................................................... 59 
Secondary Endpoints ......................................................................................... 59 
Exploratory Endpoints ....................................................................................... 59 
8.2 
Overall Study Design ................................................................................................ 60 
8.3 
Inhaled allergen (HDM) challenge ............................................................................ 62 
8.4 
Study Assessments .................................................................................................... 63 
Informed Consent ............................................................................................... 63 
Baseline Characteristics and Concomitant Medications .................................... 63 
8.4.2.1 
Baseline Characteristics .............................................................................. 63 
8.4.2.2 
Prior and Concomitant Medications ........................................................... 64 
Pharmacodynamic Assessments ........................................................................ 64 
8.4.3.1 
Exhaled nitric oxide .................................................................................... 64 
8.4.3.2 
Exhaled breath condensate (EBC) .............................................................. 64 
8.4.3.3 
Nasal lavage (NAL) .................................................................................... 64 
8.4.3.4 
Nasal brush (NAB) ..................................................................................... 65 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 27 of 100 
 
 
8.4.3.5 
IOS and Spirometry .................................................................................... 65 
8.4.3.6 
Methacholine/Histamine Challenge ........................................................... 65 
8.4.3.7 
Sputum Induction ....................................................................................... 65 
Safety and Tolerability Assessments ................................................................. 66 
8.4.4.1 
Adverse Events ........................................................................................... 66 
8.4.4.2 
Vital Signs .................................................................................................. 66 
8.4.4.3 
Weight, Height and BMI ............................................................................ 66 
8.4.4.4 
12-lead ECG ............................................................................................... 66 
8.4.4.5 
Physical Examination ................................................................................. 66 
8.4.4.6 
Allergy testing ............................................................................................ 67 
8.4.4.7 
Overall Asthma Symptoms ......................................................................... 67 
8.4.4.8 
Laboratory Assessments ............................................................................. 67 
Pharmacokinetic Assessments ........................................................................... 67 
8.4.5.1 
Timing for Sampling................................................................................... 67 
8.4.5.2 
Procedures for Sampling ............................................................................ 68 
8.4.5.3 
Labeling ...................................................................................................... 68 
8.4.5.4 
Shipping Procedures ................................................................................... 68 
8.4.5.5 
Bioanalysis.................................................................................................. 68 
Order of Assessments ........................................................................................ 68 
Allowed Time Windows for PD, Safety and PK Assessments .......................... 69 
Drug and Cotinine Screen .................................................................................. 69 
Pregnancy Test ................................................................................................... 69 
Serology ............................................................................................................. 69 
Total Blood Volume .......................................................................................... 69 
Blood Sample Storage ........................................................................................ 70 
8.5 
Study Population ....................................................................................................... 70 
Inclusion Criteria ............................................................................................... 70 
Exclusion Criteria .............................................................................................. 71 
Diet, Activities, and Other Restrictions ............................................................. 71 
8.5.3.1 
Concomitant Medication ............................................................................ 71 
8.5.3.2 
Alcohol and Party Drugs ............................................................................ 72 
8.5.3.3 
Physical Activities ...................................................................................... 72 
8.5.3.4 
Travelling.................................................................................................... 72 
8.5.3.5 
Dietary Aspects ........................................................................................... 72 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 28 of 100 
 
 
8.5.3.6 
Smoking ...................................................................................................... 73 
8.5.3.7 
Concomitant allergies ................................................................................. 73 
8.5.3.8 
Contraception.............................................................................................. 73 
8.6 
Study Drugs ............................................................................................................... 73 
Investigational Drug and Matching Placebo ...................................................... 73 
Rescue Medication ............................................................................................. 74 
Study Drug Preparation ...................................................................................... 74 
Study Drug Packaging ....................................................................................... 74 
Study Drug Labeling .......................................................................................... 74 
Study Drug Administration ................................................................................ 74 
Storage and Return of the Study Drug ............................................................... 75 
8.7 
Study Drug Discontinuation and Study Withdrawal ................................................. 75 
Study Drug Interruption or Discontinuation ...................................................... 75 
Study Discontinuation ........................................................................................ 76 
Subject’s Follow-up after Study Discontinuation .............................................. 76 
8.8 
Treatment Exposure and Compliance ....................................................................... 76 
8.9 
Treatment Assignment and Blinding......................................................................... 76 
Assignment of Subject Numbers ....................................................................... 76 
Treatment Assignment ....................................................................................... 77 
Double-blinding ................................................................................................. 77 
Emergency Procedure for Unblinding ............................................................... 77 
8.10 Study Parameters ....................................................................................................... 78 
Pharmacodynamic Parameters ........................................................................... 78 
Safety and Tolerability Parameters .................................................................... 80 
Pharmacokinetic Parameters .............................................................................. 80 
9 
Safety Definitions and Reporting Requirements ............................................................. 81 
9.1 
Adverse Events .......................................................................................................... 81 
Definitions of Adverse Events ........................................................................... 81 
Intensity of Adverse Events ............................................................................... 81 
Relationship to Study Drug ................................................................................ 82 
Reporting of Adverse Events ............................................................................. 83 
Follow-up of Adverse Events ............................................................................ 83 
9.2 
Serious Adverse Events ............................................................................................. 83 
Definitions.......................................................................................................... 83 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 29 of 100 
 
 
9.2.1.1 
Serious Adverse Events .............................................................................. 83 
9.2.1.2 
Pregnancy ................................................................................................... 84 
9.2.1.3 
Hospitalization - Prolongation of Existing Hospitalization ........................ 84 
9.2.1.4 
Serious Adverse Events Related to Study-mandated Procedures ............... 84 
Reporting of Serious Adverse Events ................................................................ 84 
9.2.2.1 
Before Study Drug Initiation ...................................................................... 84 
9.2.2.2 
During Study Drug Administration ............................................................ 85 
9.2.2.3 
After Study Drug Discontinuation .............................................................. 85 
9.2.2.4 
Reporting Procedures ................................................................................. 85 
9.2.2.5 
Procedure for Unblinding of Serious Suspected Adverse Reactions.......... 85 
Follow-up of Serious Adverse Events ............................................................... 85 
10 Statistical Methodology and Analyses ............................................................................. 87 
10.1 Statistical Analysis Plan ............................................................................................ 87 
10.2 Analysis Sets ............................................................................................................. 87 
Sample Size ........................................................................................................ 87 
Procedure for accounting for missing, unused, and spurious data ..................... 87 
10.3 Pharmacodynamic Parameters .................................................................................. 88 
10.4 Safety and Tolerability Parameters ........................................................................... 89 
10.5 Pharmacokinetic Parameters ..................................................................................... 89 
Pharmacokinetic Statistical Analysis ................................................................. 89 
10.6 Exposure to Study Drug ............................................................................................ 90 
10.7 Baseline Characteristics and Concomitant Medications ........................................... 90 
10.8 Exploratory Analyses ................................................................................................ 90 
10.9 Interim Analysis ........................................................................................................ 90 
10.10 
Clinical Study Report ............................................................................................ 90 
11 References ........................................................................................................................ 92 
12 Procedures and Good Clinical Practice ........................................................................... 94 
12.1 Procedures ................................................................................................................. 94 
Protocol Amendments ........................................................................................ 94 
12.1.1.1 
Non-substantial Amendment ...................................................................... 94 
12.1.1.2 
Substantial Amendment .............................................................................. 94 
12.1.1.3 
Urgent Amendment .................................................................................... 94 
Monitoring ......................................................................................................... 95 
Data Management .............................................................................................. 95 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 30 of 100 
 
 
12.1.3.1 
Data Collection ........................................................................................... 95 
12.1.3.2 
Database Management and Quality Control ............................................... 96 
Recording of Data and Retention of Documents ............................................... 96 
Audit .................................................................................................................. 96 
Handling of Study Drug(s) ................................................................................. 97 
Publication of Study Results .............................................................................. 97 
Disclosure and Confidentiality .......................................................................... 97 
Premature Termination or Suspension of the Study .......................................... 97 
12.2 Good Clinical Practice .............................................................................................. 98 
Ethics and Good Clinical Practice ..................................................................... 98 
Quality Control and Quality Assurance ............................................................. 98 
Ethics Committee / Institutional Review Board ................................................ 98 
Informed Consent ............................................................................................... 98 
Compensation to Subjects and Investigators ..................................................... 99 
13 Structured Risk Analysis ............................................................................................... 100 
 
List of tables 
Table 5-1: Visit and Assessment Schedule .............................................................................. 47 
Table 8-1: Summary of Clinical Laboratory Tests .................................................................. 67 
Table 8-2: Blood Volume ........................................................................................................ 69 
Table 8–3: Study drug .............................................................................................................. 73 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 31 of 100 
 
 
4 LIST OF ABBREVIATIONS 
ADME 
Absorption, Distribution, Metabolism, Excretion 
AE 
Adverse Event 
AHR 
Airway hyperresponsiveness 
ALT 
Alanine aminotransferase/serum glutamic pyruvic transaminase (SGPT) 
AMC 
Academic Medical Centre 
AST 
Aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(SGOT) 
ATC 
Anatomic Therapeutic Chemical 
AUC 
Area Under the plasma concentration Curve 
AUC0-12h 
AUC from 0-12 hours 
AUC0-24h 
AUC from 0-24 hours 
AUC0-inf 
AUC from 0-infinity 
AUC0-tau 
AUC from 0-tau 
AUC0-t 
AUC from 0 to the last measurable concentration (t) 
AX 
Area under the reactance curve (IOS) 
BID 
Twice a day (Bis In Die) 
BMI 
Body Mass Index 
CHO 
Chinese Hamster Ovary 
Cmax 
Maximum plasma concentration 
CRO 
Contract Research Organization 
CV 
Coefficient of Variation 
CS 
Corticosteroids 
CYP 
Cytochrome P450 
EAR 
Early asthmatic response 
EBC 
Exhaled Breath Condensate 
EC 
Ethics Committee 
ECG 
Electrocardiogram 
eCRF 
Electronic Case Report Form 
EOS 
End-of-Study 
EudraCT 
European drug regulatory affairs Clinical Trials 
FeNO 
Fractional exhaled Nitric Oxide 
FEV1 
Forced expiratory volume in 1 second 
FEV1 AUC0-3h 
Area under the time-FEV1 response curve from zero to 3 hours post- 
allergen 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 32 of 100 
 
 
FEV1 AUC3-8h 
Area under the time-FEV1 response curve from 3 to 8 hours post-allergen 
FEV1 AUC0-8h 
Area under the time-FEV1 response curve from zero to 8 hours post- 
allergen 
Fres 
Resonant frequency (IOS) 
FVC 
Forced vital capacity 
GCP 
Good Clinical Practice 
GGT 
Gamma-glutamyltransferase 
GLP 
Good Laboratory Practice 
GMP 
Good Manufacturing Practice 
HDL 
High-density Lipoprotein 
HDM 
House dust mite 
HIV 
Human Immunodeficiency Virus 
HR 
Heart Rate 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
ILC 
Innate Lymphoid Cell 
IOS 
Impulse-oscillometry 
i.v. 
Intravenous(ly) 
IRB 
Institutional Review Board 
LAR 
Late asthmatic response 
LDL 
Low-density Lipoprotein 
LLOQ 
Lower Limit of Quantification 
MAD 
Multiple Ascending Dose 
MedDRA 
Medical Dictionary for Regulatory Activities 
MMP 
Metalloproteinase 
MPO 
Myeloperoxidase 
NAB 
Nasal Brush 
NAL 
Nasal Lavage 
NOAEL 
No Observed Adverse Effect Level 
PBMC 
Peripheral Blood Mononuclear Cell 
PC20FEV1(Hist) 
Provocative concentration of histamine causing a 20% fall in FEV1 
PC20FEV1(Meth) Provocative concentration of methacholine causing a 20% fall in FEV1 
P-gp 
P-glycoprotein 
PK 
Pharmacokinetics 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 33 of 100 
 
 
QC 
Quality Control 
RCE 
Coefficient of excretion 
RR 
Respiration rate 
R5 
Resistance of 5 Hertz (IOS) 
R20 
Resistance of 20 Hertz (IOS) 
R5-R20 
Frequency dependence of resistance (IOS) 
SAD 
Single Ascending Dose 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SI 
Sputum Induction 
SPT 
Skin Prick Testing 
SD 
Standard Deviation 
SOC 
System Organ Class 
SOP 
Standard Operating Procedure 
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
Tau 
Dosing interval 
TEAE 
Treatment-Related Adverse Event 
tmax 
Time to reach maximum plasma concentration 
VAS 
Visual Analogue Scale 
WHO 
World Health Organization 
X5 
Reactance at 5 Hertz (IOS) 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 34 of 100 
 
 
5 PROTOCOL SYNOPSIS 
 
TITLE 
The effect of FP-025, a MMP-12 inhibitor, on allergen-induced 
airway responses, airway inflammation and aspects of airway 
remodeling in subjects with mild eosinophilic house dust mite 
(HDM)-allergic asthma 
PHASE 
IIa 
CENTERS 
2 centers: 
• QPS Netherlands B.V., Groningen, The Netherlands 
• Academic Medical Centre (AMC), Depts. of Respiratory 
Medicine and Experimental Immunology, Amsterdam, The 
Netherlands 
INVESTIGATIONAL 
DRUG and DOSAGE 
FORM 
FP-025 in capsules of 50 mg each 
COMPARATIVE DRUG 
and DOSAGE FORM 
Matching placebo capsules 
ROUTE OF 
ADMINISTRATION 
Oral administration 
OBJECTIVES 
Primary objective: 
• To determine the effect of FP-025 versus placebo on the 
allergen (HDM)-induced late asthmatic response expressed 
as FEV1 AUC3-8h in subjects with clinically stable, mild 
allergic asthma and blood eosinophilia. 
Secondary objectives: 
• To determine the pharmacodynamics of FP-025 versus 
placebo on additional markers of airway physiology, 
including (additional measures of) the early and late 
response, airway hyperresponsiveness and small airways 
function; 
inflammatory 
markers 
(including 
blood 
eosinophils and FeNO) following inhaled HDM-challenge 
in subjects with clinically stable, mild allergic asthma and 
blood eosinophilia. 
• To determine the treatment effect (i.e. Day 1 versus Day 10) 
of multiple oral doses of FP-025 versus placebo on baseline 
parameters (such as blood eosinophils, FeNO and 
PC20FEV1(Meth)/PC20FEV1(Hist)). 
• To determine the safety and tolerability of multiple oral 
doses of FP-025 versus placebo in subjects with clinically 
stable, mild allergic asthma and blood eosinophilia. 
• To assess the pharmacokinetics of multiple oral doses of 
FP-025 following inhaled HDM-challenge in subjects with 
clinically stable, mild allergic asthma and blood 
eosinophilia. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 35 of 100 
 
 
 
Exploratory objectives: 
• To explore the effect of FP-025 versus placebo on: 
o 
Cellular and soluble inflammatory biomarkers in 
nasal lavage (NAL) and sputum; 
o 
Nasal gene and microRNA expression in nasal 
brush (NAB); 
o 
(Inflammatory) biomarkers in exhaled breath 
condensate (EBC), blood (eosinophil activation 
markers and potentially others as well) and urine 
(lipid mediators); 
o 
Functional in vitro responses of peripheral blood 
mononuclear cells (PBMC); 
o 
Expression and activity of MMP-12, other 
MMP’s and markers of tissue remodeling in 
blood, sputum and potentially in NAL. 
ENDPOINTS 
Primary endpoint: 
The primary endpoint of this study is the effect of study 
treatments on FEV1 AUC3-8h during the LAR (FP-025 versus 
placebo). 
Secondary endpoints: 
• Pharmacodynamic endpoints include the effect of study 
treatments on allergen (HDM)-induced changes in: 
o 
LAR expressed as max% fall in FEV1 from post- 
diluent baseline; 
o 
Early asthmatic response (EAR) expressed as 
FEV1 AUC0-3h; 
o 
EAR expressed as max% fall in FEV1 from post- 
diluent baseline; 
o 
Joint HDM-induced airway response expressed 
as AUC0-8h; 
o 
Airway 
hyperresponsiveness 
expressed 
as 
PC20FEV1(Meth) or PC20FEV1(Hist) (Day 10- 
Day 12); 
o 
Small airway parameters following HDM- 
challenge (i.e. R5, R20, R5-R20, AX, X5, Fres); 
o 
Fractionated nitric oxide (FeNO); 
o 
Blood eosinophils. 
• Potential treatment effect (FP-025 versus placebo) on 
baseline parameters (i.e. Day 1 versus Day 10), 
including: 
o 
Blood eosinophils; 
o 
PC20FEV1(Meth) or PC20FEV1(Hist); 
o 
FeNO. 
• Safety parameters include physical examination, 
clinical signs/symptoms reporting (MedDRA), (S)AEs, 
vital signs, lung function measurements, overall asthma 
symptoms, ECG and clinical safety laboratory outcomes 
(blood/urine). 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 36 of 100 
 
 
 
• Pharmacokinetic parameters of FP-025 in blood 
(plasma) include Cmax, tmax, and AUC0-tau. 
Exploratory endpoints: 
Exploratory pharmacodynamic parameters of FP-025 (Day 10 
versus Day 12 = treatment effect on HDM-induced (airway) 
responses; and Day 1 versus Day 10 = treatment effect on 
baseline parameters) include: 
• Cellular and soluble markers of inflammation in nasal 
lavage (NAL) and sputum, i.e.: eosinophil and 
lymphocyte counts, total cell counts, levels of ECP, 
MPO, IL-1b, FGF, VEGF and IL-5 and relative 
coefficient of excretion (RCE: ratio A2M in 
sputum/NAL relative to that in serum divided by the 
ratio of albumin sputum/NAL relative to that in serum); 
• Genome-wide gene and microRNA expression and 
DNA methylation in nasal brush (NAB) samples; 
• Biomarkers of oxidative stress and cellular activation in 
exhaled breath condensate (EBC); 
• Cellular 
(eosinophil 
activation) 
and 
soluble 
inflammatory mediators (IL-5) in blood; 
• Lipid 
mediators 
in 
urine 
(to 
be 
determined; 
leukotrienes); 
• Peripheral blood mononuclear cell (PBMC) counts and 
functional parameters (cytokine release; Elispot assay); 
• Expression and activity of MMP-12, other MMP’s and 
markers of tissue remodeling in blood, NAL and 
sputum; 
• Potentially longer lasting treatment effects 14 days 
following Period 2 (FP-025 versus placebo) (spirometry 
(baseline FEV1), PC20FEV1(Meth) or PC20FEV1(Hist) 
and 
airway 
and 
systemic 
biomarkers 
(i.e. 
blood/urine/exhaled air (FeNO, EBC), NAL/NAB; 
sputum). 
DESIGN 
A randomized, placebo-controlled, double-blind, 2-way cross- 
over, 2-centre study 
TREATMENTS 
Subjects will receive 400 mg FP-025 (8x 50 mg capsules, BID) 
or matching placebo (8 capsules, BID) from Day 1 (evening = 
first dose) to Day 12 (morning = last dose); a total of 22 doses 
per study period during two study periods. 
SUMMARY OF STUDY 
DESIGN 
Prior to the study, there will be a Screening period consisting of 
3 clinic visits (within approximately 6 weeks) to test subject 
eligibility. 
On Screening Day 1, the following procedures will take place: 
signing 
of 
the 
informed 
consent, 
a 
check 
of 
the 
inclusion/exclusion criteria, medical history and demographics, 
physical examination, measurements of vital signs, height and 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 37 of 100 
 
 
 
weight, calculation of body mass index (BMI), blood sampling 
for blood eosinophils and clinical safety laboratory assessments, 
ECG, allergy testing and screening for drug and alcohol use, 
smoking (i.e. cotinine), pregnancy and HIV, Hepatitis B and 
Hepatitis C (i.e. serology). At the discretion of the Principal 
Investigator (PI) or sub-investigators, some Screening Day 1 
assessments (e.g. safety lab/pregnancy test/drug screen/cotinine 
screen/physical examination) may be moved to and/or repeated 
on Screening Day 2 and/or Screening Day 3. 
Within approximately 40 days after Screening Day 1, 
potentially eligible subjects will start with more specific 
screening procedures (on 2 separate days (Screening Day 2 and 
Screening Day 3), preferably within 5 days, but maximally 
within 8 days). Subjects will be called by a physician or research 
staff within approximately 1 week prior to Screening Day 2 to 
check their asthma stability/medication intake/general health 
status. On Screening Day 2, spirometry with subsequent 
methacholine/histamine challenge (for calculation of the 
PC20FEV1(Meth) or PC20FEV1(Hist)) will be performed, 
followed by sputum induction (SI). If logistics allow, IOS will 
be added to spirometric measurements. On Screening Day 3, 
there will be an inhaled HDM challenge with airway response 
measurements (including IOS and spirometry) during and up to 
approximately 8 hours post-allergen. On completion of all 
response measurements following both inhalational challenges 
on Screening Day 2 and 3, subjects will receive rescue 
bronchodilator medication and lung function will be measured. 
Upon leaving the clinic, all subjects will be provided with rescue 
medication (short acting beta2-agonist) to be used on an ‘as 
needed basis’ throughout the study. In addition, after each 
inhalational challenge, subjects will receive emergency 
instructions, and will be provided rescue medication (Ventolin). 
Within approximately 48 hours after Screening Day 3, subjects 
will be called by a physician or research staff to check their 
asthma status/rescue medication use and general health. 
Following a washout period of at least 3 weeks and up to 
approximately 7 weeks, eligible subjects will be enrolled into 
the study and randomized on Day 1 if their asthma is within 
continuation criteria of screening (as assessed by history, 
(rescue) medication use, baseline FEV1 and PC20FEV1(Meth) 
or PC20FEV1(Hist)). The study will consist of two identical 
study periods of 12 treatment days each, separated by a washout 
period of at least 3 weeks (and up to approximately 7 weeks). 
Approximately 36 eligible subjects will be enrolled, to yield 32 
evaluable subjects who will be treated with both FP-025 (400 
mg BID) or placebo in a cross-over design from the evening of 
Day 1 till the morning of Day 12 (22 doses per study period in 
total). Based on a double-blind randomized schedule, 16 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 38 of 100 
 
 
 
subjects will receive placebo in Period 1 and FP-025 in Period 
2 and 16 subjects will receive FP-025 in Period 1 and placebo 
in Period 2. Both study periods will follow the same schedule of 
procedures. 
Subjects will be called by a physician or research staff within 
approximately 1 week prior to Day -1 of each study period to 
check their asthma stability/ medication intake/ general health 
status. On Day -1, the checks performed on Screening Day 1 
(i.e. medical history (includes asthma medication use, Adverse 
Events and asthma stability check)), physical examination, vital 
signs, weight, ECG, blood collection for clinical safety 
laboratory assessments and drug, alcohol, cotinine and 
pregnancy testing) will be repeated to reconfirm eligibility. 
Subjects stay overnight in the unit at the discretion of the PI or 
subinvestigator. 
On Day 1, after a short checklist, the following tests will be 
performed for baseline purposes, i.e. blood and urine sampling 
(both for routine safety and biomarkers), FeNO, IOS (if logistics 
allow), spirometry, EBC, NAL, NAB, methacholine/histamine 
challenge 
(with 
calculation 
of 
PC20FEV1(Meth) 
or 
PC20FEV1(Hist) for stability/eligibility check) and SI. 
On Day 1 of Period 1, subjects should still have stable asthma 
(based on continuation criteria as applicable in the allergen 
challenge: 
i.e. 
history/medication 
use/spirometry 
and 
PC20FEV1(Meth)/PC20FEV1(Hist)) in order to be randomized 
by a blinded pharmacist and start with the study drug 
administration. Should a subject not comply to the stability 
criteria, (s)he may be rescheduled at the discretion of the (co)PI 
or co-Investigator, depending on the underlying cause. 
Starting on Day 1 with an evening dose, FP-025 or placebo will 
be given over 12 days (BID from Day 2 up to and including Day 
11, final morning dose on Day 12) to ensure stable FP-025 
levels during Days 10-12 (outcome measure days). 
To aid compliance, during Day 2-9, subjects will either receive 
study medication onsite the clinic (observed dosing) or take 
their study medication at home or combinations of these. In the 
event study medication will be taken at home (between 6-10 
am/pm), the subject will be contacted twice a day on dosing 
days to receive confirmation of study medication intake. In 
addition, from Screening Day 3 onwards and during study, 
subjects will be keeping track of their rescue medication use and 
AEs in a diary. 
On Day 5 (+/- 1 day) subjects will return to the clinic for safety 
monitoring, study requirements compliances and observed 
study medication intake during morning or evening doses. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 39 of 100 
 
 
 
In the evening of Day 9, depending on their place of residence 
and asthma status, subjects will come onsite to the clinic to 
check and ensure asthma stability +/- undergo additional checks 
(safety lab/cotinine/alcohol/drug screen; as indicated in 
flowchart) before subsequent tests on Days 10-12. 
On Day 10 (i.e. approximately 24 hours pre-allergen), 
approximately 30-60 minutes after first daily dosing, subjects 
undergo the same procedures as on Day 1 (i.e. safety/stability 
check, blood and urine collection (biomarkers), FeNO, EBC, 
NAL, 
NAB, 
IOS 
(if 
logistics 
allow), 
spirometry, 
methacholine/histamine challenge and SI. Subjects stay 
overnight in the unit. On Day 11, approx. 30-60 minutes after 
the morning dose, an inhaled allergen (HDM) challenge will be 
performed with airway response measurements (IOS and 
spirometry). During this study day, repeated PK sampling and 
blood biomarker sampling will be performed. EBC, NAL and 
NAB will be performed at approximately 6.5 hours post allergen 
challenge. Subjects stay overnight in the unit. On Day 12 
(approximately 24 hours post-allergen), 30-60 minutes after the 
last study medication (i.e. morning) dose, the same procedures 
as on Day 10 will be repeated. Furthermore, clinical safety 
laboratory assessments will be performed. Clinically stable 
subjects will receive written instructions, including emergency 
numbers, and rescue medication prior to leaving the clinic. 
Within approximately 72 hours after Day 12 of each study 
period, subjects will be called by a physician to check their 
asthma/medication intake/AEs and general health. If deemed 
necessary by the (co)PI, there may be another check on the 
subjects before and/or after each study period and in any case 
following drop-out (either by phone or if needed and in case of 
drop-out, onsite the clinic). 
Fourteen (14) days (± 2 days) after final administration of FP-
025 or placebo on Day 12 of Period 2, a follow-up visit will be 
scheduled. This visit will not only serve as a follow-up visit 
(e.g. checking weight and AEs, performing physical 
examination, ECG and pregnancy test, checking vital signs and 
collecting blood for clinical safety laboratory assessments), the 
‘duration of efficacy’ will also be explored by performing the 
same procedures as performed on Day 1 and Day 10 (i.e. blood 
and urine samplings (safety/biomarkers), FeNO, EBC, NAL, 
NAB, 
IOS 
(if 
logistics 
allow), 
spirometry, 
methacholine/histamine challenge and SI). 
STUDY POPULATION 
Approximately 100 male and female HDM-allergic asthmatics 
(between 18 and 55 years of age at Screening, inclusive) will be 
screened to yield approximately 36 eligible subjects to be 
enrolled, to yield 32 evaluable subjects. 
INCLUSION CRITERIA 
The following criteria must be met by all subjects considered 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 40 of 100 
 
 
 
for study participation: 
1. Females or males, between 18 and 55 years of age at 
Screening, inclusive, on the day of signing the Informed 
Consent Form (ICF). 
2. Apart from a clinically stable asthma and HDM-allergy, 
subjects should be generally healthy with no history of a 
clinically relevant medical condition that in the opinion of 
the investigator might interfere with successful study 
conduct and no clinically relevant abnormalities on medical 
history, physical exam, vital signs, laboratory parameters or 
ECG at Screening. 
3. Subject has a BMI ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 (and 
weighs ≥50 kg). 
4. Subjects have been diagnosed with asthma cf GINA 
guidelines. 
5. Subjects should have established allergy for HDM (serum 
HDM-specific IgE or positive SPT at Screening or 
documented within 1 year pre-screening). 
6. No severe exacerbation of asthma within past 1 year 
requiring hospital admission and/or treatment with oral 
corticosteroids; no (never) intensive care admissions for 
asthma or intubation). 
7. FEV1 should be ≥70% of predicted on Screening Day 2. 
8. On Screening Day 2, PC20FEV1(Meth) should be <16 
mg/mL if methacholine chloride is used (or adjusted by a 
factor of 1.2 if methacholine bromide is used). If histamine 
is used, PC20FEV1(Hist) should be <16 mg/mL. 
9. Baseline blood eosinophils should be ≥150 cells/μL at 
Screening or documented within 3 months before Screening 
Day 1. 
10. Subjects should have a documented airway late response to 
inhaled HDM on Screening Day 3. 
11. Subjects of childbearing potential must be willing to use 
adequate contraception (double-barrier) or must refrain 
from intercourse. 
12. Female subjects of non-childbearing potential must have 
had ≥ 12 months of spontaneous amenorrhea (with follicle- 
stimulating hormone [FSH] ≥ 30 mIU/mL). Surgically 
sterile women are defined as those who have had a 
hysterectomy, bilateral ovariectomy (for ‘benign’ reasons), 
or bilateral tubal ligation. 
13. All female subjects should have a negative pregnancy test at 
Screening and on Day -1. 
14. Negative alcohol breath test on Screening Day 1 and Day - 
1. 
15. Negative cotinine test on Screening Day 1 and Day -1. 
16. Negative urine drug screen for recreational and other drugs 
on Screening Day 1 and Day -1. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 41 of 100 
 
 
 
17. Subjects are non-smokers. A non-smoker is defined as an 
individual who has abstained from smoking for at least 1 
year prior to Screening Day 1. Number of years smoked x 
number of packs per day should be <5 pack years. 
18. Subject should be willing and able to perform the lung 
function tests and other study-related procedures and 
comply with study protocol requirements. 
19. Subject should provide a signed and dated informed 
consent. 
EXCLUSION 
CRITERIA 
Subjects will be excluded if they meet any of the following 
criteria: 
1. Subject has any active and/or chronic (physical or mental) 
condition requiring maintenance (pharmaco)therapy or 
which otherwise precludes subject from safe or adequate 
study participation (ineligibility will be assessed by the PI). 
2. Subject has a history of cancer (exception: localized 
basalioma or cervix carcinoma in situ). 
3. Subject had any major (nasal) surgery in the 6 months before 
Screening Day 1. 
4. Subject is pregnant or lactating. 
5. Subject is using immunotherapy that according to the PI 
may interfere with the study (e.g. in case of immunotherapy 
with HDM or when subject is in the updosing phase of any 
immunotherapy). 
6. Subject regularly used alcohol (intake of >21 units/wk for 
males and >14 units/wk for females) and/or recreational 
drugs within the last 6 months prior to screening. 
7. Subject had any respiratory (viral) infections (e.g. common 
cold) within 3 weeks of Screening Day 1 or on Day -1. 
8. Subject is using maintenance asthma therapy or long-acting 
bronchodilators or any other anti-asthma or anti-allergic 
medications (as detailed in the protocol) other than 
infrequent use of SABA prn only. 
9. Subject is using prohibited medications as detailed in the 
protocol. 
10. Multi-sensitized symptomatic subjects with seasonal 
(pollen) allergies should be included outside of the relevant 
allergen season and/or should not be in frequent contact with 
the relevant allergen during the study. 
11. Subject has any known allergic response for the medications 
used or known severe allergic reactions or anaphylaxis (to 
food/medications/insect venoms). 
12. Subject participated in medical studies in the past 3 months 
(non-biologicals) or in the past 6 months (biologicals). 
13. Subject is anticipated not to comply with study medication 
or other aspects of the study (at the discretion of the 
investigator). 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 42 of 100 
 
 
 
BLOOD SAMPLING 
FOR PK 
Blood sampling for PK will take place at time points indicated 
in Table 5-1. 
PHARMACODYNAMIC 
PARAMETERS 
The following pharmacodynamic parameters for FP-025 will be 
evaluated/measured: 
Primary parameter: 
Spirometry: 
• Area under the time-FEV1 response curve from 3-8 
hours post-allergen (FEV1 AUC3-8h) 
Secondary parameters: 
Spirometry: 
• Area under the time-FEV1 response curve from 0-3 
hours post-allergen (FEV1 AUC0-3h) 
• Max% fall in FEV1 from baseline between 0-3 hours 
post-allergen 
• Max% fall in FEV1 from baseline between 3-8 hours 
post-allergen 
• Area under the time-FEV1 response curve from 0-8 
hours post-allergen (FEV1 AUC0-8h) 
Methacholine/histamine challenge: 
• Provocative concentration of methacholine or histamine 
causing 20% fall of the FEV1 from baseline 
(PC20FEV1(Meth) or PC20FEV1(Hist)) 
Impulse-oscillometry (IOS) post-allergen challenge, mainly: 
• Resistance at a frequency of 5 hertz (R5) 
• Resistance at a frequency of 20 hertz (R20) 
• Frequency dependence of resistance (R5-R20) 
• Resonant frequency (Fres) 
• Reactance at 5 hertz (X5) 
• Area under reactance curve (AX) 
Exhaled air: 
• Fractional exhaled nitric oxide concentration in exhaled 
air (FeNO) in parts per billion (ppb) 
Blood 
• Eosinophil counts 
Exploratory parameters: 
Impulse-oscillometry 
(IOS) 
post-methacholine/histamine 
challenge 
Nasal lavage (NAL): 
• Inflammatory and structural cell counts (cytospin): 
o Squamous and ciliated nasal epithelial cells 
o Total cells 
o Neutrophils 
o Eosinophils 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 43 of 100 
 
 
 
o Macrophages 
o Lymphocytes 
o Mast cells 
• Supernatant (soluble markers): 
o 
Cytokines (IL-1b, a.o.) and chemokines (e.g. 
Th2/ILC2 pathway and linked to eosinophils like 
IL-5, IL-33, a.o.) 
o 
Cellular activation markers (ECP, MPO, 
tryptase, chymase) 
o 
Markers of tissue remodeling (FGF, VEGF, 
MMP-12 and other MMP’s, to be determined) 
and leakage markers (e.g. albumin, alpha2- 
macroglobulin) 
Sputum: 
• Inflammatory and structural cell counts (cytospin): 
o 
Squamous and ciliated bronchial epithelial cells 
o 
Total cells 
o 
Neutrophils 
o 
Eosinophils 
o 
Macrophages 
o 
Lymphocytes 
o 
Mast cells 
• Supernatant (soluble markers; but not limited to): 
o 
Soluble cell activation markers (but not limited 
to): ECP, MPO, tryptase, chymase, TNF-α, IL- 
1α/β, IL-6, CXCL-8, IL-5, CXCL-1, CCL4, 
CCL20, scIgA, MMP-9, MMP-12, IL-33, 
TIMP-1, elastase 
o 
Soluble airway remodeling markers (but not 
limited to): hyaluronan, tenascin C, FGF 1/2, 
MMP-9, MMP-12, MMP’s (zymogram), IL-13, 
fractalkine, 
periostin, 
TGF-ß, 
YKL-40 
(chitinase-3-like-1 protein), ADMA, VEGF 
o 
Soluble inflammatory leakage markers: alpha2- 
macroglobulin, albumin 
o 
Cytokines and chemokines of Th2/ILC2 and 
other mainstream pathways and those linked to 
eosinophils (but not limited to): IL-1α/β, IL- 
1RA, MIP-1α/β, IL-2, IL-4, IL-5, IL-10, IL-13, 
IL-17, IL-18, GMCSF, IFN-γ, IP-10, TNF-α, IL- 
33 
Nasal brush (NAB): 
• Genome-wide gene expression 
• microRNA expression 
• DNA methylation 
Exhaled breath condensate (EBC) (not limited to): 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 44 of 100 
 
 
 
• Chloro-tyrosine, 
bromo-tyrosine, 
nitro-tyrosine, 
tyrosine, 
di-tryrosine, 
arginine, 
ADMA, 
malondialdehyde, potentially also leukotrienes. 
Blood (not limited to): 
• Eosinophil activation markers (flow cytometry: CD69, 
CD11b and CD62L) 
• IL-5 
• Alpha2-macroglobulin 
• Albumin 
• Periostin 
• MMP’s (zymogram) 
Urine (not limited to): 
• Lipid mediators (to be determined) 
PBMC (to be decided): 
• Cytokine release after HDM exposure 
• Anti-oxidant response (to xanthine oxidase/xanthine) 
Parameters in italic are to be discussed and analysis will be 
decided upon after initial analyses have been performed. 
SAFETY 
PARAMETERS 
The following safety parameters will be measured: 
• Physical examination 
• (Optional) asthma symptoms evaluation (a VAS scale may 
be used for this purpose) 
• Clinical signs/symptoms reporting (MedDRA) 
• (S)AEs 
• Vital signs (HR, BP, temperature +/- SpO2) 
• Lung function measurements (FEV1, FEV1/FVC, PEF, IOS) 
• ECG 
• Clinical 
safety 
laboratory 
outcomes 
(e.g. 
blood: 
hematology, chemistry, clotting parameters and urinalysis) 
PHARMACOKINETIC 
PARAMETERS 
The 
following 
pharmacokinetic 
parameters 
will 
be 
analyzed/calculated: 
• Maximum plasma concentration (Cmax); 
• Time to Cmax (tmax); 
• Area under the concentration-time curve from time zero to 
tau (AUC0-tau). 
STATISTICAL 
METHODOLOGY 
Sample size justification: 
The sample sizes for this study are based on previous allergen 
challenge studies performed by the same researchers as 
described in literature and previous local experiences including 
several outcomes (airway physiology and several (diluted) 
biomarkers), taking into account additional variability due to a 
2 centre setup. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 45 of 100 
 
 
 
Safety and tolerability 
Safety and tolerability will be evaluated by descriptive statistics 
and listings of adverse events/signs using MedDRA, and listings 
of vital signs, safety laboratory tests, spirometry and ECGs. 
Pharmacokinetics 
PK parameters in plasma will be summarized using descriptive 
statistics. All PK parameters will be determined using non- 
compartmental analysis of plasma concentration-time profiles. 
Pharmacodynamics 
The following analyses will be performed (but not limited to): 
Primary: 
• LAR (FEV1 AUC3-8h): differences between FP025 and 
placebo 
Secondary, differences in (FP025 versus placebo): 
• EAR: as FEV1 AUC0-3h post-allergen and in max%fall 
from post-diluent baseline 0-3 h post-allergen 
• LAR: max%fall from post-diluent baseline 3-8 h post- 
allergen 
• Joint HDM-induced airway response expressed as FEV1 
AUC0-8h post-allergen 
• Changes 
in 
allergen-induced 
AHR: 
i.e: 
PC20FEV1(Meth) or PC20FEV1(Hist) pre-post allergen 
(Day 10 versus Day12) 
• Small airway parameters measured by IOS during LAR 
and during EAR and over 0-8 h post-allergen challenge 
(to be determined) 
• Changes in allergen-induced airway and systemic 
biomarkers (i.e. eosinophils (blood) and FeNO (exhaled 
air) (Day 10 versus Day12) 
• Changes 
in 
blood 
eosinophils, 
FeNO 
and 
PC20FEV1(Meth) or PC20FEV1(Hist) Day 1 versus 
Day 10 (potential treatment effect) 
Exploratory (allergen-induced changes (Day 10 versus Day 12) 
and potential treatment effects (Day 1 versus Day 10) on the 
following parameters, but not limited to): 
• Treatment effects: differences in changes in the 
following parameters (Day 1 versus Day 10): spirometry 
(baseline FEV1), PC20FEV1(Meth)/PC20FEV1(Hist) 
and 
airway 
and 
systemic 
biomarkers 
(i.e. 
in 
blood/urine/exhaled air (FeNO, EBC), NAL/NAB; 
sputum). 
• Allergen-induced changes in exploratory inflammatory 
biomarkers (Day 10 versus Day 12) (i.e.: cellular and 
soluble biomarkers in sputum / NAL; biomarkers in 
EBC; in blood/urine/ex vivo 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 46 of 100 
 
 
 
• Potentially longer lasting treatment effects 14 days 
following Period 2 (spirometry (baseline FEV1), 
PC20FEV1(Meth)/PC20FEV1(Hist) and airway and 
systemic biomarkers (i.e. in blood/urine/exhaled air 
(FeNO, EBC), NAL/NAB; sputum). 
• To relate biomarkers and physiological changes in 
different 
compartments 
(central 
airways/small 
airways/upper airways). 
• To explore the effect of study medications on gene- 
transcriptomics from NAB pre- versus post-allergen. 
• IOS measurements following inhaled allergen and 
eventual methacholine/histamine challenges to assess 
the effect of study medication on the peripheral airways 
and for additional safety. 
• Only the MedDRA (safety) and PK parameters will be 
reported descriptively; the others will be analyzed either 
by paired t-testings or by ANOVA. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 47 of 100 
 
 
 
Table 5-1: Visit and Assessment Schedule 
 
Study Period 
Screening 
within 6 weeks 
(followed by a 
washout period 
of 3-7 weeks)a 
Treatment Period 1 and 2 (consecutive days) 
(washout period of 3-approximately 7 weeks between periods) 
EOS/Follo 
w-up 
Study Day 
S1 
S2 
S3 
-1 
1b 
2-4 
5 
(± 1 
day) 
6-8 
9 
10c 
11 
12c 
<7 
days 
after 
dosing 
on Day 
12 
14 ± 2 days 
after last 
dosing 
Informed consent 
X 
Height 
X 
Weight 
X 
X 
X 
BMI 
X 
In-/exclusion criteriad 
X 
X 
X 
Reconfirmation of Eligibilitye 
X 
X 
X 
Demographics 
X 
Medical history 
X 
X 
Physical examination 
X 
X 
X 
Allergy testingf 
X 
Vital signsg 
X 
X 
X 
X 
X 
12-lead ECGg 
X 
X 
X 
X 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 48 of 100 
 
 
 
Study Period 
Screening 
within 6 weeks 
(followed by a 
washout period 
of 3-7 weeks)a 
Treatment Period 1 and 2 (consecutive days) 
(washout period of 3-approximately 7 weeks between periods) 
EOS/Follo 
w-up 
Study Day 
S1 
S2 
S3 
-1 
1b 
2-4 
5 
(± 1 
day) 
6-8 
9 
10c 
11 
12c 
<7 
days 
after 
dosing 
on Day 
12 
14 ± 2 days 
after last 
dosing 
Clinical safety laboratory tests in 
blood and urine (including blood 
eosinophil count, coagulation and 
hematology)g 
X 
X 
X 
X 
X 
Virus serology (i.e. hepatitis B and C, 
HIV) 
X 
Urine drug screeng 
X 
X 
X 
Alcohol breath testg 
X 
X 
X 
Cotinine screeng 
X 
X 
X 
Pregnancy testh 
X 
X 
X 
Inhaled allergen (HDM) challenge 
X 
X 
FeNO in exhaled air 
X 
X 
X 
X 
EBC 
X 
X 
X 
X 
X 
Nasal lavage and nasal brushi 
X 
X 
X 
X 
X 
IOSj 
X 
X 
X 
X 
X 
X 
X 
Spirometryk 
X 
X 
X 
X 
X 
X 
X 
Methacholine/histamine challenge 
X 
X 
X 
X 
X 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 49 of 100 
 
 
 
Study Period 
Screening 
within 6 weeks 
(followed by a 
washout period 
of 3-7 weeks)a 
Treatment Period 1 and 2 (consecutive days) 
(washout period of 3-approximately 7 weeks between periods) 
EOS/Follo 
w-up 
Study Day 
S1 
S2 
S3 
-1 
1b 
2-4 
5 
(± 1 
day) 
6-8 
9 
10c 
11 
12c 
<7 
days 
after 
dosing 
on Day 
12 
14 ± 2 days 
after last 
dosing 
(Optional) overall asthma symptomsl 
X 
X 
X 
X 
Randomizationm 
X 
Sputum induction 
X 
X 
X 
X 
X 
Blood collection for inflammation 
markers and biomarkersn 
X 
X 
X 
X 
X 
Urine collection for biomarkers (i.e. 
lipid mediators) 
X 
X 
(X) 
X 
X 
Oral dosing of FP-025 or placebo 
(twice daily from Day 2 onwards)o 
X 
X 
X 
X 
X 
X 
X 
X 
PK blood samplingp 
X 
X 
Ambulant visits 
X 
(X) 
(X) 
(X) 
X 
(X) 
(X) 
(X) 
X 
Residence in clinicq 
(X) 
(X) 
X 
X 
(X) 
X 
X 
X 
Dispense diary 
X 
Subject instructions and/or diary 
reviewr 
X 
X 
X 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 50 of 100 
 
 
 
Study Period 
Screening 
within 6 weeks 
(followed by a 
washout period 
of 3-7 weeks)a 
Treatment Period 1 and 2 (consecutive days) 
(washout period of 3-approximately 7 weeks between periods) 
EOS/Follo 
w-up 
Study Day 
S1 
S2 
S3 
-1 
1b 
2-4 
5 
(± 1 
day) 
6-8 
9 
10c 
11 
12c 
<7 
days 
after 
dosing 
on Day 
12 
14 ± 2 days 
after last 
dosing 
Check treatment compliance (e.g. 
observed dosing, diary and phone 
calls) 
X 
X 
X 
X 
X 
X 
X 
X 
Check health status 
(X) 
(X) 
X 
X 
(X) 
X 
X 
X 
Phone calls 
X 
X 
X 
X 
X 
X 
(X) 
X 
Adverse events 
<-------------------- Continuously --------------------- > 
Concomitant medications (including 
rescue medication)t 
<-------------------- Continuously --------------------- > 
a. 
At the discretion of the PI or sub-investigator, Screening Day S1 some assessments (e.g. safety lab//pregnancy test/drug screen/cotinine screen/physical examination) can be moved to and/or 
repeated on Screening Day S2 and/or Screening Day S3. Screening Day S2 should start within approximately 40 days after Screening Day S1. Screening Day S3 preferably should start within 
5 days after Day S2 but maximally within 8 days after Day S2. 
b. 
FeNO, EBC, NAL, NAB, spirometry, methacholine/histamine challenge and SI to be performed in the morning (pre-dose). On Day 1, spirometry will be performed immediately after FeNO 
(since eligibility criterion). 
c. 
All procedures, except ECG on Day 10, are to be started 30-60 minutes following first daily dose. On Day 10 procedures should be performed 24+/- 1 hour before starting inhaled allergen 
challenge (Day 11) and on Day 12 procedures should be performed 24+/-1 hour after (the start of) inhaled allergen challenge. 
d. 
Only on Screening Day S1, Screening Day S2 and Day-1 of Treatment Period 1. 
e. 
By Medical history/Medication use/FEV1 and PC20FEV1(Meth)/PC20FEV1(Hist). 
f. 
Not needed if allergic status can be based on historically demonstrated allergy, either by SPT or serology; otherwise by serum allergen specific IgE measurement (or SPT) at Screening. 
g. 
Assessment on Day 9 may also be performed prior to all other tests on Day 10. 
h. 
Female subjects only: serum pregnancy test at Screening, urine pregnancy test at Day -1 and EOS. 
i. 
Day 1: pre-dose, Day 10: 24 +/-1 hour before starting inhaled allergen challenge, Day 11: approx. 6.5 hours after inhaled allergen challenge, Day 12: 24+/-1 hour after the start of inhaled 
allergen challenge. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 51 of 100 
 
 
 
j. 
IOS to be performed approximately 4-5 mins before all spirometric measurements during inhaled allergen challenge, in any case at baseline, after diluent, and t=0.5, 1, 2, 3, 4, 5, 6, 7 and 8 
hours after inhaled allergen challenge, and after rescue medication. If logistics allow, IOS will also be performed approximately 4-5 minutes before spirometric measurements on days without 
inhaled allergen challenge. 
k. 
Screening Day S3 and Day 11: spirometry to be performed t=0 (i.e. pre-allergen and 10 mins post-diluent) and 10, 20, 30, 45 minutes and t=1, 1.5, 2, 3, 4, 5, 6, 7 and 8 hours after inhaled 
allergen challenge. If required for safety, additional spirometry to be performed e.g. at t=2.5, 3.5, 4.5, 5.5, 6.5 and 7.5 hours after inhaled allergen challenge. If at Screening, there is a fall of 
10-15% from baseline at 8 hours post-allergen, FEV1 can be measured up to 9 h post-allergen. 
l. 
To be performed before and after inhaled allergen challenge and methacholine/histamine challenge and after administration of ventolin. 
m. To be performed after eligibility check (including FEV1) and methacholine/histamine challenge with subsequent PC20FEV1(Meth) or PC20FEV1(Hist) calculation on Day 1 of Treatment 
Period 1. 
n. 
On Day 12 and at Follow-up, collected together with blood collection for clinical safety. On Day 11 together with pre-dose PK blood collection and approximately 6-7 hours post-allergen 
challenge. Additional PD blood sampling for PBMC collection only on Day 1 and Day 10. 
o. 
First dose in the evening of Day 1. Dosing on Day 2-4 and Day 6-8 is performed at home. Dosing on Day 5 (+/- 1 day) and Day 9 is at home or in the clinic. Last daily dose on Day 11 to be 
taken after last PK blood sample. Last dose in the morning of Day 12. Dosing times: at home: 6-10 am/pm; at the unit: 7-9 am/pm. 
p. 
Collection times PK Day 11: (before first daily dose (t=0 hours), 1, 2, 4, 6, 8 and 9 hours post first daily dose). If clashing with other measurements then the efficacy measurements will prevail. 
At Follow-up, collected together with blood collection for clinical safety and biomarkers. 
q. 
Subjects have to stay overnight from Day -1 to Day 1 and from Day 10 to Day 12 for each period. An overnight stay from S2 to S3 is optional as is an overnight stay from Day 9 to Day 10. 
Residence is preferred, but depending on the personal situation of the subject (at the discretion of the investigator, including living far or close from the clinic) and his/her medical condition a 
subject may or may not stay overnight. Subjects can only be dismissed from the unit at the discretion of the investigator and with rescue medication, personalized written instructions on how 
and when to use the rescue medication and emergency phone numbers. 
r. 
On Screening Day S3 and Day 11, instruction will be given prior to inhaled allergen challenge. The diary will be reviewed during every visit to the clinic. 
s. 
Phone call by a physician or research staff will be performed within approximately 1 week prior to Screening Day S2, within approximately 48 hours after Screening Day S3, within 
approximately 1 week prior to Day -1 of each treatment period, twice a day during the treatment periods when study medication is taken at home, within approximately 72 hours after Day 12 
of each treatment period and within approximately 1 week after dosing on Day 12 of each period. If deemed necessary by the (co)PI more frequent phone calls or check-up visits may be 
scheduled during Screening/study. 
t. 
From 3 months prior to Screening. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 52 of 100 
 
 
 
 
6 INTRODUCTION AND RATIONALE 
6.1 Introduction 
FP-025 is a novel non-hydroxamate small molecule selective inhibitor of Matrix 
Metalloproteinase 12 (MMP-12). It has 90-fold selectivity over the next closest family member 
(MMP-2) and 2-3 orders of magnitude selectivity over the seven other MMP family members 
(MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13, and MMP-14). MMP-12 has been 
shown to play an important role in several aspects of chronic inflammatory airway diseases 
like asthma and COPD, including airway inflammation, airway hyperresponsiveness, (small) 
airways remodeling and disease severity [1-7]. In addition, FP-025 attenuated allergic 
inflammation and improved lung function in two murine models of allergic inflammation 
(OVA and HDM models) and even showed normalization of lung histology in the HDM model. 
Non-Clinical Toxicology 
FP-025 was evaluated in a series of non-GLP and definitive GLP preclinical toxicology studies, 
including single- and repeat-dose toxicity studies and a core battery of genotoxicity tests. In 
both preclinical species (rat and dog), FP-025 showed a very benign toxicity profile. In rats, 
FP-025 was well tolerated at doses up to 1000 mg/kg/day (500 mg/kg BID) for 28 days. There 
were no test article related changes in any of the parameters evaluated. In dogs, FP-025 was 
well tolerated at doses up to 400 mg/kg/day (200 mg/kg BID) for 28 days. There were no test 
article related changes in any of the parameters evaluated. 
In general, Cmax and AUC values in the pivotal repeat-dose toxicity studies increased with dose, 
but the increase was much less than dose proportional at the mid to high dose levels, suggesting 
saturation of exposure. There was no significant gender difference in drug exposure in either 
species. 
FP-025 was negative in the in vitro Ames-test. In the in vitro Chromosome Aberration assay, 
FP-025 was negative to the induction of chromosome aberration in CHO cells in the absence 
of rat S9 metabolic activation, but was equivocal to the induction of chromosome aberration in 
CHO cells in the presence of rat S9 metabolic activation. As a result, a follow-up in vivo study 
in rats was conducted to generate the weight of evidence following ICH guideline S2 (R1) on 
genotoxicity testing and data interpretation for pharmaceuticals intended for human use. The 
in vivo rat micronucleus and comet assay was conducted to assess the genotoxic potential of 
FP-025 based upon its ability to induce DNA damage in liver cells of rats using the principles 
of the Comet assay and to evaluate the in vivo clastogenic activity and/or disruption of the 
mitotic apparatus by detecting micronuclei in polychromatic erythrocyte cells in rat bone 
marrow. FP-025 at doses up to and including 2000 mg/kg/day for 3 consecutive days was 
concluded to be negative in the Comet assay, and negative in the Micronucleus assay. The 
findings from this study was also supported by the in vivo mouse Micronucleus assay, where 
FP-025 did not induce the formation of micronuclei up to the dose of 1000 mg/kg/day in 
BALB/c mice. 
Preclinical Pharmacokinetics and ADME 
The absorption, distribution, metabolism, and excretion data described herein support the 
clinical development of FP-025 for chronic respiratory diseases. Overall, FP-025 exhibits a 
favorable ADME/PK/TK profile. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 53 of 100 
 
 
FP-025 is moderately absorbed in animal species. Oral bioavailability of FP-025 was 
approximately 36% in male mice. While the absolute oral bioavailability in rats has not been 
determined, the radiolabeled mass balance study in male and female rats suggested high oral 
absorption with >70% of administered radioactivity excreted in the bile following an oral dose. 
The half-life of FP-025 was relatively short in rats and dogs, generally ranging from 1 - 6 hours, 
which supported twice daily dosing in toxicity studies. 
The pharmacokinetics of FP-025 was comparable between males and females in mice, rats, and 
dogs. FP-025 was absorbed at a moderate to slow rate (tmax ~ 1- 8 hours) in animals. tmax showed 
a tendency to increase with increasing oral doses. In the toxicity species, absorption increased 
with increase of dose, but was generally less than dose proportional, and showed signs of 
exposure saturation (especially in Cmax) at high dose levels (>300 mg/kg/day in rats, and >200 
mg/kg/day in dogs). The toxicity species were generally well exposed to FP-025 with relatively 
high Cmax and AUC values. At the NOAEL toxicology dose (> 1000 mg/kg/day) for the 28-day 
repeat-dose rat study, the steady-state Cmax was 2,915 and 2,722 ng/mL for male and female 
rats, respectively, and AUC0-24h was 36,194 and 36,748 ng*h/mL for male and female rats, 
respectively. At the NOAEL toxicology dose (> 400 mg/kg/day) for the 28-day repeat-dose 
dog study, the steady-state Cmax was 7,923 and 9,388 ng/mL for male and female dogs, 
respectively, and AUC0-24h was 96,085 and 11,6058 ng*h/mL for male and female dogs, 
respectively. There was no significant change in systemic exposure (Cmax and AUC) upon 
repeat oral dosing. 
FP-025 was bound to plasma proteins to the extent of approximately 99.9 % in the rat, dog, 
and human. Following a single oral administration of 14C-FP-025 to male and female rats, there 
was limited partitioning of the drug-derived radioactivity into blood cells with blood-to-plasma 
ratio of total radioactivity to be approximately 0.7-0.9 during initial time points (up to 2 hours 
post-dose). The blood-to-plasma ratio of total radioactivity, however, increased at the 8 and 24 
hour time points, probably due to a different distribution of metabolites. In vitro, FP-025 
showed low permeability with no significant efflux in a Caco-2 intestinal transport model, 
suggesting it is not likely a substrate of human P-glycoprotein (P-gp). 
The tissue distribution of FP-025 was evaluated. Following a single oral dose of 14C-FP-025 
(10 mg/kg) to male and female rats, the 14C-FP-025-derived radioactivity was found to 
distribute extensively to various tissues (brain, stomach, spleen, lung, heart, testis, muscle, 
liver, kidney, small intestine, large intestine and fat). The majority of the radioactivity in tissues 
exhibited the maximum radioactivity concentrations at 0.5 h, and then steadily decreased with 
increasing time (2, 8 to 24 h) post-dose. The radioactivity was most abundant in stomach, small 
intestine, and liver. 
The in vitro intrinsic clearance of FP-025 was moderate to high in liver microsomes of the dog 
and human, and very high in the rat. When incubated in vitro with liver microsomes of the rat, 
dog, and human, FP-025 was shown to be extensively metabolized. Nine metabolites (M1-M9) 
were identified. All metabolites had a shorter retention time than the parent. The oxygenation, 
dehydrogenation, hydrogenation and dealkylation pathways were found. Qualitatively, there 
was not a significant species difference in the biotransformation of FP-025, suggesting that the 
toxicity species (rat and dog) are appropriate. 
In vivo, following a single oral dose of 14C-FP-025 to male and female rats, 18 metabolites 
were identified and further characterized in the bile, plasma, urine and feces. Metabolism of 
FP-025 occurred via multiple pathways, including di-oxygenation and hydrogenation (M1); 
acetylation (M2); tri-oxygenation and hydrogenation (M3); dealkylation and hydrogenation 
(M4 and M6); dehydrogenation (M5); mono-oxygenation (M7 and M10); di-oxygenation 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 54 of 100 
 
 
(M8); mono-oxygenation and glucuronidation (M9); dealkylation (M11); di-oxygenation and 
dehydrogenation (M12); di-oxygenation and hydrogenation (M13); hydrogenation (M14); 
dealkylation and di-hydrolysis (M15 and M17); mono-oxygenation and hydrogenation (M16); 
mono-oxygenation and dehydrogenation (M18). In the pooled bile samples, 12 metabolites 
(M4, M5, M6, M7, M8, M9, M10, M11, M12, M13, M14 and M16) were detected, but the 
parent was not detected. M7, M8, M9 and M10 were major metabolites. In the pooled plasma 
samples, 3 metabolites (M11, M15 and M17) and the parent were detected at 0.5 and 2 h. M11 
was a major metabolite. In the pooled urine samples, M18 was detected, but no parent was 
detected. In the pooled feces samples, 10 metabolites (M1, M2, M3, M5, M7, M8, M10, M12, 
M13 and M18) were detected, but no parent was detected. M12 and M13 were major 
metabolites. 
FP-025 was not an inhibitor of CYP2A6, CYP2C19, CYP2D6, CYP2E1 and CYP3A4/5, but 
showed weak inhibition of CYP1A2, CYP2B6, CYP2C8, and CYP2C9 with an IC50 value of 
32.87, 14.72, 20.6, and 28.44 µM, respectively. In vitro in human hepatocytes, FP-025 showed 
very limited potential of inducing CYP1A, 2B and 3A enzyme activity and gene expression at 
concentrations up to 10 μM. Preliminary reaction phenotyping data showed that CYP3A4 may 
be involved in the oxidative metabolism of FP-025. FP-025 showed no significant efflux in a 
Caco-2 assay, suggesting it is not likely a P-gp substrate. 
Following oral administration, fecal excretion was the major route of elimination in male and 
female rats. Approximately 94-98% of the administered dose was excreted in feces, while only 
3-4% was excreted in the urine. In bile duct cannulated male and female rats, biliary excretion 
was predominant with over 73% of the dose found in the bile. In general, the excretion of FP- 
025 was rapid and occurred largely within the first 48 hours post-dose. 
Clinical pharmacology 
A single ascending dose study of FP-025 (FP02C-14-001) was conducted in Taiwan as the 
first-in-human study. Pharmacokinetics of FP-025 following single doses was evaluated using 
two formulations – API-in-Capsule and ASD-in-Capsule. After receiving a single dose of FP- 
025 by oral administration, median tmax ranged from 3.5 to 6.01 hours for FP-025 API-in- 
Capsule formulation and was 1.0 to 2.5 hours for FP-025 ASD-in-Capsule formulation. Mean 
Cmax and AUC0-t values of FP-025 API-in-Capsule increased in a greater than dose proportional 
manner over the dose range of 200 mg to 400 mg but the drug exposure of API-in-Capsule was 
increased in a less than dose proportional manner from 400 mg to 800 mg. Mean Cmax, AUC0- 
t, and AUC0-inf values of FP-025 ASD-in-Capsule increased in a greater than dose proportional 
manner over the dose range of 50 mg to 100 mg and in an approximately dose proportional 
manner from 100 to 450 mg. Based on the pharmacokinetics profiles of FP-025, ASD-in- 
Capsule formulation appeared to have better drug exposure and oral absorption compared to 
the API-in-Capsule formulation. Highest exposure to FP-025 was observed in the 450 mg 
ASD-in-Capsule group, with mean Cmax and AUC0-inf of 2570 ng/mL and 26000 ng*h/mL, 
respectively. 
Subsequently, a multiple ascending dose/food effect study (FP02C-17-001) was conducted in 
the Netherlands. Healthy male subjects, and female subjects with non-childbearing potential, 
were administered 14 doses of FP-025 (or placebo, in a 6:2 ratio) orally using the ASD-in- 
capsule formulation in 8 days. Single doses were given on Days 1 and 8 of the study, whereas 
from Day 2 to Day 7, the subjects received twice-daily doses. The dose levels used in the study 
were 100 mg, 200 mg, and 400 mg. Moreover, 8 additional subjects received 200 mg single 
dose of FP-025 in two occasions, once after an overnight fast, and once after a high-fat, high- 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 55 of 100 
 
 
calorie meal. The safety and tolerability, as well as the pharmacokinetics of FP-025, were 
evaluated. 
Exposure of FP-025 increased with dose after multiple dosing. A 2- and 4- fold increase in 
dose from 100 mg BID to 200 mg BID and 400 mg BID resulted in 3.0- and 5.6- fold increases 
in steady-state AUC (AUC0-12h on Day 8). FP-025 is rapidly absorbed, with average tmax 
between 1.5-2 hours. At the highest dose tested (400 mg BID), Cmax of 3710 ng/mL (∼9 µM) 
and daily AUC of ∼ 50,000 ng*h/mL were observed. The half-life of FP-025 was 6.6-8.4 hours. 
Compared to the pharmacokinetic profile obtained following an overnight fast, co- 
administration of FP-025 with a high-fat, high-calorie meal resulted in a delay of average tmax 
from 1.0 to 2.5 hours, and a ∼25% lowering of Cmax. However, the overall exposure of FP-025, 
as estimated by AUC0-inf, did not change significantly. 
Clinical safety 
The safety and tolerability profile in the single ascending dose study supported that single dose 
administration of FP-025 in both formulations (API-in-Capsule and ASD-in-Capsule) was 
well-tolerated in healthy volunteers. The only treatment-related adverse event (TEAE) was 
diarrhea, which was mild in severity and was observed in both the placebo and FP-025 API- 
in-Capsule formulation. No TEAE was reported with FP-025 ASD-in-Capsule formulation. 
In the multiple ascending dose/food effect study, FP-025 oral doses were safe and well- 
tolerated at all groups tested. The most common (≥ 5%) TEAEs summarized by preferred term 
(PT) in all subjects were fatigue observed in 2 subjects (2/24, 8.33%), dizziness observed in 2 
subjects (2/24, 8.33%), headache observed in 2 subjects (2/24, 8.33%), cough observed in 2 
subjects (2/24, 8.33%), nasal congestion observed in 2 subjects (2/24, 8.33%), and 
oropharyngeal pain observed in 2 subjects (2/24, 8.33%). 
With regard to severity, all TEAEs were mild in severity and only 1 (1/6, 16.67%) subject in 
the 100 mg of FP-025 group was given concomitant medication due to a study drug unrelated 
AE (toothache). None of the subjects had dose changed or discontinued the study due to AEs. 
With regard to relationship of TEAEs to FP-025, 7 events reported in 5 subjects (5/24, 20.83%) 
were judged as possibly related to study drug by investigator. Of these 7 events, 2 events 
reported in 2 (2/6, 33.33%) subjects were in the 100 mg FP-025 group, which were fatigue and 
cough. Other 5 events reported in 3 (3/6, 50%) subjects were in the 200 mg FP-025 group, 
which were eye irritation twice and erythema in one subject, dizziness in one subject, and rash 
in one subject. 
All TEAEs recovered or resolved spontaneously by the end of the study. No clinically 
significant abnormalities in hematology, urinalysis, clinical chemistry, vitals, and ECGs were 
observed. 
Detailed information on clinical safety can be found in the Investigator’s Brochure [8]. 
The current study will be conducted in compliance with the protocol, GCP and the applicable 
regulatory requirement(s). 
 
6.2 Study Rationale 
As part of the clinical development of FP-025 for the indication of chronic inflammatory 
respiratory diseases such as asthma, the efficacy of FP-025 needs to be tested. Inhaled allergen 
challenge is an established exacerbation model of asthma linking allergen-induced changes in 
airway inflammation to changes in airway physiology (bronchoconstriction, increases in 
airway hyperresponsiveness). Therefore, allergen challenge - often complemented with 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 56 of 100 
 
 
(non)invasive airway samplings - has been broadly and successfully implemented into early 
drug development to explore clinical effectiveness of novel medications interfering with the T- 
helper 2 pathway [9]. Recent evidence has been provided for the involvement of the small 
airways in dual responders (i.e., with both an EAR and a LAR) following inhaled allergen [10]. 
Apart from airway hyperresponsiveness, small airways dysfunction has been associated with 
features of airway remodeling [11], therefore, the allergen challenge could be an ideal model 
to study the physiology, inflammatory and more structural changes of both the central and 
peripheral airways. 
In an allergic sheep model, an MMP-12 inhibitor effectively protected against allergen-induced 
EAR and LAR [1]. In addition, inhaled HDM has been shown to increase sputum MMP-12 
levels in allergic asthmatics and in chronic HDM-sensitized mice (Jordana model) inhibition 
of MMP-12 resulted in an improved lung function, long-lasting reduction of airway 
inflammation and apparent restoration of tissue remodeling (unpublished data). 
Study aims: The current study is expected to provide a proof of mechanism on the anti- 
inflammatory (mainly, anti-eosinophilic), bronchoprotective, and possibly, on anti-remodeling 
potential (exemplified by effect on small airways and allergen-induced hyperresponsiveness) 
of FP-025 in subjects with HDM-allergic asthma. 
In view of the well-known one airway concept where evidence has been provided for 
interaction between the upper and lower airways [12, 13] as an explanation for concomitant 
allergic rhinitis and asthma [14], it is anticipated that systemic therapeutic modalities may be 
beneficial for the treatment of CARAS (concomitant allergic rhinitis with asthma). This has 
been shown for other systemic approaches, including anti-leukotrienes (e.g. montelukast), 
biologicals targeting IgE, IL5 and IL4/IL13, and allergen-immunotherapy. Therefore, in this 
study, the effects of inhaled HDM and concomitant study treatments (FP025 versus placebo) 
on the upper airways will be explored by inflammatory biomarkers from nasal lavage (NAL) 
and transcriptomic analysis from nasal brushes (NAB). 
Dose Selection 
The active FP-025 dose level that will be used in this study, 400 mg BID, showed an overall 
safe and tolerable profile in an 8-day MAD study in healthy subjects conducted at QPS- 
Netherlands. In addition, the exposure achieved at this dose level is in line with exposure that 
has previously shown anti-inflammatory efficacy in preclinical models of asthma (unpublished 
data). 
The duration of dosing (22 doses over 12 days) is based on the number of days to reach stable 
plasma concentrations irrespective of food effect (i.e. <5 days) plus another 7 days of dosing. 
This will allow us to investigate both the anti-inflammatory/bronchoprotective efficacy of FP- 
025 at stable plasma concentrations in a relevant human inflammatory model and the 
safety/tolerability of multiple dosings in the target population. 
Allergen Challenge Model 
Inhaled allergen challenge is a standardized and reproducible research tool reflecting several 
key features of asthma. Combined with non- or semi-invasive biomarker samplings, allergen 
challenge is a valuable tool to evaluate clinical effectiveness of novel medications interfering 
with the T-helper 2 pathway [9]. Inhaled allergen challenge can be safely conducted in 
dedicated research settings with ample expertise and experience with this disease model and 
the management of acute bronchoconstriction. Safety aspects and rescue medication will be 
managed and customized per subject by the investigator [9], and may include combinations of 
the following: administration of rescue medication (i.e. short-acting beta2-agonist) following 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 57 of 100 
 
 
allergen challenge, written instructions, emergency phone numbers, a follow-up phone call and 
rescue medication; or any other safety measures as deemed necessary by the investigator. 
Methacholine/Histamine Challenge 
Currently, there is a ubiquitous shortage of the raw materials to produce methacholine, making 
it difficult to obtain the methacholine needed for the methacholine challenges in this study. In 
case of insufficient supply of methacholine, histamine will be used instead in this study. 
Although interacting with different receptors, both histamine and methacholine are regarded as 
‘a direct agent’ as outlined in the international guidelines by leading societies (ATS/ERS)), and 
both have been (interchangeably) used to assess nonspecific airway hyperresponsiveness 
according to the same protocol in standard clinical practice as well as in the context of the 
allergen bronchoprovocation test [15, 16]. Furthermore, both histamine (which was historically 
the first agent) and methacholine have been used to predict the allergen PC20 in a similar way 
[9, 16]. Therefore, switching to histamine will not harm the subject safety nor the study 
objectives, particularly as the allergen-induced airway response on several (bio)markers will 
be compared within subjects. To allow for scientifically sound within-subject comparisons, 
whenever possible, subjects will receive the same challenge agent (i.e. methacholine or 
histamine) throughout the study. Both methacholine and histamine challenges will be 
performed according to the QPS standard operating procedures/work instructions in line with 
the above-mentioned international guidelines. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 58 of 100 
 
 
7 STUDY OBJECTIVES 
7.1 Primary objective 
• To determine the effect of FP-025 versus placebo on the allergen (HDM)-induced late 
asthmatic response expressed as FEV1 AUC3-8h in subjects with clinically stable, mild 
allergic asthma and blood eosinophilia. 
 
7.2 Secondary objectives 
• To determine the pharmacodynamics of FP-025 versus placebo on additional markers 
of airway physiology, including (additional measures of) the early and late response, 
airway hyperresponsiveness and small airways function; inflammatory markers 
(including blood eosinophils and FeNO) following inhaled HDM-challenge in subjects 
with clinically stable, mild allergic asthma and blood eosinophilia. 
• To determine the treatment effect (i.e. Day 1 versus Day 10) of multiple oral doses of 
FP-025 versus placebo on baseline parameters (such as blood eosinophils, FeNO and 
PC20FEV1(Meth)/PC20FEV1(Hist)). 
• To determine the safety and tolerability of multiple oral doses of FP-025 versus placebo 
in subjects with clinically stable, mild allergic asthma and blood eosinophilia. 
• To assess the pharmacokinetics of multiple oral doses of FP-025 following inhaled 
HDM-challenge in subjects with clinically stable, mild allergic asthma and blood 
eosinophilia. 
 
7.3 Exploratory objectives 
• To explore the effect of FP-025 versus placebo on: 
o Cellular and soluble inflammatory biomarkers in nasal lavage (NAL) and 
sputum; 
o Nasal gene and microRNA expression in nasal brush (NAB); 
o (Inflammatory) biomarkers in exhaled breath condensate (EBC), blood 
(eosinophil activation markers and potentially others as well) and urine (lipid 
mediators); 
o Functional in vitro responses of peripheral blood mononuclear cells (PBMC); 
o Expression and activity of MMP-12, other MMP’s and markers of tissue 
remodeling in blood, sputum and potentially in NAL. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 59 of 100 
 
 
8 STUDY DESIGN 
8.1 Endpoints 
Primary Endpoint 
The primary endpoint of this study is the effect of study treatments on FEV1 AUC3-8h during 
the LAR (FP-025 versus placebo). 
Secondary Endpoints 
• Pharmacodynamic endpoints include the effect of study treatments on allergen (HDM)- 
induced changes in: 
o LAR expressed as max% fall in FEV1 from post-diluent baseline; 
o Early asthmatic response (EAR) expressed as FEV1 AUC0-3h; 
o EAR expressed as max% fall in FEV1 from post-diluent baseline; 
o Joint HDM-induced airway response expressed as AUC0-8h; 
o Airway 
hyperresponsiveness 
expressed 
as 
PC20FEV1(Meth) 
or 
PC20FEV1(Hist) (Day 10-Day 12); 
o Small airway parameters following HDM-challenge (i.e. R5, R20, R5-R20, AX, 
X5, Fres); 
o Fractionated nitric oxide (FeNO); 
o Blood eosinophils. 
• Potential treatment effect (FP-025 versus placebo) on baseline parameters (i.e. Day 1 
versus Day 10), including: 
o Blood eosinophils; 
o PC20FEV1(Meth) or PC20FEV1(Hist); 
o FeNO. 
• Safety parameters include physical examination, clinical signs/symptoms reporting 
(MedDRA), (S)AEs, vital signs, lung function measurements, overall asthma 
symptoms, ECG and clinical safety laboratory outcomes (blood/urine). 
• Pharmacokinetic parameters of FP-025 in blood (plasma) include Cmax, tmax, and AUC0- 
tau. 
Exploratory Endpoints 
Exploratory pharmacodynamic parameters of FP-025 (Day 10 versus Day 12 = treatment effect 
on HDM-induced (airway) responses; and Day 1 versus Day 10 = treatment effect on baseline 
parameters) include: 
• Cellular and soluble markers of inflammation in nasal lavage (NAL) and sputum, i.e.: 
eosinophil and lymphocyte counts, total cell counts, levels of ECP, MPO, IL-1b, FGF, 
VEGF and IL-5 and relative coefficient of excretion (RCE: ratio A2M in sputum/NAL 
relative to that in serum divided by the ratio of albumin sputum/NAL relative to that in 
serum); 
• Genome-wide gene and microRNA expression and DNA methylation in nasal brush 
(NAB) samples; 
• Biomarkers of oxidative stress and cellular activation in exhaled breath condensate 
(EBC); 
• Cellular (eosinophil activation) and soluble inflammatory mediators (IL-5) in blood; 
• Lipid mediators in urine (to be determined; leukotrienes); 
• Peripheral blood mononuclear cell (PBMC) counts and functional parameters (cytokine 
release; Elispot assay); 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 60 of 100 
 
 
• Expression and activity of MMP-12, other MMP’s and markers of tissue remodeling in 
blood, NAL and sputum; 
• Potentially longer lasting treatment effects 14 days following Period 2 (FP-025 versus 
placebo) (spirometry (baseline FEV1), PC20FEV1(Meth) or PC20FEV1(Hist) and 
airway and systemic biomarkers (i.e. blood/urine/exhaled air (FeNO, EBC), 
NAL/NAB; sputum). 
 
8.2 Overall Study Design 
This is a randomized, placebo-controlled, double-blind, 2-way cross-over, 2-centre study in 
male and female subjects with stable, mild HDM-allergic asthma. 
Prior to the study, there will be a Screening period consisting of 3 clinic visits (within 
approximately 6 weeks) to test subject eligibility. 
On Screening Day 1, the following procedures will take place: signing of the informed consent, 
a check of the inclusion/exclusion criteria, medical history and demographics, physical 
examination, measurements of vital signs, height and weight, calculation of body mass index 
(BMI), blood sampling for blood eosinophils and clinical safety laboratory assessments, ECG, 
allergy testing and screening for drug and alcohol use, smoking (i.e. cotinine), pregnancy and 
HIV, Hepatitis B and Hepatitis C (i.e. serology). At the discretion of the Principal Investigators 
(PI) or sub-investigators, some Screening Day 1 assessments (e.g. safety lab/pregnancy 
test/drug screen/cotinine screen/physical examination) may be moved to and/or repeated on 
Screening Day 2 and/or Screening Day 3. 
Within approximately 40 days after Screening Day 1, potentially eligible subjects will start 
with more specific screening procedures (on 2 separate days (Screening Day 2 and Screening 
Day 3), preferably within 5 days but maximally within 8 days). Subjects will be called by a 
physician or research staff within approximately 1 week prior to Screening Day 2 to check their 
asthma stability/medication intake/general health status. On Screening Day 2, spirometry with 
subsequent methacholine/histamine challenge (for calculation of the PC20FEV1(Meth) or 
PC20FEV1(Hist)) will be performed, followed by sputum induction (SI). If logistics allow, IOS 
will be added to spirometric measurements. On Screening Day 3, there will be an inhaled HDM 
challenge [9] with airway response measurements (including IOS and spirometry) during and 
up to approximately 8 hours post-allergen. On completion of all response measurements 
following both inhalational challenges on Screening Day 2 and 3, subjects will receive rescue 
bronchodilator medication and lung function will be measured. Upon leaving the clinic, all 
subjects will be provided with rescue medication (short acting beta2-agonist) to be used on an 
‘as needed basis’ throughout the study. In addition, after each inhalational challenge, subjects 
will receive emergency instructions, and will be provided rescue medication (Ventolin). Within 
approximately 48 hours after Screening Day 3, subjects will be called by a physician to check 
their asthma status/rescue medication use and general health. 
Following a washout period of at least 3 weeks and up to approximately 7 weeks, eligible 
subjects will be enrolled into the study and randomized on Day 1 if their asthma is within 
continuation criteria of screening (as assessed by history, (rescue) medication use, baseline 
FEV1 and PC20FEV1(Meth) or PC20FEV1(Hist)). The study will consist of two identical study 
periods of 12 treatment days each, separated by a washout period of at least 3 weeks (and up 
to approximately 7 weeks). Approximately 36 eligible subjects will be enrolled, to yield 32 
evaluable subjects who will be treated with both FP-025 (400 mg BID) or placebo in a cross- 
over design from the evening of Day 1 till the morning of Day 12 (22 doses per study period 
in total). Based on a double-blind randomized schedule, 16 subjects will receive placebo in 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 61 of 100 
 
 
Period 1 and FP-025 in Period 2 and 16 subjects will receive FP-025 in Period 1 and placebo 
in Period 2. Both study periods will follow the same schedule of procedures. 
Subjects will be called by a physician or research staff within approximately 1 week prior to 
Day -1 of each study period to check their asthma stability/ medication intake/ general health 
status. On Day -1, the checks performed on Screening Day 1 (i.e. medical history (includes 
asthma medication use, Adverse Events and asthma stability check)), physical examination, 
vital signs, weight, ECG, blood collection for clinical safety laboratory assessments and drug, 
alcohol, cotinine and pregnancy testing) will be repeated to reconfirm eligibility. Subjects stay 
overnight in the unit at the discretion of the PI or subinvestigator. 
On Day 1, after a short checklist, the following tests will be performed for baseline purposes, 
i.e. blood and urine sampling (both for routine safety and biomarkers), FeNO, IOS (if logistics 
allow), spirometry, EBC, NAL, NAB, methacholine/histamine challenge (with calculation of 
PC20FEV1(Meth) or PC20FEV1(Hist) for stability/eligibility check) and SI. 
On Day 1 of Period 1, subjects should still have stable asthma (based on continuation criteria 
as applicable in the allergen challenge: i.e. history/medication use/spirometry and 
PC20FEV1(Meth)/PC20FEV1(Hist)) in order to be randomized by a blinded pharmacist and 
start with the study drug administration. Should a subject not comply to the stability criteria, 
(s)he may be rescheduled at the discretion of the(co)PI, depending on the underlying cause. 
Starting on Day 1 with an evening dose, FP-025 or placebo will be given over 12 days (BID 
from Day 2 up to and including Day 11, final morning dose on Day 12) to ensure stable FP- 
025 levels during Days 10-12 (outcome measure days). 
To aid compliance, during Day 2-9, subjects will either receive study medication onsite the 
clinic (observed dosing) or take their study medication at home or combinations of these. In 
the event study medication will be taken at home (between 6-10 am/pm), the subject will be 
contacted twice a day on dosing days to receive confirmation of study medication intake. In 
addition, from Screening Day 3 onwards and during study, subjects will be keeping track of 
their rescue medication use and AEs in a diary. 
On Day 5 (+/- 1 day) subjects will return to the clinic for safety monitoring, study requirements 
compliances and observed study medication intake during morning or evening doses. 
In the evening of Day 9, depending on their place of residence and asthma status, subjects will 
come onsite to the clinic to check and ensure asthma stability +/- undergo additional checks 
(safety lab/cotinine/alcohol/drug screen; as indicated in flowchart) before subsequent tests on 
Days 10-12. 
On Day 10 (i.e. approximately 24 hours pre-allergen), approximately 30-60 minutes after first 
daily dosing, subjects undergo the same procedures as on Day 1 (i.e. safety/stability check, 
blood and urine collection (biomarkers), FeNO, EBC, NAL, NAB, IOS (if logistics allow), 
spirometry, methacholine/histamine challenge and SI. Subjects stay overnight in the unit. On 
Day 11, approx. 30-60 minutes after the morning dose, an inhaled allergen (HDM) challenge 
will be performed with airway response measurements (IOS and spirometry). During this study 
day, repeated PK sampling and blood biomarker sampling will be performed. EBC, NAL and 
NAB will be performed at approximately 6.5 hours post allergen challenge. Subjects stay 
overnight in the unit. On Day 12 (approximately 24 hours post-allergen), 30-60 minutes after 
the last study medication (i.e. morning) dose, the same procedures as on Day 10 will be 
repeated. Furthermore, clinical safety laboratory assessments will be performed. Clinically 
stable subjects will receive written instructions, including emergency numbers, and rescue 
medication prior to leaving the clinic. Within approximately 72 hours after Day 12 of each 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 62 of 100 
 
 
study period, subjects will be called by a physician to check their asthma/medication 
intake/AEs and general health. If deemed necessary by the (co)PI, there may be another check 
on the subjects before and/or after each study period and in any case following drop-out (either 
by phone or if needed and in case of drop-out, onsite the clinic). 
Fourteen (14) days (± 2 days) after final administration of FP-025 or placebo on Day 12 of 
Period 2, a follow-up visit will be scheduled. This visit will not only serve as a follow-up visit 
(e.g. checking weight and AEs, performing physical examination, ECG and pregnancy test, 
checking vital signs and collecting blood for clinical safety laboratory assessments), the 
‘duration of efficacy’ will also be explored by performing the same procedures as performed 
on Day 1 and Day 10 (i.e. blood and urine samplings (safety/biomarkers), FeNO, EBC, NAL, 
NAB, IOS (if logistics allow), spirometry, methacholine/histamine challenge and SI). 
For details regarding the timing of specific procedures, see Table 5-1. 
 
8.3 Inhaled allergen (HDM) challenge 
The allergen challenge will be conducted using a standardized technique with incremental 
doses of inhaled house dust mite (HDM) extract as described in the literature [9] and as further 
detailed in the standard operating procedure (SOP) and work instruction (WI). Underneath a 
short description of the allergen challenge methodology is outlined; however, the SOP will be 
leading as it will contain additional details on the equipment, HDM extract, additional safety 
and consistency measures. 
At Screening, an inhaled HDM challenge will be conducted for dose-finding purposes. Before 
the test, baseline FEV1 measurements will be conducted (for safety+/-stability/reproducibility). 
The allergen challenge will be preceded by inhalation of the allergen’s diluent. Post-diluent 
FEV1 should not drop by more than 10% from baseline. Subsequently, eligible subjects will 
inhale serial doubling concentrations of HDM extract by tidal breathing with the nose clipped 
during 2 minutes at approximately 12-15 minutes intervals. Ten minutes after each HDM dose, 
FEV1 will be measured in duplicate and the highest, technically satisfactory FEV1 will be 
implicated in the analysis and will be expressed as %fall from post-diluent baseline. Once the 
FEV1 drops by at least 20% from post-diluent baseline, no further allergen will be administered 
and the airway response will be further measured at 20, 30, 45, 60, 90, 120 minutes and (at 
least) at 3, 4, 5, 6, 7, and 8 hours post-allergen (if during screening, at 8 hours post-allergen the 
FEV1 drops between 10-15% from post-diluent baseline, additional FEV1 measurements may 
be conducted until 9 hours post-allergen (8.5 and 9 hours). In case of a drop of FEV1 of at least 
15% from post-diluent baseline during this time-span, subject is considered a dual responder 
and can be included into the study. For the sake of safety, additional spirometric measurements 
and/or measurements of peripheral oxygenation (SpO2) may be added at the discretion of the 
investigator. 
An early asthmatic/allergic airway responses (EAR) will be defined as a fall in FEV1 of at least 
20% from post-diluent baseline occurring within 10-20 min of an allergen dose, while a late 
asthmatic/allergic airway response (LAR) will be defined as a drop in FEV1 of at least 15% 
from post-diluent baseline occurring within 8 hours post-allergen (or ultimately 9 hours at 
Screening, i.e. if at 8 hours post-allergen, there is a drop of >10% and < 15%). During the 
study, IOS recordings (see Section 8.4.3.5) will precede spirometric measurements, and hence, 
will be performed within approximately 4-5 min before actual spirometry time points at pre-, 
during and post-allergen challenge. 
After completion of the last spirometric response measurement (i.e., usually at 8 hours post- 
allergen), subjects will receive salbutamol to enable the FEV1 to return within approx. 10% 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 63 of 100 
 
 
from pre-challenge baseline. Clinically stable subjects may be sent home with written 
instructions, rescue medication and emergency phone numbers. Subjects with a LAR will be 
contacted for a phone call check up by research staff usually within 24-48 hours after the 
challenge day, or otherwise at the discretion of the investigator. Subjects with a dual airway 
response will be eligible for the study, provided that all other in- and exclusion criteria are met. 
Potentially eligible subjects who just fail to meet the criteria of HDM-induced airway responses 
may be re-challenged at the discretion of the Principle Investigator. Subjects with concomitant 
other sensitizations will be instructed to refrain as much as possible from exposure to co- 
sensitizing allergens. Pollen-sensitized symptomatic subjects will be challenged outside of the 
relevant pollen season. 
During both study periods, generally, the 3 highest incremental doses of HDM extract will be 
used that provoked (an EAR and subsequently) a LAR during Screening. If during screening 
the EAR (and subsequent LAR) was reached following inhalation of 1 or 2 allergen doses, an 
additional lower dose (to complete in total 3 doses) may be added at the discretion of the 
investigator to ensure consistency of the procedure across subjects. However, safety will 
always prevail, meaning that in some cases, subjects will receive fewer allergen doses during 
Screening and the study periods. While allergen challenge (number and allergen 
concentrations) will be customized per subject, the same number and concentrations of allergen 
extract will be inhaled during both study periods by the same subject. All details will be 
described in the SOP and WI. 
During the allergen challenge and subsequent measurements (i.e. from the start of the challenge 
until post-bronchodilator spirometry), subjects will stay inside the unit to prevent exposure to 
environmental triggers. 
Continuation criteria allergen challenge: 
Baseline FEV1 at least 70% of predicted value at Screening Day 2 (inclusive) and FEV1 on 
Screening Day 3 within 10% (counted from the absolute value in liters) of Screening Day 2 
and ≥65% predicted (and ≥1.8 L). On Day 1 of Period 1, FEV1 should be within 10% (again 
from absolute value in liters) of Screening baseline FEV1 (i.e. mean baseline FEV1 Screening 
Day 2 and Screening Day 3; and ≥65% predicted (and ≥1.8 L). Baseline FEV1 (in liters) in both 
study periods should be within 10% and ≥65% predicted (and ≥1.8 L). 
Furthermore, PC20FEV1(Meth) or PC20FEV1(Hist) on Day 1 of Period 1 should be within 1.5 
doubling doses of Screening and on Day 1 of Period 2 within 1 doubling dose of Day 1 of 
Period 1. Should the subject’s values on Day 1 of either study period fall outside these ranges, 
subject may be rescheduled depending on the cause and at the discretion of the investigator. 
 
8.4 Study Assessments 
Informed Consent 
After adequate explanation of the aims, methods, objectives of the study and potential hazards 
of the study drug, a written informed consent from each individual participating in this study 
will be obtained. 
Baseline Characteristics and Concomitant Medications 
8.4.2.1 Baseline Characteristics 
The following subject characteristics and baseline assessments are documented as part of the 
screening: 
• Medical history (all relevant medical history will be documented) 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 64 of 100 
 
 
• Demographics including sex, date of birth (month and year), ethnicity, weight, and 
height. 
• Vital signs (refer to Section 8.4.4.2) 
• Physical examination (refer to Section 8.4.4.5) 
• Hematology and clinical chemistry and urinalysis (refer to Section 8.4.4.8) 
• Virus serology (refer to Section 8.4.10) 
• Allergy testing (refer to Section 8.4.4.6) 
• 12-lead ECG (refer to Section 8.4.4.4) 
Eligible subjects will furthermore be screened for the following baseline assessments/inclusion 
criteria: 
• Spirometry (refer to Section 8.4.3.5) 
• Methacholine/histamine challenge (refer to Section 8.4.3.6) 
Additionally, at Screening, sputum induction (Section 8.4.3.7) will be conducted for training 
purposes. 
8.4.2.2 Prior and Concomitant Medications 
All lung and anti-allergic medications and vaccines taken from 3 months prior to screening 
until EOS or started during the course of the study and all other medications taken from 
screening until EOS or started during the course of the study will be recorded on the 
Concomitant Medications page. 
Concomitant Medications initiated, stopped, up-titrated or down-titrated for an AE will be 
recorded on a specific Concomitant Medications page. 
A summary of allowed and prohibited Concomitant Medications is given in Section 8.5.3.1. 
Pharmacodynamic Assessments 
8.4.3.1 Exhaled nitric oxide 
Fractionated nitric oxide (FeNO) will be measured from exhaled air by Niox Vero® device 
(Circassia, Oxford, United Kingdom) according to guidelines as detailed in our SOP/WI. 
8.4.3.2 Exhaled breath condensate (EBC) 
Exhaled breath condensate will be collected according to our SOP/WI using an Ecoscreen 
condenser (CareFusion, San Diego, CA, United States). Subjects will breathe calmly into the 
Ecoscreen collector for 10 (and maximally 20) minutes until at least 2 mL of EBC has been 
collected. Immediately following collection, EBC will be stored at -80°C pending analysis of 
inflammatory markers. Analysis will be performed in the AMC according to local SOP. In 
addition, FP-025 concentration may be exploratively quantified in (some of) the samples. 
8.4.3.3 Nasal lavage (NAL) 
Nasal lavage (NAL) will be collected, processed and analyzed according to previously 
standardized methodology detailed in the SOPs. 
NAL will be performed in the same nostril throughout the study (any exceptions will be 
clarified in the source documents). 
Processing, storage and analysis of the NAL samples will be described in the SOPs. Analysis 
will be performed in the AMC. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 65 of 100 
 
 
8.4.3.4 Nasal brush (NAB) 
Nasal cells will be collected by a nasal brush (NAB) according to the SOP. NAB will be 
performed in the same nostril throughout the study (any exceptions will be clarified in the 
source documents). 
Processing, storage and analysis of the NAB samples will be described in the respective 
SOPs/WIs. Analysis will be performed in UMCG. 
8.4.3.5 IOS and Spirometry 
Spirometry: 
Lung function tests will be performed with a standardized/calibrated spirometer according to 
the SOPs/WIs in line with current guidelines. For baseline purposes (i.e., pre-testing and post- 
diluent), several FEV1 maneuvers will be performed to yield at least 3 technically satisfactory 
FEV1 measurements for the determination of the baseline value. 
IOS: 
Airway resistance and reactance will be measured using a Vyntus Impulse Oscillometry 
System (IOS) (CareFusion, San Diego, CA, United States) according to the SOP. IOS 
measurements will be performed approximately 4-5 minutes before all spirometric 
measurements during and after allergen challenge, in any case at baseline, after diluent, and at 
0.5, 1, 2, 3, 4, 5, 6, 7, 8 h post-allergen challenge and at recovery (post-salbutamol). If logistics 
allow, IOS measurements will also be performed approximately 4-5 minutes before spirometric 
measurements scheduled on days without allergen challenge, or, in case of 
methacholine/histamine challenge, as defined in the respective SOPs/WIs. 
8.4.3.6 Methacholine/Histamine Challenge 
Methacholine/histamine challenge will be performed according to the SOP in line with current 
guidelines. When methacholine bromide is not available, histamine should be used for the 
challenge. Whenever possible, subjects should receive the same challenge agent (i.e. 
methacholine or histamine) throughout the study. 
Shortly, incremental doses of methacholine bromide/histamine will be inhaled for 2 minutes 
by tidal breathing at approximately 5 minutes intervals. The challenge will be discontinued if 
a fall in FEV1 of ≥20% from post-diluent baseline has been reached, or until the highest 
concentration has been administered. If a fall in FEV1 of ≥20% from baseline has been reached, 
a PC20FEV1(Meth) or PC20FEV1(Hist) will be calculated by extrapolation as defined in the 
manual/SOP/WI. After the challenge, subjects will be given salbutamol to aid recovery and 
lung function will be measured after approximately 15-30 minutes (as per manual/SOP/WI). 
8.4.3.7 Sputum Induction 
Sputum induction will be performed according to guidelines as detailed in the SOP/WI. 
Following administration of salbutamol (to protect against airway narrowing), baseline FEV1 
will be recorded. Subsequently, hypertonic saline (NaCl 4.5%) will be aerosolized by an 
ultrasonic nebulizer during 5 minutes and inhaled by tidal breathing with the nose clipped, as 
detailed in the SOP. Three (3) cycles of 5 minutes NaCl 4.5% inhalations will be conducted; if 
after the last inhalation no or not enough sputum has been obtained, the investigator can decide 
to do one more inhalation (max 5 mins). After each inhalation cycle, subjects will be asked to 
blow their nose, to rinse their oral cavity with water and subsequently to expectorate sputum 
into a clean plastic jar without clearing their throat. FEV1 measurements (in duplicate) will be 
performed after each inhalation before engaging on the next inhalation cycle. If needed, and at 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 66 of 100 
 
 
the discretion of the investigator, subjects will be administered additional bronchodilator after 
finalizing the procedure. 
Sputum samples will be processed by a trained and qualified technician within 2 hours of 
induction onsite the respective research center, according to the SOP/WI. The cell pellets will 
be cytospinned and supernatants will be frozen in tubes pending analysis. Staining (DiffQui(c)k 
or Giemsa (when required)) of the cytospins and differential cell counts in addition to analysis 
of soluble biomarkers from the supernatants will be performed in the AMC according to 
respective SOPs. 
Safety and Tolerability Assessments 
The definitions, reporting, and follow-up of AEs and SAEs are described in Section 9. Table 
5-1 provides an overview of all time points on which safety assessments will be performed. 
8.4.4.1 Adverse Events 
Adverse events will be recorded according to the SOP/Work instruction of the clinic. 
8.4.4.2 Vital Signs 
Vital signs measured during the Screening and the study will include heart rate (HR), 
respiration rate (RR), blood pressure (BP), body temperature (Temp) and peripheral oxygen 
saturation (SpO2) using adequately maintained and calibrated automatic equipment. 
BP and HR measurements will be recorded in supine position after having rested for a 5-minute 
period. Respiration rate will be measured manually by counting the number of breaths over a 
full minute. Body temperature will be assessed tympanically. SpO2 will be measured by a pulse 
oximeter. 
8.4.4.3 Weight, Height and BMI 
The subject’s body weight will be measured using a validated balance according to the SOP. 
Body weight will be recorded with 1 decimal. The subject's height is measured without wearing 
shoes. The BMI will be calculated from the weight and height recorded at screening. BMI 
(kg/m2) = weight (kg)/height (m2). 
8.4.4.4 12-lead ECG 
Subjects will be in a supine position for 5 minutes prior to the recording. ECGs will be 
evaluated and classified as normal/abnormal. In case of “abnormal”, the abnormality has to be 
described. HR, RR, PR, QRS, QT and QTc (Bazett and Fridericia) will be reported on the 
eCRF. Bazett (QT/RR1/2) and Fridericia (QT/RR1/3) are automatically calculated by the ECG 
apparatus and provided on the print-out. RR will be calculated in the database. For the 
screening ECG and the baseline ECG, three recordings will be made with a 1-minute interval 
between recordings. For the evaluation of the corrected QT intervals, the average of the 3 
recordings will be taken as baseline. All other recordings will be single (one recording of at 
least 3 complexes). 
8.4.4.5 Physical Examination 
Physical examination will be performed consisting of inspection, percussion, palpation, and 
auscultation. Clinically relevant findings that are observed at the screening must be recorded 
on the relevant Medical History eCRF page. Clinically relevant findings found after signing of 
the informed consent form (ICF) and meeting the definition of an AE (new AE or worsening 
of previously existing condition) must be recorded on an AE page of the eCRF. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 67 of 100 
 
 
8.4.4.6 Allergy testing 
Allergy assessment will be conducted at screening by serum total and specific IgE or a skin 
prick test. Allergy testing will include at least the following allergens: house dust mite (D. 
Pteronyssinus/ D. farinae), animal dander (at least cat, dog and horse), fungi (Asp Fumigatus, 
Alternaria Alternata), and pollen (grass, trees, Artemisia Vulgaris). 
A positive test for HDM either in serum or by SPT documented in the past 12 months of 
screening will be acceptable and hence will not need to be repeated. 
8.4.4.7 Overall Asthma Symptoms 
Overall asthma symptoms will be assessed using a visual analogue scale (VAS). A standard 
VAS includes a scale of 100 mm. When a scale of another size is used, the values will be 
adjusted to match the standard VAS size of 100 mm. 
8.4.4.8 Laboratory Assessments 
Clinically significant laboratory abnormalities must be reported by the investigator as an AE 
or SAE as appropriate (see Section 9). 
The samples will be taken under fasted conditions. Subjects will not be allowed to eat or drink 
(except water) for a period of 4 h prior to blood sampling. As a rule, the blood samples will be 
taken from the subject by puncture of a vein in the cubital or the antebrachial region. The 
samples will be sent to the local certified laboratory in accordance with specifications. 
Table 8-1: Summary of Clinical Laboratory Tests 
 
Hematology 
Chemistry 
Urinalysis 
Others 
Hemoglobin 
Hematocrit 
RBC count 
Platelet count 
WBC count 
Neutrophils (total) 
Eosinophils 
Monocytes 
Basophils 
Lymphocytes 
Mean corpuscular volume 
(MCV) 
BUN 
Creatinine 
Fasting glucose 
Sodium 
Potassium 
ALT 
AST 
GGT 
Bilirubin (total, direct and 
indirect) 
Alkaline phosphatase 
Albumin 
Cholesterol (total) 
LDL 
HDL 
Triglycerides 
Lactate dehydrogenase 
Total protein 
Urobilinogen 
Nitrites 
pH 
Glucosea 
Proteina 
Blooda 
Ketonesa 
Microscopyb 
Specific gravity 
Bilirubin 
Leukocytes 
Serum HDM-specific 
IgE 
Serum pregnancy testc 
FSHd 
Serology (HIV, hepatitis 
B and hepatitis C)e 
Coagulation (PT, INR, 
PTT, thrombocytes) 
Urine drug screen 
Alcohol breath test 
Cotinine test 
a Dipstick. 
b Only if urine dipstick is positive for blood or protein. 
c Only during screening, other pregnancy tests will be done with urine. 
d Required of postmenopausal females only during screening. 
e Only at Screening 
Pharmacokinetic Assessments 
8.4.5.1 Timing for Sampling 
Blood PK sampling will be conducted during Day 11 and at Follow-up, as detailed in Table 
5-1. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 68 of 100 
 
 
8.4.5.2 Procedures for Sampling 
About 6.0 mL blood for the PK samples will be collected via vena puncture or via an 
intravenous (i.v.) catheter following the local standard procedures. Information on equipment 
and further details on the procedures on the sampling are documented in a separate instruction 
manual. 
8.4.5.3 Labeling 
The tubes will be pre-labeled and will carry the following information: 
• Foresee Pharmaceuticals Co., Ltd 
• Type of sample, e.g., blood, urine, etc. 
• Study number 
• Sample number 
• Study day and scheduled time of sampling 
• Subject number 
8.4.5.4 Shipping Procedures 
The site staff will take care of the shipment of the samples. Samples must be sent to QPS 
Netherlands B.V. (see contact details on page 2) at time intervals agreed with the sponsor. The 
samples must be packed securely together with completed shipment forms in polystyrene- 
insulated shipping containers together with enough dry ice to last for 48 hours. More details on 
shipping procedures can be found in the Laboratory Manual. 
8.4.5.5 Bioanalysis 
The concentrations of FP-025 in plasma will be determined using a validated LC-MS/MS 
assay. The LLOQ is 5.0 ng/mL. Concentrations will be calculated by interpolation from a 
calibration curve. Quality control samples will be analyzed throughout the study. Their 
measured concentrations will be used to determine between-run, overall precision, and 
accuracy of the analyses. No analysis will be done for placebo samples. Therefore, a designated 
person in the laboratory will be unblinded. In order to minimize the risks associated with 
unblinding study staff, this person from the laboratory is not involved in any other aspect of 
the study. 
Order of Assessments 
In case several study procedures are scheduled at the same time point, the order will be detailed 
in the workflow sheet. During allergen challenge, spirometry measurements will be conducted 
at the indicated time – being the primary parameter. 
Approximately 6.5 h post-allergen challenge, the following assessments will be conducted in 
this order: blood sampling (eosinophils/biomarkers); EBC; NAL; NAB, followed by the IOS 
and spirometry at 7 hours post-allergen. 
Blood biomarker sampling (eosinophils and biomarkers): Day 1; Day 10 (together with the 
safety lab); Day 11 (together with pre-dose PK measurements) and approximately 6-7 hours 
post-allergen challenge; Day 12; and at Follow-up (together with the safety lab). 
During the study periods, all protocol related-assessments will be conducted at the same time 
of the day +/- 1 hour. This means that, e.g. if the methacholine/histamine challenge has been 
conducted on Day 1 at 10:00, then on Day 10 and 12 this should be done between 9-11 am 
(starting time); applicable for both study periods. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 69 of 100 
 
 
Allowed Time Windows for PD, Safety and PK Assessments 
Time deviations allowed are tabulated below: 
 
Scheduled time for blood sample collection for PD, safety 
and PK 
Allowed time deviation 
≤ 4 hours after study drug administration 
± 5 min 
> 4 hours and ≤24 hours after study drug administration 
± 10 min 
Follow-up 
± 2 days 
Scheduled time for ECGs and blood pressure measurements 
Allowed time deviation 
≤ 4 hours after study drug administration 
± 15 min 
> 4 hours and ≤24 hours after study drug administration 
± 30 min 
Follow-up 
± 2 days 
Scheduled time for exhaled air, EBC, NAL, NAB, IOS, 
spirometry, methacholine/histamine challenge and SI 
Allowed time deviation 
≥30 minutes and ≤ 60 minutes after study drug administration 
± 60 min 
In case deviations are more than allowed, a comment should be provided in the eCRF. 
Drug and Cotinine Screen 
For a urine drug screening, the following compounds will be assessed: amphetamine, 
barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine, morphine, 
phencyclidine, and tricyclic antidepressants. To check if a subject has been smoking, cotinine 
levels will be assessed. 
Pregnancy Test 
A serum pregnancy test will be performed at Screening. A urine pregnancy test will be performed 
at Day -1 of each study period and at Follow-up. The results of the test performed on Day -1 
must be available prior to dosing. 
Serology 
At screening, virus serology will be assessed (HIV, hepatitis B and hepatitis C). 
Total Blood Volume 
The total volume of blood to be taken per subject during the entire course of the study will be 
as follows: 
Table 8-2: Blood Volume 
 
Vol x Frequency 
Total (mL) 
Blood Chemistry (incl. virus 
serology, pregnancy testing) 
4.5 mL x 8 and 3.5 mL x 1 
39.5 mL 
Hematology 
3.0 mL x 8 
24.0 mL 
Coagulation 
2.7 mL x 8 
21.6 mL 
PK 
6.0 mL x 15 
90.0 mL 
PD (inflammation markers and 
biomarkers) 
3.0 mL x 11 (EDTA) and 
3.5 mL x 11 (serum) and 4.0 
mL x 11(heparin) 
115.5 mL 
PD (PBMC) 
18.0 mL x 4 (heparin) 
72.0 mL 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 70 of 100 
 
 
 
Total blood volume 
362.6 mL 
Blood Sample Storage 
Blood samples will be stored for 15 years for possible future research (genetic analysis 
excluded). 
 
8.5 Study Population 
The subject population will include adult male and female asthmatic subjects who satisfy all 
entry criteria. Any assessments may be repeated at the discretion of the (Principle or co-) 
investigators. 
Inclusion Criteria 
The following criteria must be met by all subjects considered for study participation: 
1. Females or males, between 18 and 55 years of age at Screening, inclusive, on the day 
of signing the Informed Consent Form (ICF). 
2. Apart from a clinically stable asthma and HDM-allergy, subjects should be generally 
healthy with no history of a clinically relevant medical condition that in the opinion of 
the investigator might interfere with successful study conduct and no clinically relevant 
abnormalities on medical history, physical exam, vital signs, laboratory parameters or 
ECG at Screening. 
3. Subject has a BMI ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 (and weighs ≥50 kg). 
4. Subjects have been diagnosed with asthma cf GINA guidelines. 
5. Subjects should have established allergy for HDM (serum HDM-specific IgE or 
positive SPT at Screening or documented within 1 year pre-screening). 
6. No severe exacerbation of asthma within past 1 year requiring hospital admission 
and/or treatment with oral corticosteroids; no (never) intensive care admissions for 
asthma or intubation). 
7. FEV1 should be ≥70% of predicted on Screening Day 2. 
8. On Screening Day 2, PC20FEV1(Meth) should be <16 mg/mL if methacholine chloride 
is used (or adjusted by a factor of 1.2 if methacholine bromide is used). If histamine is 
used, PC20FEV1(Hist) should be <16 mg/mL. 
9. Baseline blood eosinophils should be ≥150 cells/μL at Screening or documented within 
3 months before Screening Day 1. 
10. Subjects should have a documented airway late response to inhaled HDM on Screening 
Day 3. 
11. Subjects of childbearing potential must be willing to use adequate contraception 
(double birthbarrier) or must refrain from intercourse. 
12. Female subjects of non-childbearing potential must have had ≥ 12 months of 
spontaneous amenorrhea (with follicle-stimulating hormone [FSH] ≥ 30 mIU/mL). 
Surgically sterile women are defined as those who have had a hysterectomy, bilateral 
ovariectomy (for ‘benign’ reasons), or bilateral tubal ligation. 
13. All female subjects should have a negative pregnancy test at Screening and on Day -1. 
14. Negative alcohol breath test on Screening Day 1 and Day -1. 
15. Negative cotinine test on Screening Day 1 and Day -1. 
16. Negative urine drug screen for recreational and other drugs on Screening Day 1 and 
Day -1. 
17. Subjects are non-smokers. A non-smoker is defined as an individual who has abstained 
from smoking for at least 1 year prior to Screening Day 1. Number of years smoked x 
number of packs per day should be <5 pack years. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 71 of 100 
 
 
18. Subject should be willing and able to perform the lung function tests and other study- 
related procedures and comply with study protocol requirements. 
19. Subject should provide a signed and dated informed consent. 
Exclusion Criteria 
Subjects will be excluded if they meet any of the following criteria: 
1. Subject has any active and/or chronic (physical or mental) condition requiring 
maintenance (pharmaco)therapy or which otherwise precludes subject from safe or 
adequate study participation (ineligibility will be assessed by the PI). 
2. Subject has a history of cancer (exception: localized basalioma or cervix carcinoma in 
situ). 
3. Subject had any major (nasal) surgery in the 6 months before Screening Day 1. 
4. Subject is pregnant or lactating. 
5. Subject is using immunotherapy that according to the PI may interfere with the study 
(e.g. in case of immunotherapy with HDM or when subject is in the updosing phase of 
any immunotherapy). 
6. Subject regularly used alcohol (intake of >21 units/wk for males and >14 units/wk for 
females) and/or recreational drugs within the last 6 months prior to screening. 
7. Subject had any respiratory (viral) infections (e.g. common cold) within 3 weeks of 
Screening Day 1 or on Day -1. 
8. Subject is using maintenance asthma therapy or long-acting bronchodilators or any 
other anti-asthma or anti-allergic medications (as detailed in the protocol) other than 
infrequent use of SABA prn only. 
9. Subject is using prohibited medications as detailed in the protocol. 
10. Multi-sensitized symptomatic subjects with seasonal (pollen) allergies should be 
included outside of the relevant allergen season and/or should not be in frequent contact 
with the relevant allergen during the study. 
11. Subject has any known allergic response for the medications used or known severe 
allergic reactions or anaphylaxis (to food/medications/insect venoms). 
12. Subject participated in medical studies in the past 3 months (non-biologicals) or in the 
past 6 months (biologicals). 
13. Subject is anticipated not to comply with study medication or other aspects of the study 
(at the discretion of the investigator). 
Diet, Activities, and Other Restrictions 
8.5.3.1 Concomitant Medication 
During screening and study, subjects may only use a short-acting beta2agonist (SABA) on an 
infrequent, as needed basis for their asthma. More frequent intake of SABA will be allowed 
following allergen challenge as per instructions by the investigator with close monitoring. As 
an on-demand analgetic, only paracetamol is allowed on infrequent basis. 
The use of other types of concomitant medication is only allowed at the discretion of the 
investigator and in consent with the sponsor. If concomitant medication is needed during the 
study, this medication must be recorded on the eCRF, stating its generic name, date/time of 
administration, dose, route and duration, as well as the indication. 
The following medications are not allowed (and should be stopped) before screening and 
should be refrained from throughout the study: 
• Systemic corticosteroids (<16 weeks and ≤ 1x per year in the previous 3 years); 
• Inhaled corticosteroids or combinations with bronchodilators (<6 weeks); 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 72 of 100 
 
 
• Nasal corticosteroids (<4 weeks); 
• Cutaneous corticosteroids: only acceptable if infrequent use and small body surfaces – 
to be evaluated on an individual basis by the investigator/agreed by sponsor. 
• Anti-IgE (<6 months); 
• Allergen immunotherapy for HDM (never; for other allergens <3 months of start and 
only sublingual immunotherapy for pollen at stable levels for >3 months); 
• Long-acting beta agonists (LABA) < 48 hours or ultraLABA ( <2 weeks); 
• Long-acting muscarinic agonists (LAMA) (< 3 weeks); 
• LABA/LAMA combinations (<3 weeks); 
• Short-acting beta agonists (SABA) (< 6 hours; SABA prn is allowed if at stable doses 
and if on average no more than 2x daily during 1 month pre-screening); 
• Short-acting muscarinic antagonists (ipratropium bromide) (<48 h); 
• Leukotriene modifiers including Leukotriene receptor agonists 
(Montelukast/Zafirlukast/Pranlukast) (<2 weeks); 
• Cromoglycate (oral or topical) (<2 weeks); 
• Theophylline/PDE4 inhibitors (<2 weeks); 
• Antihistamines (< 1 week); 
• Living vaccines (<3 months); 
• Other vaccines or medications at the discretion of the investigator and with mutual 
consent of the sponsor; 
• Other study medication (<3 months); 
• Biologicals (<6 months); 
• Prior dosing of FP025 (< 6 months). 
8.5.3.2 Alcohol and Party Drugs 
Drinking of alcoholic beverages is not permitted from 48 hours prior to Day -1 until the last 
PK sample of that treatment period has been collected. During wash-out period and between 
treatment periods, 1 unit of alcohol per 24 hours is allowed. Use of party drugs is not permitted 
during the study. 
8.5.3.3 Physical Activities 
During Screening and study periods, subjects should refrain from excessive physical exercise 
and strenuous sports activities (e.g. endurance sports) at least 48 hours before onsite testing. 
After allergen challenge strenuous exercise should be discouraged (for at least 48 hours). 
Subjects should have generally a good night rest and should not be working in irregular night 
shifts during the study periods (i.e. from Day 1 to Day 12). 
8.5.3.4 Travelling 
During each study period, subjects will be discouraged to travel. Any long term travel plans 
(especially traveling abroad) should be discussed with site study staff. 
8.5.3.5 Dietary Aspects 
Drinking of xanthine-containing beverages, such as coffee/tea/cocoa/Coca-Cola, is not 
permitted 12 hours before onsite tests until the end of testing. For Day 10-12, this means no 
xanthine-containing beverages after approximately noon on Day 9 through Day 12 after testing. 
Decaffeinated drinks including green tea or rooibos tea are allowed during the study. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 73 of 100 
 
 
8.5.3.6 Smoking 
Use of any tobacco- or nicotine-containing product is prohibited until Follow-up. Furthermore, 
subjects will be instructed to as much as possible avoid passive (second-hand) smoking and 
other irritants (e.g. open fires/chemical paints/etc.) during the study. 
8.5.3.7 Concomitant allergies 
Symptomatic subjects with allergies to animals (e.g. cats) should not be exposed to these 
animals during the study. Subjects with symptomatic pollen allergies will be challenged outside 
of the relevant season. 
8.5.3.8 Contraception 
During the study, adequate (double-barrier) contraception should be used by male participants 
and/or their female partners. Acceptable methods of contraception include (but are not limited 
to): a condom, vasectomy, diaphragm, cervical/vault cap, oral contraceptives, intra-uterine 
device, spermicidal jelly, sexual abstinence. 
Females participating in the study must either be postmenopausal with no menses for at least 
12 months or surgically sterile (hysterectomy, bilateral ovariectomy or bilateral tubal ligation) 
or agree to use double birth barrier of contraception. Acceptable methods of contraception 
include (but are not limited to): diaphragm, cervical/vault cap, oral contraceptives, intra-uterine 
device, sexual abstinence, condom, vasectomy of the sexual partner (performed at least 90 days 
prior to Screening and medically assessed as successful). 
 
8.6 Study Drugs 
Study drugs include the investigational drug FP-025 and matching placebo administered during 
the study. 
Investigational Drug and Matching Placebo 
Foresee Pharmaceuticals Co., Ltd will provide FP-025 and matching placebo (Table 8–3Table 
8–3). FP-025 is available for clinical trial use in the form of capsules. Placebo is available as 
matching FP-025 for administration. 
Table 8–3: Study drug 
 
Study drug 
FP-025 
Placebo 
Form 
ASD-in-Capsule, 50 mg (size 0) 
Capsule (size 0) 
Supplier 
Foresee Pharmaceuticals Co., Ltd. 
Foresee Pharmaceuticals Co., Ltd. 
Manufacturer 
WuXi AppTec Co., Ltd. 
Site address: 299 FuTe Zhong 
Road, Waigaoqiao Free Trade 
Zone, Shanghai, 200131, P.R. 
China 
Email: joe_tu@wuxiapptec.com 
Tel: +86-21-20663130 
WuXi AppTec Co., Ltd. 
Site address: 299 FuTe Zhong 
Road, Waigaoqiao Free Trade 
Zone, Shanghai, 200131, P.R. 
China 
Email: joe_tu@wuxiapptec.com 
Tel: +86-21-20663130 
Storage 
condition 
Refrigerator 
Refrigerator 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 74 of 100 
 
 
Rescue Medication 
On Screening Day 3, all subjects will be provided with a short acting beta2-agonist (100 µg 
salbutamol/dose). Subjects will be instructed to use it throughout the study as rescue 
medication on an ‘as needed basis’. No other rescue medications will be permitted. 
Study Drug Preparation 
All study drugs will be prepared (i.e., packaged and labeled in individual doses) at QPS 
Netherlands B.V. by an unblinded pharmacist, or his/her designee. In order to minimize the 
risks associated with unblinding study staff, the pharmacist/designee is not involved in any 
other aspect of the study. All study drugs will be dispensed by the investigator or a person 
under his supervision. 
Study Drug Packaging 
Foresee Pharmaceuticals Co., Ltd will be responsible for the supply of the following drugs: 
• Oral capsules, each containing 50 mg of FP-025; 
• Matching placebo. 
The study drug will be packed and dispatched in containers. A batch release certificate will be 
provided, stating that the batches have been manufactured according to GMP. Study drugs are 
provided as capsules and supplied to the study center as a bulk shipment. Under the supervision 
of the pharmacist, the study drug will be packed per subject for each dosing occasion, according 
to the randomization list. 
Study Drug Labeling 
The labeling complies with the applicable (local) laws and regulations. At the minimum, the 
following information will be stated on the labels: 
• Study number 
• FP-025 (strength) or placebo 
• Name, address and telephone number of sponsor, CRO or investigator 
• Name of the investigator 
• Batch number 
• Subject identification/treatment number 
• Quantity of dosage units 
• Route of administration (e.g., oral), pharmaceutical dosage form and quantity of dosage 
units 
• Directions for use 
• Storage conditions 
• Retest or expiry date 
• “For clinical trial use only” or similar wording 
• “Keep out of reach of children” 
Study Drug Administration 
Dosing will take place twice daily: i.e., in the unit between 7:00 and 9:00 in the morning and 
in the evening and if at home between 6:00 and 10:00 in the morning and in the evening. Study 
medication is taken with a glass of water (approximately 240 ml, or extra if needed). In the 
event the study medication is taken at home the number of capsules taken will be recorded in 
a subject dairy. The subject will also be instructed to store the medication in the refrigerator 
and to secure limited access to the study medication. In total, subjects will receive 22 doses of 
400 mg FP-025 (8x 50 mg capsules, BID) or 22 doses of matching placebo (8 capsules, BID) 
during two study periods. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 75 of 100 
 
 
On PK sampling day (Day 11 and Follow-up), subjects are allowed to eat a light (not fat) 
breakfast. 
The time of administration of study medication and the initials of the person supervising the 
administration will be recorded in the eCRF. 
Storage and Return of the Study Drug 
Upon receipt of the study medication, the responsible pharmacists will inspect all study drugs 
for 
completeness. 
Subsequently, 
he/she 
must 
immediately 
return 
the 
enclosed 
acknowledgement of receipt form; duly completed and signed (the date of receipt must be 
noted). 
The pharmacists are responsible for storage of the study drug at the study site in an appropriate 
lockable room at adequate temperature (see Table 8–3). The study drug will be stored according 
to the instructions provided by the Sponsor. Only the pharmacist or his/her assistant, who are 
otherwise not involved in the study, will handle the study drug. 
A Drug Preparation Protocol as well as a Drug Accountability Record must be kept current and 
should contain the following information: 
• Subject number for whom the drug was prepared 
• Initials and date of the person who prepared the study drug 
• Name of the person who dispensed the study drug 
• Date(s) on which drug was prepared and quantity of the drug prepared 
• Quantity of drug provided to the subject for home use 
• Number of capsules returned 
• The inventory must be available for inspection by the monitor 
After sponsor confirmation, all unused investigational material (drugs and packaging) must be 
returned to the Sponsor after a drug accountability check by the monitor, listing the following: 
• All FP-025 and placebo administered 
• All unused FP-025 
• All FP-025 returned at the end of the study, and the date of return/destroyed by the site 
The pharmacist will be responsible for the inventory and accountability of all Clinical Trial 
Material, exercising accepted pharmaceutical practices. An accurate, timely record of the 
Clinical Trial Material will be maintained. Only after completion of the study (to avoid 
breaking the blind), the Clinical Trial Material and the inventory will be available for inspection 
by the designated representatives of Foresee Pharmaceuticals Co., Ltd upon request. The 
original Drug Preparation Protocol and Drug Accountability Record are considered as source 
data and will be archived at the site. 
 
8.7 Study Drug Discontinuation and Study Withdrawal 
Study Drug Interruption or Discontinuation 
The investigator must discontinue the study drug if continued administration of the study drug 
is believed to be contrary to the best interests of the subject. 
The premature discontinuation of study drug might be triggered by an Adverse Event (AE), a 
diagnostic or therapeutic procedure, an abnormal assessment (e.g., ECG or laboratory 
abnormalities), or for administrative reasons (in particular withdrawal of the subject’s consent). 
The reason for study drug discontinuation must be documented in the eCRF and the sponsor 
must be informed. If the reason for discontinuation from study drug is an abnormal result on a 
laboratory test, vital sign, ECG recording, or physical examination, this information will be 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 76 of 100 
 
 
recorded as an AE in the eCRF. The subject will remain under the supervision of the 
investigator until satisfactory health has returned. 
Study Discontinuation 
Subjects may prematurely discontinue the study at any time. Premature discontinuation from 
the study is to be understood as: 
• Subject did not undergo the EOS examination 
and/or 
• Subject is missing pivotal study related assessments 
The premature discontinuation of the study might be triggered by non-compliance with the 
study-related procedures, worsening of the underlying disease (asthma), an AE, withdrawal of 
the subject’s consent, administrative reasons, or because the subject is lost to follow up. A 
subject will be considered as lost to follow-up if, and only if, he or she cannot be reached after 
exhausting all means of contact. 
The reasons for premature discontinuation of the study must be documented in the eCRF and 
the Sponsor must be informed. 
Drop-outs may be replaced but only upon mutual agreement between the investigator and the 
Sponsor, unless withdrawal is due to a drug-related AE. The replacing subject will receive the 
same treatment as was assigned to the subject whom he/she replaces. 
Subject’s Follow-up after Study Discontinuation 
The subjects will be advised that participation in these investigations is voluntary. Furthermore, 
the subjects may request that from the time point of withdrawal no more data will be recorded 
and that all biological samples collected in the course of the study will be destroyed. 
In the case of premature discontinuation after study drug intake, the assessments scheduled for 
the EOS examination will be performed as soon as possible after study drug intake. 
 
8.8 Treatment Exposure and Compliance 
Records of study drug used, dosages administered, and intervals between visits are kept during 
the study. Study drug accountability is performed on an ongoing basis by the study staff and 
checked by the monitor during site visits and at the completion of the study. 
During the study, observed dosing will apply. Drug administrations in the clinic will be done 
under direct medical supervision by site staff. A hand and cavity check will be done 
immediately after each drug administration. When the drug is taken at home, compliance will 
be checked using a diary with on demand (video) phone calls. The measurement of plasma 
levels of FP-025 during the analytical phase will serve as a further check of compliance. 
 
8.9 Treatment Assignment and Blinding 
Assignment of Subject Numbers 
Subjects will receive a 4-digit number on Day 1 before the start of procedures/assessments. 
The assignment of number and code for subject identification is based on the obligation for 
anonymity. Screen-failures will be tracked and recorded on a screening log, which will be 
discussed during site initiation visit. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 77 of 100 
 
 
Subjects enrolled at QPS will be assigned a subject number in a rising, sequential manner, 
beginning with 1001, regardless of gender. Subjects enrolled at the AMC will be assigned a 
subject number in a rising, sequential manner, beginning with 2001, regardless of gender. 
Subjects who replace discontinuing subjects who have started procedures/assessments on Day 
1 will receive the number of this subject +100, e.g., subject 1106 will replace subject 1006, 
subject 1206 will replace subject 1106, etc. The substitute subject will receive the treatment 
assigned to the withdrawn subject. 
In the case of discontinuation before Day 1 procedures/assessments have started, the substitute 
subject will receive the same number as the subject he/she replaces. 
Treatment Assignment 
Subjects will be randomly allocated to start with either placebo or FP-025 in Period 1. The 
randomization code is stored securely. It is accessible only to authorized persons who are not 
involved in the conduct and analysis of the study, until time of unblinding. Individual sealed 
randomization codes are kept by the appropriate QPS representative, and these are used for 
emergency unblinding only. 
Randomization is controlled by the study drug packaging. The number on the medication 
container equals the randomization number. Subjects must be randomized in a consecutive 
order starting with the lowest medication container number. 
Randomization will be performed by the Biostatistics department of QPS Qualitix Taiwan, 
according to QPS Qualitix Taiwan SOPs. The randomization code and the randomization list 
will be generated using SAS version 9.3. 
For the purpose of an interim analysis (see Section 10.9), the randomization code of the subjects 
who have completed the study will be unblinded and made available for data analysis. 
Unblinding of the randomization code will also apply after study closure, i.e., when the study 
has been fully completed, the protocol deviations determined and the clinical database declared 
complete, accurate, and locked. 
Double-blinding 
The study is performed in a double-blinded fashion. The investigational drug and its matching 
placebo are indistinguishable and medication containers will be packaged in the same way. The 
randomization code will be kept strictly confidential. It is accessible only to the pharmacist on 
site, who is not involved in the conduct and analysis of the study, and will keep the 
randomization code/scheme strictly confidential. 
The investigator and research staff, the subjects, the monitors and the sponsor’s staff will 
remain blinded to the treatment until study closure. For the interim analysis (see Section 10.9), 
only the independent statistician will be unblinded to the study treatment of those subjects who 
have completed the study and have been included in the interim analysis. 
Emergency Procedure for Unblinding 
The investigator receives emergency envelopes for each subject containing the identity of the 
study drug dispensed. The investigator and the study staff must remain blinded to the subject's 
treatment assignment, even if the subject refuses to participate in any study procedures or 
experiences an AE. The identity of the study drug may be revealed only if the subject 
experiences a medical emergency whose management would be improved by the knowledge 
of the blinded treatment assignment. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 78 of 100 
 
 
The occurrence of any code break during the study must be clearly justified and explained by 
the investigator. Before opening the emergency envelope, every attempt must be made by the 
investigator to discuss the intended code break with Foresee Pharmaceuticals Co., Ltd. In all 
cases, the sponsor must be informed as soon as possible before or after the code break. 
Any code break must be documented on the emergency envelope and in a detailed report with 
the date and time of the code break and signed by the investigator. This report is to be attached 
to the eCRF. 
At each monitoring visit, the monitor checks the emergency envelopes. 
 
8.10 Study Parameters 
Pharmacodynamic Parameters 
The following pharmacodynamic parameters for FP-025 will be evaluated/measured: 
Primary parameter: 
Spirometry: 
• Area under the time-FEV1 response curve from 3-8 hours post-allergen (FEV1 AUC3- 
8h) 
Secondary parameters: 
Spirometry: 
• Area under the time-FEV1 response curve from 0-3 hours post-allergen (FEV1 AUC0- 
3h) 
• Max% fall in FEV1  from baseline between 0-3 hours post-allergen 
• Max% fall in FEV1  from baseline between 3-8 hours post-allergen 
• Area under the time-FEV1 response curve from 0-8 hours post-allergen (FEV1 AUC0- 
8h) 
Methacholine/histamine challenge: 
• Provocative concentration of methacholine or histamine causing 20% fall of the FEV1 
from baseline (PC20FEV1(Meth) or PC20FEV1(Hist)) 
Impulse-oscillometry (IOS), mainly: 
• Resistance at a frequency of 5 hertz (R5) 
• Resistance at a frequency of 20 hertz (R20) 
• Frequency dependence of resistance (R5-R20) 
• Resonant frequency (Fres) 
• Reactance at 5 hertz (X5) 
• Area under reactance curve (AX) 
Exhaled air: 
• Fractional exhaled nitric oxide concentration in exhaled air (FeNO) in parts per billion 
(ppb) 
Blood 
• Eosinophil counts 
Exploratory parameters: 
Impulse-oscillometry (IOS) post-methacholine/histamine challenge 
Nasal lavage (NAL): 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 79 of 100 
 
 
• Inflammatory and structural cell counts (cytospin): 
o Squamous and ciliated nasal epithelial cells 
o Total cells 
o Neutrophils 
o Eosinophils 
o Macrophages 
o Lymphocytes 
o Mast cells 
• Supernatant (soluble markers): 
o Cytokines (IL-1b, a.o.) and chemokines (e.g. Th2/ILC2 pathway and linked to 
eosinophils like IL-5, IL-33, a.o.) 
o Cellular activation markers (ECP, MPO, tryptase, chymase) 
• Markers of tissue remodeling (FGF, VEGF, MMP-12 and other MMP’s, to be 
determined) and leakage markers (e.g. albumin, alpha2-macroglobulin) 
Sputum: 
• Inflammatory and structural cell counts (cytospin): 
o Squamous and ciliated bronchial epithelial cells 
o Total cells 
o Neutrophils 
o Eosinophils 
o Macrophages 
o Lymphocytes 
o Mast cells 
• Supernatant (soluble markers; but not limited to): 
o Soluble cell activation markers (but not limited to): ECP, MPO, tryptase, 
chymase, TNF-α, IL-1α/β, IL-6, CXCL-8, IL-5, CXCL-1, CCL4, CCL20, 
scIgA, MMP-9, MMP-12, IL-33, TIMP-1, elastase 
o Soluble airway remodeling markers (but not limited to): hyaluronan, tenascin 
C, FGF 1/2, MMP-9, MMP-12, MMP’s (zymogram), IL-13, fractalkine, 
periostin, TGF-ß, YKL-40 (chitinase-3-like-1 protein), ADMA, VEGF 
o Soluble inflammatory leakage markers: alpha2-macroglobulin, albumin 
o Cytokines and chemokines of Th2/ILC2 and other mainstream pathways and 
those linked to eosinophils (but not limited to): IL-1α/β, IL-1RA, MIP-1α/β, 
IL-2, IL-4, IL-5, IL-10, IL-13, IL-17, IL-18, GMCSF, IFN-γ, IP-10, TNF-α, IL- 
33 
Nasal brush (NAB): 
• Genome-wide gene expression 
• microRNA expression 
• DNA methylation 
Exhaled breath condensate (EBC) (not limited to): 
• Chloro-tyrosine, bromo-tyrosine, nitro-tyrosine, tyrosine, di-tryrosine, arginine, 
ADMA, malondialdehyde, potentially also leukotrienes. 
Blood (not limited to): 
• Eosinophil activation markers (flow cytometry: CD69, CD11b and CD62L) 
• IL-5 
• Alpha2-macroglobulin 
• Albumin 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 80 of 100 
 
 
• Periostin 
• MMP’s (zymogram) 
Urine (not limited to): 
• Lipid mediators (to be determined) 
PBMC (to be decided): 
• Cytokine release after HDM exposure 
• Anti-oxidant response (to xanthine oxidase/xanthine) 
Parameters in italic are to be discussed and analysis will be decided upon after initial analyses 
have been performed. 
Safety and Tolerability Parameters 
Pre-treatment baseline is defined as the last value measured prior to (the first) study drug intake 
(vital signs, ECG, laboratory parameters, safety lung function), unless otherwise specified. 
The following parameters have been defined as parameters regarding safety and tolerability: 
• Physical examination 
• Overall asthma symptoms (VAS) 
• Clinical signs/symptoms reporting (MedDRA) 
• (S)AEs 
• Vital signs (HR, BP, temperature +/- SpO2) 
• Lung function measurements (FEV1, FEV1/FVC, PEF, IOS) 
• ECG 
• Clinical safety laboratory outcomes (e.g. blood: hematology, chemistry, clotting 
parameters and urinalysis). 
Pharmacokinetic Parameters 
The PK parameters for FP-025 in plasma will be derived by non-compartmental analysis of the 
plasma concentration-time profiles. 
The following pharmacokinetic parameters will be analyzed/calculated: 
• Maximum plasma concentration (Cmax); 
• Time to Cmax (tmax); 
• Area under the concentration-time curve from time zero to tau (AUC0-tau) 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 81 of 100 
 
 
9 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
9.1 Adverse Events 
Definitions of Adverse Events 
An Adverse Event (AE) is  any  adverse  change  from  the  subject’s  baseline  condition,  
i.e., any unfavorable and unintended sign including an abnormal laboratory finding, symptom 
or disease that occurs during the course of the study, whether or not considered related to the 
study drug. A treatment-emergent AE is any AE temporally associated with the use of a study 
drug, whether or not considered related to the study drug. 
Adverse events include: 
• Exacerbation of a pre-existing disease. 
• Increase in frequency or intensity of a pre-existing episodic disease or medical 
condition. 
• Disease or medical condition detected or diagnosed after study drug administration 
even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at baseline that worsen following 
the start of the study. 
• Events considered by the investigator to be related to study-mandated procedures and/or 
requiring any medical intervention. 
• Abnormal assessments, e.g., ECG, vital signs or physical examination findings, must 
be reported as AEs if they represent a clinically significant finding that was not present 
at baseline or worsened during the course of the study. 
• Laboratory test abnormalities must be reported as AEs if they represent a clinically 
significant finding, symptomatic or not, which was not present at baseline or worsened 
during the course of the study or led to dose reduction, interruption or permanent 
discontinuation of study drug. 
Adverse events do not include: 
• Medical or surgical procedure, e.g., surgery, endoscopy, tooth extraction, transfusion. 
However, the event leading to the procedure is an AE. If this event is serious, the 
procedure must be described in the SAE narrative. 
• Pre-existing disease or medical condition that does not worsen. 
• Situations in which an adverse change has not occurred, e.g., hospitalizations for 
cosmetic elective surgery or for social and/or convenience reasons. 
• Overdose of either study drug or concomitant medication without any signs or 
symptoms. However, overdose must be mentioned in the Study Drug Log. 
Intensity of Adverse Events 
The intensity of clinical AEs is graded on a three-point scale: mild, moderate, severe, and 
reported on specific AE pages of the eCRF. 
If the intensity of an AE worsens during study drug administration, the AE will be closed and 
a new AE with enhanced severity will be generated in the eCRF. If the AE lessens in intensity, 
no change in the severity is required. 
If an AE occurs during a washout or placebo run-in phase and afterwards worsens during the 
treatment phase, a new AE page must be filled in with the intensity observed during study drug 
administration. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 82 of 100 
 
 
Mild: Event may be noticeable to subject; does not influence daily activities; usually does not 
require intervention. 
Moderate: Event may make subject uncomfortable; performance of daily activities may be 
influenced; intervention may be needed. 
Severe: Event may cause noticeable discomfort; usually interferes with daily activities; subject 
may not be able to continue in the study; treatment or intervention is usually needed. 
A mild, moderate or severe AE may or may not be serious. These terms are used to describe 
the intensity of a specific event (as in mild, moderate, or severe myocardial infarction). 
However, a severe event may be of relatively minor medical significance (such as severe 
headache) and is not necessarily serious. For example, nausea lasting several hours may be 
rated as severe, but may not be clinically serious. Fever of 39 °C that is not considered severe 
may become serious if it prolongs hospital discharge by a day (see Section 9.2.1.2). Seriousness 
rather than severity serves as a guide for defining regulatory reporting obligations. On the other 
hand, a mild chest tightness – turning out to be a myocardial infarction requiring hospitalization 
will be termed an SAE (serious adverse event). 
These definitions do not apply to clinically significant and asymptomatic laboratory test 
abnormalities or abnormal assessments (e.g., ECG findings) considered as AEs. The 
investigator should tick non-applicable on the AE page of the eCRF to qualify the intensity of 
the AE. 
Relationship to Study Drug 
Adverse events should be assessed by the investigators as to whether or not there is a reasonable 
possibility of causal relationship to the study drug and reported as either related or unrelated. 
Related to study drug: This category applies to any AE (serious or not) that appears to have 
a reasonable possibility of causal relationship to the use of the study drug (i.e., a relationship 
cannot be ruled out). Guidelines to determine whether an event might be considered related 
include (but are not limited to) the following: 
• The event occurred in close temporal relationship to study drug administration. 
• The event abated (diminished) or disappeared when treatment with the study drug was 
down-titrated, interrupted, or discontinued. 
• The event re-occurred when treatment was re-introduced. 
• Environmental factors such as clinical state and other treatments could equally have 
caused the event. 
Related AEs should be considered as one of the following categories: 
Definite 
A clinical event, including laboratory test abnormality, occurring in a 
plausible time relationship to drug administration, and which cannot be 
explained by concurrent disease or other drugs or chemicals. The 
response to withdrawal of the drug (de-challenge) should be clinically 
plausible. The event must be definitive pharmacologically or 
phenomenologically, using a satisfactory re-challenge procedure if 
necessary. 
Probable 
A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and which 
follows a clinically reasonable response on withdrawal (de-challenge). 
Re-challenge information is not required to fulfill this definition. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 83 of 100 
 
 
Possible 
A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administration of the drug, but which 
could also be explained by concurrent disease or other drugs or 
chemicals. Information on drug withdrawal may be lacking or unclear. 
Unrelated to study drug: This category applies to any AE (serious or not) that does not appear 
to have a reasonable relationship to the use of study drug (see above guidelines). 
Unrelated AEs should be considered as one of the following categories: 
Unlikely 
A clinical event, including laboratory test abnormality, with a temporal 
relationship to drug administration which makes a causal relationship 
improbable, and in which other drugs, chemicals or underlying disease 
provide plausible explanations. 
Unrelated 
A clinical event, including laboratory test abnormality, which is clearly 
not related to drug administration. 
Reporting of Adverse Events 
All AEs occurring after signing the informed consent form and up to Follow-up must be 
recorded on specific AE pages of the eCRF. 
For randomized subjects only, all adverse events that occur after the consent form is signed but 
before randomization must be reported by the investigator if they are the result of a protocol 
specified intervention. 
Follow-up of Adverse Events 
Adverse events still ongoing after drug intake must be followed until resolution, or to a 
maximum of 28 days after study drug discontinuation. Follow-up will consist of a phone call 
or any other relevant procedures (e.g. repeating of a laboratory value or inspection or referral 
to a specialist, if deemed necessary by the investigator). 
If an AE is present at the follow-up visit/ end-of-study visit, it should be followed to resolution 
or stabilization unless the subject is lost to follow-up. Resolution means the subject has returned 
to baseline state of health or the Investigator does not expect any further improvement or 
worsening of the event. 
 
9.2 Serious Adverse Events 
Definitions 
9.2.1.1 Serious Adverse Events 
A Serious Adverse Event (SAE) is defined by the International Conference on Harmonization 
(ICH) guidelines as any AE fulfilling at least one of the following criteria: 
• Fatal. 
• Life-threatening. 
• Requiring subject's hospitalization or prolongation of existing hospitalization. 
• Resulting in persistent or significant disability or incapacity. 
• Congenital anomaly or birth defect. 
• Medically significant or requires intervention to prevent at least one of the outcomes 
listed above. 
• Life-threatening refers to an event in which the subject was at risk of death at the time 
of the event. It does not refer to an event that hypothetically might have caused death if 
it were more severe. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 84 of 100 
 
 
• Important medical events that may not immediately result in death, be life-threatening, 
or require hospitalization may be considered as SAEs when, based upon appropriate 
medical judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in the definitions above. 
The reference safety document to assess whether or not an SAE should be reported by the 
sponsor to Health Authorities, ECs/IRBs and investigators in an expedited fashion is the 
Investigator's Brochure. 
9.2.1.2 Pregnancy 
All initial reports of pregnancy, including pregnancy outcome (follow-up) in female subjects 
or in partners of male subjects, must be reported to the QPS Safety Unit (SU) by the investigator 
within 24 hours of his/her knowledge of the event using a Pregnancy Form. 
The investigator will contact the subject at the expected time of delivery for follow-up. 
Abnormal pregnancy outcomes (e.g., spontaneous or induced abortion, stillbirth, neonatal 
death, congenital abnormality, birth defect) are considered SAEs and must be reported using 
the Serious Adverse Event Form. 
9.2.1.3 Hospitalization - Prolongation of Existing Hospitalization 
Hospitalization is defined as an overnight stay in a hospital unit and/or emergency room. 
An additional overnight stay for monitoring of an AE defines a prolongation of existing 
hospitalization. Allergen-challenge related overnight stays without the need for maintenance 
asthma therapy (e.g. prednisone), will not qualify for an SAE. 
The following is not considered an SAE and should be reported as an AE only: 
• Treatment on an emergency or outpatient basis for an event not fulfilling the definition 
of seriousness given above and not resulting in hospitalization. 
The following reasons for hospitalizations are not considered AEs, and therefore not SAEs: 
• Extra overnight stay before or following study related procedures/including challenge 
testing which do not require intervention other than with bronchodilators. 
• Hospitalizations for cosmetic elective surgery, social and/or convenience reasons. 
• Standard monitoring of a pre-existing disease or medical condition that did not worsen, 
e.g., hospitalization for coronary angiography in a patient with stable angina pectoris. 
• Elective treatment of a pre-existing disease or medical condition that did not worsen, 
e.g., hospitalization for chemotherapy for cancer, elective hip replacement for arthritis. 
9.2.1.4 Serious Adverse Events Related to Study-mandated Procedures 
Such SAEs are defined as SAEs that appear to have a reasonable possibility of causal 
relationship (i.e., a relationship cannot be ruled out) to study-mandated procedures (excluding 
administration of study drug) such as discontinuation of subject's previous treatment during a 
washout period, or complication of a mandated study related challenge test or invasive 
procedure (e.g., blood sampling, HDM challenge test). 
Reporting of Serious Adverse Events 
9.2.2.1 Before Study Drug Initiation 
Serious adverse events occurring after signature of the Informed Consent and up to study drug 
initiation must be reported to QPS Safety unit only if they are considered by the investigator to 
be related to study- mandated procedures. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 85 of 100 
 
 
9.2.2.2 During Study Drug Administration 
All SAEs regardless of causal relationship must be reported, including those related to study- 
mandated procedures. These SAEs occurring during study drug administration, i.e., between 
study drug initiation and EOS after study drug discontinuation, are defined as treatment 
emergent SAEs. 
These SAEs are reported on SAE forms and also on AE pages in the eCRF. Therefore, they are 
entered both in the drug safety and clinical databases, and must be reconciled before study 
closure. 
9.2.2.3 After Study Drug Discontinuation 
New SAEs, including those related to study-mandated procedures, occurring during study drug 
administration, i.e., between study drug initiation and EOS, must be reported. 
All SAEs occurring after study drug discontinuation must be recorded on an SAE form and as 
AEs in the eCRF. Therefore, these treatment-emergent SAEs are entered both in the QPS drug 
safety and clinical databases, and must be reconciled before study closure. 
9.2.2.4 Reporting Procedures 
All SAEs must be reported by the investigator to QPS Safety unit within 24 hours of the 
investigator's knowledge of the event. 
All SAEs must be recorded on SAE forms, irrespective of the study drug received by the 
subject, whether or not this event is considered by the investigator to be related to study drug. 
These SAE forms must be e-mailed to QPS Safety unit (see contact details page 4). The 
investigator must complete the SAE form in English (unless otherwise specified) and assess 
the relationship to study drug. 
Such preliminary reports will be followed by detailed descriptions that should include copies 
of hospital case reports, autopsy reports, hospital discharge summaries and other documents 
when requested and applicable. Follow-up information about a previously reported SAE must 
also be reported within 24 hours of receiving it. QPS Safety unit may contact the investigator 
to obtain further information. 
Suspected (considered related to the study drug) and Unexpected (not previously described in 
the reference safety document), Serious Adverse Reactions (SUSARs) will be expedited by 
QPS Safety unit to Health Authorities, ECs/IRBs and investigators, as appropriate. SUSARs 
will not be subject to systematic unblinding. 
9.2.2.5 Procedure for Unblinding of Serious Suspected Adverse Reactions 
The unblinding procedure for serious suspected adverse reactions is defined in the safety 
management plan. 
Follow-up of Serious Adverse Events 
Serious adverse events still ongoing at the End-of-Study visit must be followed until resolution 
or stabilization or until the event is otherwise explained. 
New SAEs occurring at any time after the End-of-Study or after the 28-day follow-up period 
after study drug discontinuation (whichever comes first) may be reported to QPS Safety unit 
within 24 hours of the investigator's knowledge of the event, if felt appropriate by the 
investigators. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 86 of 100 
 
 
Such information will only be entered into the drug safety database and hence will not affect 
study closure. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 87 of 100 
 
 
10 STATISTICAL METHODOLOGY AND ANALYSES 
10.1 Statistical Analysis Plan 
The effect of FP-025 on primary and secondary outcome parameters will be statistically tested 
using paired tests comparing observations in the placebo period versus observations during 
active treatment with FP-025. Presence of period and carry-over effects will be evaluated using 
a two-group two-period within-subject analysis of variance. 
A statistical analysis plan (SAP) will be written and finalized before the final study closure, 
i.e., database closure and unblinding of the randomization code of the study. The SAP will 
provide full details of the individual analyses, the data displays and the algorithms to be used 
for data derivations. A SAP for safety, tolerability and PD will be written by QPS Qualitix 
Taiwan. A PKAP for the PK analyses will be written by QPS LLC. All analyses on efficacy 
outcomes including their relationships or relationships between PK and PD/clinical/biomarker 
outcomes will be overseen by the independent statistician (Prof A.H. Zwinderman). 
The SAP will include the link of major protocol deviations/violations to the analysis sets. 
Any deviations from the original statistical plan will be described and justified in the final 
report. 
 
10.2 Analysis Sets 
Three different analysis sets will be defined. Subjects who withdraw from the study, or who 
have missing data, will be included in the statistical analyses provided that they are eligible for 
inclusion in the analysis population as described below. 
All-treated set: This analysis set includes all randomized subjects who received study drug (at 
least one dose). 
Safety set: This analysis set includes subjects from the all-treated set who had at least one 
safety assessment post-baseline. The safety set will be employed in the analysis of tolerability 
and safety variables. 
Per-protocol set: This analysis set comprises all subjects included in the All-treated set who 
did not violate the protocol in a way that might affect the evaluation of the effect of the study 
drug on the primary endpoint, i.e., without major protocol violations or deviations. The Per- 
protocol set will be employed in the analysis of PK variables. 
Sample Size 
Approximately 100 male and female HDM-allergic asthmatics (between 18 and 55 years of 
age at Screening, inclusive) will be screened to yield approximately 36 eligible subjects to be 
enrolled, to yield 32 evaluable subjects. 
The sample sizes for this study are based on previous allergen challenge studies [9] and 
previous local experiences including several outcomes (airway physiology and several 
(diluted) biomarkers), taking into account additional variability due to a 2 centre setup. 
Procedure for accounting for missing, unused, and spurious data 
All analyses will be performed on data available at the time point considered. In summary 
tables, the number of subjects with missing data will be presented unless otherwise specified. 
In the calculation of percentages, subjects with missing data if not included in an analysis will 
not be considered in numerator or denominator unless otherwise specified. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 88 of 100 
 
 
10.3 Pharmacodynamic Parameters 
All FEV1 values post-allergen will be expressed as %fall from post-diluent baseline (FEV1) 
and the highest, technically satisfactory FEV1 value per pre-defined time point will be included 
into analysis. This excludes additional time points from analysis (e.g. if between a time interval 
additional spirometry has been performed for safety reasons – these values do not need to be 
included into analysis). PC20FEV1(Meth) or PC20FEV1(Hist) will be calculated as defined in 
the SOP. Analyses of all (including additional) PD parameters and any relationships between 
parameters will be detailed in the SAP. 
A definition of the PD parameters is described in Section 8.10.1. 
The following analyses will be performed (but not limited to): 
Primary: 
• LAR (FEV1 AUC3-8h): differences between FP025 and placebo 
Secondary, differences in (FP025 versus placebo): 
• EAR: as FEV1 AUC0-3h post-allergen and in max%fall from post-diluent baseline 0-3 h 
post-allergen 
• LAR: max%fall from post-diluent baseline 3-8 h post-allergen 
• Joint HDM-induced airway response expressed as FEV1 AUC0-8h post-allergen 
• Changes in allergen-induced AHR: i.e: PC20FEV1(Meth) or PC20FEV1(Hist) pre-post 
allergen (Day 10 versus Day12) 
• Small airway parameters measured by IOS during LAR and during EAR and over 0-8 
h post-allergen challenge (to be determined) 
• Changes in allergen-induced airway and systemic biomarkers (i.e. eosinophils (blood) 
and FeNO (exhaled air) (Day 10 versus Day12) 
• Changes in blood eosinophils, FeNO and PC20FEV1(Meth) or PC20FEV1(Hist) Day 1 
versus Day 10 (potential treatment effect) 
Exploratory (allergen-induced changes (Day 10 versus Day 12) and potential treatment effects 
(Day 1 versus Day 10) on the following parameters, but not limited to): 
• Treatment effects: differences in changes in the following parameters (Day 1 versus 
Day 10): spirometry (baseline FEV1), PC20FEV1(Meth)/PC20FEV1(Hist) and airway 
and systemic biomarkers (i.e. in blood/urine/exhaled air (FeNO, EBC), NAL/NAB; 
sputum). 
• Allergen-induced changes in exploratory inflammatory biomarkers (Day 10 versus Day 
12) (i.e.: cellular and soluble biomarkers in sputum / NAL; biomarkers in EBC; in 
blood/urine/ex vivo 
• Potentially longer lasting treatment effects 14 days following Period 2 (spirometry 
(baseline FEV1), PC20FEV1(Meth)/PC20FEV1(Hist) and airway and systemic 
biomarkers (i.e. in blood/urine/exhaled air (FeNO, EBC), NAL/NAB; sputum). 
• To relate biomarkers and physiological changes in different compartments (central 
airways/small airways/upper airways). 
• To explore the effect of study medications on gene-transcriptomics from NAB pre- 
versus post-allergen. 
• IOS measurements following inhaled allergen and eventual methacholine/histamine 
challenges to assess the effect of study medication on the peripheral airways and for 
additional safety. 
• Only the MedDRA (safety) and PK parameters will be reported descriptively; the others 
will be analyzed either by paired t-testings or by ANOVA. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 89 of 100 
 
 
All output will be reported using tables and/or figures including descriptive statistics. 
Individual results will be listed and plots (versus baseline) will be generated. 
PK values will be used to evaluate safety but also to ensure that efficacy data can be adequately 
interpreted and eventually to compare PK between asthmatic subjects and healthy subjects (in 
the previous MAD study). 
 
10.4 Safety and Tolerability Parameters 
Definitions of the safety and tolerability parameters are described in Section 8.10.2. 
The safety set is used to perform all safety analyses. 
The medical history is coded using the MedDRA version 20.1 or higher and listed. 
All AEs and SAEs are coded using the MedDRA version 20.1 or higher. 
The treatment-emergent AEs are tabulated by system organ class (SOC), and individual 
preferred terms within each SOC by treatment group. The number and percentage of subjects 
who experienced AEs coded with the same preferred term and SOC will be summarized by 
treatment group (in descending order according to the incidence in the investigational study 
drug group). Adverse events will also be tabulated by severity and by relationship to study 
drug. Summary tables will be accompanied by individual subject listings broken down by 
treatment group, including pre-dose events. 
SAEs will be listed and summarized similarly to AEs. 
Reasons for death will only be listed. 
Reasons for premature discontinuation of study drug will be listed and summarized by 
frequency tables. 
ECG variables, vital sign measurements, lung function measurements and laboratory 
measurements will be summarized at each time point using mean, median, standard deviation 
(SD), min, max, number of available observations, and change from baseline. Individual patient 
listings of ECG data, vital sign data, lung function data and laboratory measurements will be 
provided. 
Standard numeric laboratory parameters are presented in the units supplied. If needed, a 
conversion will be made to standard units. 
 
10.5 Pharmacokinetic Parameters 
The PK parameters (i.e., Cmax, tmax, AUC0-tau) will be calculated on the basis of the actual blood 
sampling time points. Please refer to Section 8.4.5.1 for details on the usage of timing of 
sampling. 
Pharmacokinetic Statistical Analysis 
A definition of the PK parameters is described in Section 8.10.3. PK parameters will be 
described descriptively. 
The per-protocol analysis set will be used for all PK analyses. No analysis will be done for 
placebo samples. Individual subject listings will be provided. Mean and individual plasma 
concentration-time profiles for FP-025 will be presented graphically. 
PK parameters will be summarized using arithmetic mean, SD, geometric mean, median, 
minimum, maximum, CV%, and two-sided 95% confidence limits of the geometric mean. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 90 of 100 
 
 
10.6 Exposure to Study Drug 
A listing with information about the drug administration will be provided. 
 
10.7 Baseline Characteristics and Concomitant Medications 
Summary statistics (mean, median, SD, min, max, number of available observations) will be 
provided for continuous demographic variables (e.g., age, height, weight). Individual subject 
listings of demographic data will be provided. 
Qualitative demographic characteristics (gender, race) will be summarized by counts and 
percentages. Other baseline subject characteristics (medical history, physical examination 
clinical findings, previous medications, inclusion/exclusion checklist) will only be listed. 
Distributions of these characteristics will be compared between the treatment groups only 
descriptively. No statistical inference will be performed. 
Previous and concomitant medications will be coded by the sponsor according to the WHO 
drug code and the ATC class code. Previous medications will be summarized by tabulating the 
number and percentages of patients treated. 
 
10.8 Exploratory Analyses 
Exploratory data-driven analyses can be performed at a later time point, i.e. after finalizing the 
CSR and can be added as an addendum later on. 
 
10.9 Interim Analysis 
After at least 11 subjects have successfully completed both treatment periods (with fully 
analyzable data sets of airway responses and sputum cytospins), an interim analysis will be 
conducted in order to compute the conditional power of a significant difference between FP-
025 and placebo treatment on the LAR as well as on the sputum eosinophil counts (reflecting 
target engagement), at the planned end of the trial in the presence of sufficiently high PK 
levels and at the original expectation of the effect of FP-025 on the LAR. If the conditional 
power is less than 25%, the trial may be stopped for futility. However, such a decision will 
depend on the size of the FP-025 treatment-effect on secondary and exploratory outcomes. 
In addition, the size of a potential carry-over effect of active treatment in the first treatment 
period into effects of treatment in the second treatment period will be investigated. If the size 
of the carry-over is larger than expected, the statistical analysis for the remaining subjects may 
be amended. 
No adjustment of the sample size is made because with the intended sample size of 32 evaluable 
subjects, the power of the original effect is over 95% and this remains the case with the addition 
of the interim analysis. 
In the absence of any clinically relevant AEs, recruitment and study conduct will continue 
during (preparation of) the interim analysis. 
 
10.10 Clinical Study Report 
Safety and tolerability parameters as well as PD (efficacy) and PK parameters will be evaluated 
in a Clinical Study Report. The CSR will include the data and the analysis of both the primary 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 91 of 100 
 
 
and secondary parameters; exploratory parameters and analyses may be added in an addendum 
to the CSR later on. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 92 of 100 
 
 
11 REFERENCES 
1. 
Mukhopadhyay S, Sypek J, Tavendale R, Gartner U, Winter J, Li W, Page K, Fleming M, 
Brady J, O'Toole M, Macgregor DF, Goldman S, Tam S, Abraham W, Williams C, Miller 
DK, Palmer CN. (2010) Matrix metalloproteinase-12 is a therapeutic target for asthma in 
children and young adults, J Allergy Clin Immunol. 126(1): 70-76.e16 
2. 
Cataldo DD, Tournoy KG, Vermaelen K, Munaut C, Foidart JM, Louis R, Noël A, 
Pauwels RA. (2002) Matrix metalloproteinase-9 deficiency impairs cellular infiltration 
and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J 
Pathol. 161(2): 491-498 
3. 
Pouladi MA, Robbins CS, Swirski FK, Cundall M, McKenzie AN, Jordana M, Shapiro 
SD, 
Stämpfli 
MR. 
(2004) 
Interleukin-13-dependent 
expression 
of 
matrix 
metalloproteinase-12 is required for the development of airway eosinophilia in mice. Am 
J Respir Cell Mol Biol. 30(1): 84-90 
4. 
Hinks TS, Brown T, Lau LC, Rupani H, Barber C, Elliott S, Ward JA, Ono J, Ohta S, 
Izuhara K, Djukanović R, Kurukulaaratchy RJ, Chauhan A. (2016) Howarth PH. 
Multidimensional endotyping in patients with severe asthma reveals inflammatory 
heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin 
Immunol. 138(1): 61-75. 
5. 
Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, 
Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich 
TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. (2011) Effects of interleukin-13 
blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit 
Care Med. 183(8): 1007-1014 
6. 
Churg A, Zhou S, Wright JL. (2012) Matrix metalloproteinases in COPD. Eur Respir J. 
39: 197–209 
7. 
Chaudhuri R, McSharry C, Brady J, Donnelly I, Grierson C, McGuinness S, Jolly L, Weir 
CJ, Messow CM, Spears M, Miele G, Nocka K, Crowther D, Thompson J, Brannigan M, 
Lafferty J, Sproule M, MacNee W, Connell M, Murchison JT, Shepherd MC, Feuerstein 
G, Miller DK, Thomson NC. (2012) Sputum matrix metalloproteinase-12 in patients with 
chronic obstructive pulmonary disease and asthma: Relationship to disease severity. J 
Allergy Clin Immunol. 129:655-663 
8. 
Investigator’s Brochure, Version 6, 25 January 2018 
9. 
Diamant Z, Gauvreau GM, Cockcroft DW, Boulet LP, Sterk PJ, de Jongh FH, Dahlén B, 
O'Byrne PM. (2013) Inhaled allergen bronchoprovocation tests, J Allergy Clin Immunol 
132(5): 1045-1055.e6 
10. Stenberg H, Diamant Z, Ankerst J, Bjermer L, Tufvesson E. (2017) Small airway 
involvement in the late allergic response in asthma. Clin Exp Allergy 47 (12), 1555-1565 
11. Al-Muhsen S, Johnson JR, Hamid Q. (2011) Remodeling in asthma. J Allergy Clin 
Immunol. 128(3), 451-462 
12. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. (2000) 
Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. 
Am J Respir Crit Care Med.161(6):2051-2057 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 93 of 100 
 
 
13. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. (2001) 
Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia 
in upper and lower airways. J Allergy Clin Immunol. 107(3):469-476 
14. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena- 
Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, 
Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl 
R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, 
Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer 
EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, 
Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, 
Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, 
Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman 
ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, 
Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, 
Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo 
JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, 
Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams 
D; World Health Organization; GA(2)LEN; AllerGen. (2008) Allergic Rhinitis and its 
Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health 
Organization, GA(2)LEN and AllerGen). Allergy 63 Suppl 86:8-160. 
15. Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE. (1978) Reproducibility 
and comparison of responses to inhaled histamine and methacholine. Thorax. 33(6): 705– 
710. 
16. Ravensberg AJ, Van Rensen ELJ, Grootendorst DC, De Kluijver J, Diamant Z, 
Ricciardolo FLM, Sterk PJ. (2007) Validated safety predictions of airway responses to 
house dust mite in asthma. Clin Exp Allergy 37(1):100-7. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 94 of 100 
 
 
12 PROCEDURES AND GOOD CLINICAL PRACTICE 
12.1 Procedures 
Protocol Amendments 
Any substantial change to a protocol has to be considered as an amendment as soon as these 
documents have been submitted to ECs/IRBs or Health Authorities. Therefore, an amendment 
could occur before or after the approval of these documents by ECs/IRBs or Health Authorities. 
Each amendment must be documented in writing and approved by Foresee Pharmaceuticals 
Co., Ltd. It should be reviewed by the Principal Investigator(s). 
Adaptations of the core subject Information and Informed Consent requested by ECs/IRBs are 
not considered as amendments, as long as they do not significantly change the core document 
or affect the protocol. 
12.1.1.1 Non-substantial Amendment 
Administrative or logistical minor changes require a non-substantial amendment. Such changes 
include but are not limited to changes in study staff or contact details (e.g., Foresee 
Pharmaceuticals Co., Ltd instead of CRO monitors) or minor changes in the packaging or 
labeling of study drug. 
The implementation of a non-substantial amendment could be done with or without (according 
to national regulations) notification to the appropriate ECs/IRBs and Health Authorities. It does 
not require their approval or to be signed by the investigators. 
12.1.1.2 Substantial Amendment 
Significant changes require a substantial amendment. Significant changes include but are not 
limited to: new data affecting the safety of subjects, change of the objectives/ parameters of the 
study, eligibility criteria, dose regimen, study assessments/procedures, treatment or study 
duration, with or without the need to modify the core Subject Information and Informed 
Consent. 
Substantial amendments are to be approved by the appropriate ECs/IRBs and in some countries 
by the Health Authorities. The implementation of a substantial amendment can only occur after 
formal approval by the appropriate ECs/IRBs and/or Health Authorities and must be signed by 
the investigators. 
12.1.1.3 Urgent Amendment 
An urgent amendment might become necessary to preserve the safety of the subjects included 
in the study. The requirements for approval should in no way prevent any immediate action 
being taken by the investigators or Foresee Pharmaceuticals Co., Ltd in the best interests of the 
subjects. Therefore, if deemed necessary, an investigator can implement an immediate change 
to the protocol for safety reasons. This means that, exceptionally, the implementation of urgent 
amendments will occur before submission to and approval by ECs/IRBs and Health 
Authorities. 
In such cases, the investigator must notify Foresee Pharmaceuticals Co., Ltd within 24 hours. 
A related substantial amendment will be written within 10 working days by Foresee 
Pharmaceuticals Co., Ltd and submitted to the appropriate ECs/IRBs and Health Authorities. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 95 of 100 
 
 
Monitoring 
The monitor will contact and visit the investigator regularly and will be allowed, on request, to 
have access to all source documents needed to verify the entries on the eCRF and other protocol 
related documents; provided that subject confidentiality is maintained in agreement with local 
regulations. It will be the monitor's responsibility to inspect the eCRF at regular intervals 
throughout the study, to verify the adherence to the protocol and the completeness, consistency 
and accuracy of the data being entered on them. Foresee Pharmaceuticals Co., Ltd monitoring 
standards require full verification for the presence of informed consent, adherence to the 
inclusion/exclusion criteria, documentation of SAEs and the recording of the main efficacy, 
safety and tolerability parameters. Additional checks of the consistency of the source data with 
the eCRFs are performed according to the study-specific monitoring plan. 
The investigator must ensure that subjects' anonymity will be maintained. On eCRFs or other 
documents submitted to Foresee Pharmaceuticals Co., Ltd, subjects should not be identified by 
their names, but by the subject number. The investigator must keep a subject identification 
code list showing the randomization number, the subject's name, date of birth and address or 
any other locally accepted identifiers. Documents identifying the subjects (e.g., subjects' signed 
informed consent forms) should not be sent to Foresee Pharmaceuticals Co., Ltd and must be 
kept by the investigator in strict confidence. 
The investigator and co-investigators agree to cooperate with the monitor(s) to ensure that any 
issue detected in the course of these monitoring visits is resolved. If the subject is hospitalized 
or dies in a hospital other than the study center, the investigator or co-investigator is in charge 
of contacting this hospital in order to document this SAE. 
The investigator will supply Foresee Pharmaceuticals Co., Ltd on request with any required 
background data from the study documentation or clinic records. This is particularly important 
when eCRFs are illegible or when errors in data transcription are suspected. In case of special 
problems and/or governmental queries, it is also necessary to have access to the complete study 
records, provided that subject confidentiality is protected. 
An initiation visit will be performed before the first subject is included. Monitoring visits and 
contacts will occur at regular intervals thereafter, according to a frequency defined in the study- 
specific monitoring plan. A close-out visit will be performed after study closure. 
Data Management 
12.1.3.1 Data Collection 
A Subject Screening and Enrollment Log will be completed for all eligible or non-eligible 
subjects with the reasons for exclusion. 
For each subject enrolled, regardless of study drug initiation, an eCRF must be completed and 
signed by the Principal Investigator. This also applies to those subjects who fail to complete 
the study. If a subject withdraws from the study, the reason must be noted on the eCRF. Case 
report forms are to be completed on an ongoing basis. 
Designated investigator staff will enter the data required by the protocol into the electronic 
Case Report Forms. Designated investigator site staff will not be given access to the EDC 
system until they have been trained. The Investigator must certify that the data entered into the 
Electronic Case Report Forms are complete and accurate. 
Furthermore, subjects will be completing diaries. In these diaries subjects will record 1) asthma 
control (good – fair – uncontrolled); 2) any asthma triggers (allergens, environmental, 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 96 of 100 
 
 
physical); 3) rescue medication (number of puffs); 4) any AEs (changes in physical condition; 
5) drug intake (during study), how many capsules and time point of administration. 
12.1.3.2 Database Management and Quality Control 
Data from the source documents will be entered into the eCRF as specified in QPS Netherlands 
SOPs. After completion of the eCRF, each subject will be electronically approved (signed) by 
the investigator. 
The CRA will perform source data verification according to the monitoring plan and the SOPs 
of the CRS department. The CRA will use the eCRF system to track the monitoring queries 
and their resolution by the site. 
The entered data is systematically checked by Data Management of the CRS department, QPS 
Netherlands, according to specifications described in the Data Management Plan and the 
applicable SOPs. The Data Management Plan will include the definition of major and minor 
protocol deviations/violations. 
After the eCRF has been declared complete and accurate, the eCRF will be locked, after written 
approval of the Sponsor. Any changes to the eCRF after that time require a database unlock 
and can only be made after receipt of written approval of the Sponsor. 
Recording of Data and Retention of Documents 
The investigator will maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents will 
be classified into two different categories: investigator's file, and subjects’ clinical source 
documents. 
The investigator's file will contain the protocol/amendments, financial disclosure forms, eCRFs 
and data clarification and query forms, EC/IRB and Health Authority approval with 
correspondence, informed consent, drug records, participating staff curriculum vitae and 
authorization forms, screening and enrolment logs, delegation log and other appropriate 
documents/correspondence as per ICH/Good Clinical Practice (GCP) and local regulations. 
Subjects’ clinical source documents include, but are not limited to, subjects’ hospital/clinic 
records, physician's and nurse's notes, appointment book, original laboratory, ECG, lung 
function, and other special assessment reports, consultant letters, diaries etc. 
These two categories of documents must be kept on file by the investigator and site for as long 
as needed to comply with national and international regulations (generally 2 years after 
discontinuing clinical development or after the last marketing approval). No study document 
should be destroyed without prior written approval from Foresee Pharmaceuticals Co., Ltd. 
Should the investigator wish to assign the study records to another party, or move them to 
another location, Foresee Pharmaceuticals Co., Ltd must be notified in advance. 
When source documents are required for the continued care of the subject, appropriate copies 
should be made for storing outside of the site. 
Audit 
Foresee Pharmaceuticals Co., Ltd may conduct audits of clinical research activities in 
accordance with internal standard operating procedures (SOPs) to evaluate compliance with 
the principles of GCP and ICH related guidelines. 
Health Authorities may also wish to conduct an inspection (during the study or after its 
completion). Should an inspection be requested by Health Authorities, the investigator must 
inform Foresee Pharmaceuticals Co., Ltd immediately that such request has been made. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 97 of 100 
 
 
The investigator will permit such audits by Foresee Pharmaceuticals Co., Ltd. or Health 
Authorities and facilitate them by providing access to the relevant source documents. 
Handling of Study Drug(s) 
Foresee Pharmaceuticals Co., Ltd will supply all study drug(s) to the site according to local 
regulations. Drug supplies must be kept in an appropriate, secure area and stored according to 
the conditions specified on the drug labels. The site must maintain an accurate record of the 
shipment and dispensing of study drug(s) on an accountability form, which must be given to 
the monitor at the end of the study. An accurate record of the date and amount of study drug(s) 
dispensed to each subject must be available for inspection at any time. 
All drug supplies are to be used only for this protocol and not for any other purpose. The 
responsible person must not destroy any drug labels, or unused drug supply. Upon termination 
of the study, the monitor will collect used and unused drug subject kits. They will be sent to 
the warehouse, where the sponsor or its deputy will check drug accountability. In certain 
circumstances, used and unused drug containers can be destroyed at the site once drug 
accountability is final and checked by the sponsor or its deputy and written permission for 
destruction has been obtained from Foresee Pharmaceuticals Co., Ltd. 
Publication of Study Results 
In accordance with standard editorial and ethical practice, Foresee Pharmaceuticals Co., Ltd 
will support publication of the data by the investigators and eligible staff conform ICMJE 
recommendations. This will be done under the responsibility of Foresee Pharmaceuticals Co., 
Ltd. in close collaboration with the investigators. The Principle investigators (ZD, RL) and co- 
investigators (KAE, MvdB) will be granted co-authorship and will work with Foresee 
Pharmaceuticals on any future publications. 
Disclosure and Confidentiality 
By signing the protocol, the investigator agrees to keep all information provided by Foresee 
Pharmaceuticals Co., Ltd in strict confidence and to request similar confidentiality from his/her 
staff and the EC/IRB. Study documents provided by Foresee Pharmaceuticals Co., Ltd 
(investigators' brochures, protocols, eCRFs and other protocol-related documents) will be 
stored appropriately to ensure their confidentiality. The information provided by Foresee 
Pharmaceuticals Co., Ltd to the investigator may not be disclosed to others without direct 
written authorization from Foresee Pharmaceuticals Co., Ltd, except to regulatory bodies as 
required including EC/IRB, the auditor from the Health Authority, a representative of the 
sponsor and to the extent necessary to obtain informed consent from subjects who wish to 
participate in the trial. 
Premature Termination or Suspension of the Study 
Both Foresee Pharmaceuticals Co., Ltd and the investigator reserve the right to terminate the 
study at any time. 
If a study is prematurely terminated or suspended, Foresee Pharmaceuticals Co., Ltd will 
promptly inform the investigators, the ECs/IRBs and Health Authorities, as appropriate, and 
provide the reason(s) for the termination or suspension. 
If the study is prematurely terminated or suspended for any reason, the investigator in 
agreement with Foresee Pharmaceuticals Co., Ltd should promptly inform the enrolled subjects 
and ensure their appropriate treatment and follow-up. 
In addition, if the investigator terminates or suspends a study without prior agreement of the 
sponsor, the investigator should promptly inform Foresee Pharmaceuticals Co., Ltd and the 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 98 of 100 
 
 
EC/IRB, and should provide the sponsor and the EC/IRB with a detailed written explanation 
of the termination or suspension. 
If the EC/IRB terminates or suspends its approval/favorable opinion of a study, the investigator 
should promptly notify Foresee Pharmaceuticals Co., Ltd and provide Foresee Pharmaceuticals 
Co., Ltd with a detailed written explanation of the termination or suspension. 
 
12.2 Good Clinical Practice 
Ethics and Good Clinical Practice 
The investigator will ensure that this study is conducted in full conformance with the principles 
of the "Declaration of Helsinki" (as amended in Tokyo, Venice, Hong Kong, Somerset-West, 
Edinburgh, Washington DC, Tokyo, Seoul and Fortaleza) and with the laws and regulations of 
the country in which the clinical research is conducted. 
All studies must follow the ICH GCP Guidelines and, if applicable, the Code of Federal 
Regulations. 
Quality Control and Quality Assurance 
Quality control will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly. 
The Sponsor can decide to conduct an audit at the clinical study center. The audit will be 
conducted with the aim to ensure that the clinical study is performed and data are generated, 
documented (recorded) and reported according to the protocol and in compliance with GCP 
and applicable regulatory requirements. An external party may be contracted for this purpose. 
On request of the sponsor, QA may perform a study audit including the data management 
process. 
Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related documents provided to the subject 
(such as subject information used to obtain informed consent) to an Ethics Committee (EC) or 
Institutional Review Board (IRB). Approval from the committee must be obtained before 
starting the study, and should be documented in a dated letter to the investigator, clearly 
identifying the trial, the documents reviewed and the date of approval. A list of members 
participating in the meeting must be provided, including the functions of these members. If 
study staff were present, it must be clear that none of these persons voted. 
Modifications made to the protocol after receipt of the EC/IRB approval must also be submitted 
as amendments by the investigator to the EC/IRB in accordance with local procedures and 
regulations (see Section 12.1.1). 
Informed Consent 
It is the responsibility of the investigator to obtain written informed consent from each 
individual participating in this study after adequate explanation of the aims, methods, and 
objectives of the study and potential hazards of the study drug. The investigator must also 
explain to the subjects that they are completely free to refuse to enter the study or to withdraw 
from it at any time for any reason. Appropriate forms for documenting written informed 
consent will be provided to the sites prior to the study. 
The Informed Consent and Subject Information will be provided in the local language. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 99 of 100 
 
 
Compensation to Subjects and Investigators 
Foresee Pharmaceuticals Co., Ltd will provide an insurance in order to indemnify (legal and 
financial coverage) the investigator/center against claims arising from the study, except for 
claims that arise from malpractice and/or negligence. The compensation of the subject in the 
event of study-related injuries will comply with the applicable regulations. 

QPS: 160509 
Sponsor: FP02C-18-001 
Clinical Study Protocol 
06 September 2021, Amendment 3 
Template TSP820.01-2, effective date 10 January 2017 
Confidential 
Page 100 of 100 
 
 
13 STRUCTURED RISK ANALYSIS 
A risk analysis (TSP603.02) will be made by the Division CP of QPS Netherlands B.V.